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 Familial hypercholesterolemia (FH) is a genetic disorder characterized by 
abnormally high concentrations of low-density lipoprotein-cholesterol (LDL-
cholesterol) in the blood that can contribute to heart disease. FH can result from a 
defect in the gene for the LDL receptor (LDL-R). FH patients lacking functional 
LDL-R may benefit from viral-mediated transfer of a functional copy of the open 
reading frame (ORF) of the LDL-R. Since a recombinant adeno-associated virus 
(rAAV) is not immunogenic and can be mass-produced, it shows promise for 
gene therapy applications. AAV6 and AAV8 have been shown to specifically 
transduce hepatocytes in several species, which normally remove the majority of 
LDL-cholesterol from the blood via LDL-R-mediated endocytosis. Because of the 
potential of rAAV to treat FH by delivery of a correct LDL-R ORF to 
hepatocytes, the liver specificity of these two AAV serotypes was evaluated. 
Additionally, rabbits were chosen as the animal model for this study because a 
specific strain of rabbits, Watanabe heritable hyperlipidemic (WHHL), adequately 
mimics the pathology of FH in humans. Exposure of rabbit liver to rAAV with the 
marker LacZ and subsequent inspection of liver tissue showed that AAV8 
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transduced rabbit liver more efficiently than AAV6. To assess the feasibility of 
producing a rAAV capable of transferring the LDL-R ORF to rabbit hepatocytes 
in vivo, rAAV8-LDL-R was mass-produced by a baculovirus system in 
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CHAPTER 1: INTRODUCTION 
1.1 Team Gene Therapy 
The Gemstone Program at the University of Maryland, College Park is a 
four-year multidisciplinary Honors program in which undergraduate students, as a 
team, create and execute a research project with the help of a faculty mentor. 
Students gain a unique perspective on the research process by directing all aspects 
of their project, from inception to completion. This longitudinal project 
culminates in a thesis defense and provides undergraduates a valuable experience 
that often focuses on science and technology in society.  
Team Gene Therapy was founded in the spring of 2010 with the 
purpose of exploring gene therapy as a treatment of prevalent genetic diseases. 
More specifically, the team decided to focus on familial hypercholesterolemia 
(FH), a good candidate for gene therapy, due to its monogenic nature and limited 
current treatment options.    
 
1.2 Prevalence of Familial Hypercholesterolemia 
Heart disease, the leading cause of death in Americans, ranges from 
coronary artery disease to irregular heart rhythm (1). One particular metabolic 
disorder, FH, is an inherited genetic condition in which poor lipid metabolism 
predisposes individuals to severe premature cardiovascular disease (2). This 
disorder results in heart attacks at a young age through the elevation of blood 
lipoproteins, specifically low-density lipoprotein-cholesterol (LDL-cholesterol).  
The most common cause of this elevation is a mutation in the LDL-
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receptor (LDL-R) gene. In most countries, about one in 500 people are 
heterozygous for a mutation in the LDL-R gene (2). Those possessing the 
heterozygous mutation may suffer from heart attacks starting at the age of thirty 
because of an approximate two-fold increase in LDL-cholesterol levels (3). 
Homozygotes for the mutation, however, typically have a six- to ten-fold increase 
in LDL-cholesterol levels, which leads to severe atherosclerosis throughout 
childhood and adolescence (4). By studying the population of FH homozygotes, 
the manifestations of the mutant allele can be observed without any confounding 
effects, providing genetic proof that elevated LDL-cholesterol alone produces 
atherosclerosis in humans (3).  
 
1.3 The Role of Gene Therapy in Modern Medicine 
Gene therapy is an approach involving the delivery of genetic material 
to host cells to treat disease. Several challenges to the progress of gene therapy 
include limited transgene expression, toxicity, inflammatory responses, and 
random gene integration. Despite these existing challenges, this relatively young 
field is rapidly expanding. 
In 1972, Dr. Theodore Friedmann and Dr. Richard Roblin first began to 
investigate gene therapy as a solution to address human genetic diseases (5). In 
1990, the National Institutes of Health (NIH) gained approval to conduct the first 
experiment using gene therapy in humans. The subject was a four-year-old girl 
with an adenosine deaminase deficiency. Although the improvement was only 
temporary, the initial success further validated the approach of gene therapy (6). 
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The momentum gained from this study was set back by the death of a patient, 
Jessie Gelsinger, during Dr. James Wilson’s study in 1999, calling into question 
the safety of gene therapy practices. As a result, numerous clinical studies were 
suspended pending further review of both procedural and ethical principles. 
Though this incident resulted in many obstacles to the progress of gene therapy, 
including government investigations and congressional hearings, these efforts also 
refined the field and ensured the safety of future patients (7). 
In 2012, the European Union approved Glybera®, a gene therapy 
pharmaceutical for those suffering from the rare genetic disorder familial 
lipoprotein lipase deficiency (8). This drug treatment, produced by Amsterdam 
Molecular Therapeutics, is the first to be approved on a significant international 
scale (8). Ultimately, this approval legitimizes the potential of gene therapy as a 
realistic treatment option. 
 
1.4 Animal Models Currently Used in Gene Therapy Trials 
In the field of gene therapy, a wide variety of animal models ranging in 
complexity and applicability to humans have been used to study inherited 
diseases. Though mice have been commonly utilized, problems include their short 
lifespan and their inability to adequately mimic many human diseases and genetic 
backgrounds (9). To address these limitations, researchers have instead used 
animal models tailored to the particular disease of interest. For example, 
researchers have used canines, felines, equines, and bovines, in order to study 
hemophilia, alpha-mannosidosis, osteoarthritis, and citrullinemia, respectively (9). 
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The longer lifespan and similar disease etiology lend these animals to the optimal 
study of these diseases.  
 For this study, rabbits were selected as the animal model rather than mice 
given that rabbits are better able to represent FH in humans. The pathology of FH 
in a certain strain, Watanabe heritable hyperlipidemic (WHHL) rabbits, closely 
mimics the pathology of FH in humans. Specifically, these rabbits are genetically 
inbred to have defective LDL-R, which causes them to exhibit similar lipid 
metabolism and symptoms as those seen in humans with FH. In comparison, a 
knockout mouse model does not produce the LDL-R protein at all and requires a 
high fat diet to induce hypercholesterolemia. In humans, however, 
hypercholesterolemia can result from defective LDL-R alone; therefore, knockout 
mice are a poor representation of FH in humans. The selection of WHHL rabbits 
for this study proved to have the highest potential clinical applicability. 
 
1.5 Project Overview  
This study was conducted to design and mass-produce the most 
effective gene delivery system for transduction of the liver of the WHHL rabbit 
strain to treat hypercholesterolemia. First, the LDL-R mRNA of the New Zealand 
White (NZW) rabbit was isolated, cloned, and sequenced. Then, the most 
effective recombinant adeno-associated virus (rAAV) serotype for transduction 
and long-term expression of the NZW rabbit liver was determined via β-
galactosidase assays and quantitative polymerase chain reaction (qPCR) analysis 
of liver samples. After determination of the optimal serotype, the rAAV serotype 
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of choice containing a liver-specific promoter and the LDL-R open reading frame 
(ORF) was mass-produced for injection into WHHL rabbits. 
 
1.6 Research Aims 
The team chose to implement a gene therapy approach in both NZW 
and WHHL rabbit models to study FH using the following three aims: 
 
 Aim 1: Sequencing of the full coding region of the LDL-R mRNA 
In order to insert the functional wild type (WT) gene for delivery via 
gene therapy into the WHHL model, the complete LDL-R mRNA sequence in 
NZW rabbits was first determined. Previous research had attempted to sequence 
the gene in its entirety; however, nearly 20% of the mRNA, including the 5’ 
untranslated region (UTR), remained unknown. Team Gene Therapy looked to 
discover the complete sequence to aid in development of an optimal recombinant 
viral vector. 
 
Aim 2: In vivo delivery of rAAV6-LacZ and rAAV8-LacZ in NZW rabbits 
Rabbits were injected with uniform concentrations of saline and either 
rAAV6-LacZ or rAAV8-LacZ in order to determine which serotype was most 
effective for liver transduction. Rabbits were sacrificed either 10 or 28 days post-
injection and liver samples were analyzed for expression of LacZ and 




Aim 3: Large-scale production of rAAV8-LSP-LDL-R  
The shuttle plasmid containing the LDL-R ORF and a liver-specific 
promoter was prepared for rAAV8-LSP-LDL-R production by baculovirus 
infection of insect cells in suspension. This system produced the necessary 
quantity of viral particles for injection into WHHL rabbits, verified by real-time 
PCR. 
 
1.7 General Research Hypothesis 
Since different AAV serotypes show a wide range of tissue tropisms, 
we hypothesized that one serotype would more significantly transduce the NZW 
rabbit liver and express the marker protein β-galactosidase. We also hypothesized 
that shuttle plasmid transfection and recombinant viral infection would show 
LDL-R expression in vitro. 
 
1.8 Project Significance  
Determining the optimal serotype for rabbit liver transduction will aid 
in future gene therapy modeling in the WHHL rabbit, which is known to closely 
mimic FH in humans. Future implementation of rAAV with a functional LDL-R 
gene into WHHL rabbits would contribute to modern medicine. This study will 
contribute to the development of gene therapy to treat FH in higher mammals and 
could provide justification for further research into the efficacy of this approach in 
humans. A previous study has shown that gene expression in WHHL rabbits 
transduced with a recombinant adenovirus containing a human LDL-R 
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complementary DNA (cDNA) is transient, lasting less than a week (10). To 
improve on past studies, we suggest the following innovations to the gene 
delivery approach in rabbits:  
 
A) Injection of WHHL rabbits with an AAV vector, rather than an 
adenovirus, carrying the LDL-R gene; 
 
B) Transduction of rabbit hepatocytes with the rabbit LDL-R gene 
rather than with LDL-R from another species or chimeric constructs; 
 
C) Mass-production of the appropriate viral vector using the 
baculovirus system;  
 




Chapter 2: Literature Review 
2.1 Genetic Disorders 
 Genetic disorders are those caused by defective genetic material. Such a 
defect can result in disease by causing a deleterious change in a biologically 
important molecule such as catalytic RNA or a protein (11). Some genetic 
diseases result in developmental defects and may not be treatable by subsequent 
correction of expression. For instance, correcting gene expression in individuals 
with Down’s syndrome (trisomy 21) during adulthood is unlikely to be effective 
in treating the disease (12). On the other hand, some genetic disorders are caused 
by constitutive abnormal expression. Unlike developmental defects, diseases that 
result from constitutive lack of or abnormal expression may be treated by its 
correction. For example, factor IX deficiency, in particular, is an X-linked 
recessive disorder has been treated in mouse and canine models using a gene 
therapy approach (13).  
Several causes of genetic disorders exist including chromosomal 
abnormalities, single gene defects, and polygenic disorders. Chromosomal 
abnormalities can assume different forms. Certain disorders stem from an 
abnormal number of chromosomes. Other abnormalities include deletions, 
inversions, and translocations (11). Single gene defects are caused by the 
inheritance of one defective gene. Methods of inheritance include dominant and 
recessive. In the case of dominant inheritance, only one abnormal allele may 
cause phenotypic expression of the disorder. Two defective alleles are required 
for disease manifestation in recessively inherited disorders (11). Polygenic 
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disorders are caused by variations in multiple genes. Contributions of multiple 
genes to a phenotype may cause a particular trait to show varying degrees of 
penetrance. While diseases resulting from chromosomal abnormalities and 
variations in multiple genes may not be amenable to treatment by gene therapy, 
gene therapy may be effective for treating individuals suffering from disorders 
that result from constitutive lack of expression of a single functional gene (11).  
Different methods of treatment and prevention exist for these various 
genetic disorders. For example, for a genetic disorder that affects metabolism and 
disrupts the production of certain enzymes, a dietary change may be sufficient to 
prevent the accumulation of toxic substances that are normally broken down by 
these essential enzymes (14). Other treatments for genetic diseases specifically 
address the symptoms. For instance, a heart defect may be managed with surgery, 
and defective blood cell formation may be treated with a bone marrow transplant 
(14). These treatments do not address the disorder at the genetic level; rather, they 
aim to alleviate the symptoms. A different treatment strategy, however, accounts 
for the mutation itself by introducing genetic material via a gene therapy 
approach. 
 
2.2 Familial Hypercholesterolemia 
 FH is an autosomal dominant genetic disorder of lipid metabolism. In 
many individuals with this disease, LDL-R has a diminished ability to remove 




2.2.1 Genetics of the Disease 
Phenotypic expression of clinical hypercholesterolemia results from 
mutations at one of three gene loci. Most frequently, FH arises from a mutation in 
the gene that encodes LDL-R. This gene is located on chromosome 19p13.2 from 
11,200,038 bp to 11,244,506 bp, making the gene 44,469 bp long with 18 exons 
(17). The full-length WT protein product is comprised of 860 amino acids (16). 
Over 700 variants of the gene have been shown to lead to FH (17, 18).  
Mutations in the apolipoprotein B-100 gene (APOB) may also lead to 
FH. Located on chromosome 2p23-24, the APOB gene is 43 kb long with 29 
exons. The 4,536 amino acid APOB protein serves as a ligand for LDL-R for 
internalization of LDL-cholesterol. Alterations of this gene can lead to 
hypercholesterolemia and are termed familial defective apolipoprotein B-100 
(17).  
Finally, FH symptoms may result from mutations in the proprotein 
convertase subtilisin/kexin type 9 gene (PCSK9). Located on chromosome 
1p32.3, the PCSK9 gene is 25 kb long, from 55,505,149 bp to 55,530,526 bp. The 
protein aids in cholesterol homeostasis by binding to the epidermal growth factor-
like repeat A domain of the LDL-R and inducing its degradation. (19) 
Mutations in the above three loci, the LDL-R, APOB, or PCSK9 genes, 
can be categorized within one of the following 5 classes of mutations: (17, 18) 
 
Class 1 
The class 1 mutation is termed a null mutation in that it results in a complete lack 
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of production of LDL-R. This may result from a deletion of the LDL-R promoter 
upstream of the gene itself, or a nonsense, frameshift, or splicing mutation. 
 
Class 2 
Because the LDL-R protein is a membrane protein used for internalization of 
extracellular particulate matter, it must be transported to the cell surface before it 
is effective. Class 2 mutations result in intracellular LDL-R transport defects 
between the endoplasmic reticulum and the Golgi complex. Within the class 2 
mutations are two further specifications termed class 2A and class 2B. In class 2A 
mutations, the LDL-R protein fails to be transported out of the endoplasmic 
reticulum. In class 2B mutations, termed “leaky” transport, the rate of LDL-R 
transport to the Golgi complex is significantly reduced. 
 
Class 3 
Class 3 mutations, which are most common, result in the failure of LDL-R to bind 
LDL-cholesterol. Such mutations are often located in the ligand-binding and 
epidermal growth factor precursor regions of the gene. It is important to note that 
WHHL rabbit strain is an apt model for the resulting disease in that they have this 
class of mutation. 
 
Class 4 
Class 4 mutations are the rarest of all the classes. In such cases, while the LDL-R 
binds to LDL-cholesterol, it cannot internalize it. Specifically, the amino acid 
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mutation occurs in the cytoplasmic domain or the membrane-spanning domain, 
preventing LDL-R collection on the cell surface and endocytosis. 
 
Class 5 
In a class 5 mutation, which is also rare, the LDL-R can bind and internalize 
LDL-cholesterol, but cannot dissociate from it. That is, the LDL-R cannot release 
the particles in the endosome. Thereby, the LDL-R is not recycled to the cell 
surface. 
 
2.2.2 Prevalence of the Disorder 
 The prevalence of FH is different between its heterozygous and 
homozygous forms. Heterozygous FH is the most common inherited metabolic 
disorder present in one of 300 to 500 people depending on ethnicity (20). This 
approximate 0.2 to 0.33% occurrence pertains to people in the United States and 
United Kingdom (21). For certain populations, such as Chinese Canadians, 
French Canadians, Finns, Dutch, Icelanders, Lebanese Christians, Lithuanian 
Jews, and South African Afrikaners, the prevalence of heterozygous FH is higher 
due to the founder effect (21). The founder effect is the lack of genetic variation 
in a new population due to the genetic similarity among individuals that founded 
that small population. On the other hand, homozygous FH is much rarer, 
occurring one in one million people. This is because it requires two mutated 





Individuals with FH have elevated blood levels of total cholesterol and 
LDL-cholesterol. Individuals who are homozygous for a polymorphism that 
causes a lack of LDL-R function show LDL-cholesterol levels between 650 to 
1,000 mg/dL (20). Heterozygous individuals, however, have approximately 220 
mg/dL of LDL-cholesterol (20). Normal levels of LDL-cholesterol are 
approximately 70 to 100 mg/dL of LDL-cholesterol. Total cholesterol levels in 
homozygous mutants are between 500 and 1,000 mg/dL. In heterozygous 
individuals, total cholesterol averages 325 to 450 mg/dL (21). When diagnosis or 
treatment is delayed or not performed, homozygous individuals develop 
accelerated atherosclerosis and may die in the first few years of life from coronary 
heart disease (20). However, blood tests report that individuals with FH maintain 
normal levels of triglycerides (15).  
High blood LDL-cholesterol predisposes individuals to early 
atherosclerosis and severe premature cardiovascular disease (9). In some cases, 
heart attacks and death occur before the age of thirty (22). Other symptoms of FH 
include xanthomas over the elbows, knees, buttocks, tendons, and around the 
cornea of the eye, cholesterol deposits in the eyelids, and angina (15). Tendon 
xanthomas, specifically, occur in at least 70% of patients affected by the age of 50 
(21). When coronary angiography is used, proximal obstructive lesions, coronary 
ectasia, thickened aortic valves, and supravalvular aortic stenosis are generally 
observed (21). Some of these symptoms can develop as early as infancy (22). A 
strong family history of high levels of total and LDL cholesterol, early heart 
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attacks, or therapy-resistant levels of LDL-cholesterol is a risk factor for FH (22). 
A clinical diagnosis can be made from these family history factors, the presence 
of tendon xanthomas, and high levels of LDL-cholesterol in the blood (21). 
 
2.2.4 Role of Defects of LDL-R in FH 
LDL is a chylomicron that transports cholesterol in the blood to tissues. 
It originates from VLDL after losing most of its triglycerides and exchanging 
apolipoproteins (23). LDL-cholesterol remains circulating in the bloodstream 
until it is taken up by LDL-R located within the plasma membrane of the liver via 
specific receptor-mediated endocytosis (23). The LDL-R diffuses through the 
plasma membrane until it associates in clathrin-coated pits. When these coated 
pits pinch off to form coated vesicles, LDL-cholesterol particles bound to the 
LDL-R in the coated pits are internalized by hepatocytes (24).  
Once inside hepatocytes, the LDL-cholesterol is delivered to the early 
endosomes, late endosomes, and finally the lysosomes, where cholesteryl esters in 
LDL-cholesterol are metabolized and released as free cholesterol to be utilized as 
necessary (24,25). Because LDL-R is responsible for the uptake of LDL-
cholesterol, it helps regulate the amount of LDL-cholesterol in the bloodstream. 
The LDL-R in the liver clears approximately 70% of circulating LDL-cholesterol 
(26). Therefore, it makes the largest contribution to the removal of LDL-
cholesterol from the blood. When this function is disrupted, levels of LDL-





2.2.5 Current Available Treatments 
Treatments varying in degree of intensity and invasiveness are currently 
available for the heterozygous and homozygous forms of FH. They function by 
lowering the levels of LDL-cholesterol in the bloodstream and thus decreasing the 
possibility of atherosclerotic heart disease. One treatment option is lifestyle 
change; exercising as well as dieting to limit the total amount of fat to 30% of the 
total daily caloric intake can, to a certain point, help lower cholesterol levels (22). 
 The next option of treatment for FH involves drug therapy, which is often 
suggested in combination with a healthier lifestyle. Statins, for example, are 
capable of lowering the risk of cardiovascular disease by 80% when initiated 
during adulthood (20). These drugs are competitive inhibitors of 3-hydroxy-3-
methylglutaryl-CoA reductase, an enzyme that catalyzes the rate-limiting step of 
cholesterol synthesis (21). This inhibition causes a decrease in cholesterol levels 
inside the cell. Liver cells respond to this decrease by increasing production of 
LDL-R (21). Because the mechanism by which statins lower LDL-cholesterol in 
the blood relies upon the functionality of LDL-R, in homozygotes, statins alone 
are ineffective (20). Other contraindications include statin intolerance, which can 
lead to severe rhabdomyolysis and kidney failure (20).  
Other drugs include bile acid sequestrant resins, ezetemibe, nicotinic 
acid, gemfibrozil, and fenofibrate (22). These drugs can be used in combination 
with statins, which may lower LDL cholesterol levels by an additional 25%. 
These drugs also lower levels of triglycerides and lipoprotein(a), both of which 
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are linked to cardiovascular heart disease but are not targets of statin treatment 
(20). Thus, combining several drug treatments further eliminates the potential for 
complications from FH.    
The above treatments have been sufficient for some individuals who are 
heterozygous for FH. However, homozygotes and some heterozygotes may 
require stronger treatment options to compensate for higher levels of LDL. 
Medicines alone are only capable of lowering LDL-cholesterol in the bloodstream 
of homozygous patients by at most 10% (20). As an alternative to drug therapies, 
these individuals may require a transplant to obtain a liver with functional LDL-R 
or need LDL apheresis to remove LDL-cholesterol from their blood circulation 
(22). LDL apheresis, though invasive, has many benefits including decreasing 
LDL-cholesterol levels by 50%, reducing lipoprotein(a) levels, and mitigating 
atherosclerosis (20).    
Ultimately, the ideal FH treatment may be a gene therapy approach in 
order to deliver functional genes of interest to targeted cells. This strategy is 
promising, as it would directly address the problem of defective LDL-R.  
 
2.3 Gene Therapy  
Gene therapy is an approach that entails delivering genetic material into a 
patient in order to treat diseases. For example, gene therapy might entail 
introducing DNA encoding for a functional protein into the host’s cell. 
Introduction of the therapeutic genetic material may require a vector, such as a 
viral vector. (27).  
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Two major classes of methods for gene therapy exist: 1) the usage of non-
viral methods and 2) the usage of viral vectors. 
 
2.3.1 Non-Viral-Mediated Gene Therapy 
Non-viral-mediated gene therapy focuses on inserting and maintaining 
DNA into a host’s cell without the use of a virus. Although non-viral vectors are 
less efficient at long-term foreign gene expression than viral vectors, non-viral 
vectors hold several advantages compared to their counterpart. These include the 
non-pathogenicity, non-immunogenicity, ease of use, inexpensive large-scale 
manufacturing, and flexibility of transgene size. Further, non-viral delivery 
methods pose less of a risk of integration of the gene causing a mutagenic effect 
(28). However, despite the advantages of non-viral-mediated gene therapy, low 
gene expression and transfection efficiency may limit the practical applications 
and commercial viability of these treatment options for genetic diseases (29).  
 
2.3.1.1 Naked DNA 
Naked DNA, which has no other additives to protect it from degradation, 
can either be safely injected directly into areas of the body such as skeletal 
muscle, skin, liver, and thyroid or be administered systemically to affect an entire 
system or body (30). For example, intramuscular injection of naked DNA has 
been used to express pharmacologically active molecules such as erythropoietin 
and leptin (31). Additionally, antitumor immunity has been induced by intra-
tissue injection of a variety of tumor inhibitory genes (31). However, without the 
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assistance of a carrier vector, either the liver quickly clears the foreign DNA from 
the body or restriction nucleases degrade the DNA (32). In recent years various 
physical technological advances have improved the efficiency of DNA uptake by 
allowing direct penetration of DNA through the cell membrane. Naked DNA can 
be administered to cells via electroporation, sonoporation, or use of a gene gun. 
Electroporation uses pulses of high voltage to temporarily form pores in the cell 
membrane. Sonoporation involves ultrasonic waves rather than electricity. The 
use of a gene gun entails shooting gold particles coated with DNA through the 
cell membrane into the cytoplasm and the nucleus, bypassing the endosomal 
compartment (30). In general, naked DNA delivery systems are much less 
effective in higher primates compared to small laboratory animals.  
 
2.3.1.2 Lipoplexes and Polyplexes 
Because of the inherent problems with using viral vectors, liposome-based 
gene delivery, which was first created by Dr. Philip Felgner in 1987, is still one of 
the most promising techniques for gene delivery into cells. Lipoplexes have found 
the most success in treatment of cancer cells, where injections of genetic material 
have activated tumor suppressor control genes and decreased oncogenic activity 
(33). Anionic and neutral lipids were first used to construct liposomes and 
polymers that when combined with DNA are labeled as “lipoplexes” or 
“polyplexes,” respectively (33). Because the construction of anionic lipids is time 
and labor intensive, researchers chose to use cationic lipids instead. Cationic 
lipids, because of their positive charge, were first used to condense negatively 
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charged DNA molecules so that DNA can then be bundled into liposomes for 
genetic insertion. Cells take up these charged particles via endocytosis, which 
creates endosomes within the cell. If the membrane of the endosome does not 
degrade, nucleic acids cannot be released into the cytoplasm and can be easily 
destroyed by lysosomes before fulfilling their purpose (30). Because cationic 
lipids, which are toxic, do not allow for “endosomal escaping,” transfection 
efficiency is low (33). 
 
2.3.1.3 Inorganic Nanoparticles 
Inorganic nanoparticles have also been used for gene delivery. For 
instance, calcium phosphates, gold, magnesium phosphates, and iron oxides can 
be used to deliver genetic material into cells. Nanosized inorganic materials 
approximately 100 nm in length have shown the capacity to trap and protect the 
DNA efficiently from degradation, allowing the whole DNA to escape 
endosomes. Additional benefits associated with inorganic particles include low 
manufacturing costs, resistance to microbial attack in a host, low immunogenicity, 
and greater ability than organics to attach to cell lines in tissue cultures, leading to 
greater gene transfer efficiency. However, inorganic nanoparticles exhibit no 
tissue specificity (34). 
Although these non-viral-mediated methods have shown some 
effectiveness in gene delivery and advantages compared to the use of viral vectors 
when used in vitro, viral vectors currently show more promise in the field of gene 




2.3.2 Viral-Mediated Gene Therapy 
It was shown in the late 1960s that polyomaviruses such as SV40 were 
capable of incorporating their genetic information into the genomes of target cells. 
More importantly, target cells retained expression of this transferred viral genome 
(35). This discovery opened the gateway for the use of viruses as the agent to 
introduce therapeutic genes to ultimately overcome genetic diseases. 
Viral-mediated gene therapy involves transduction, the process in which DNA is 
introduced into a cell by a virus (36). After assembling the viral vector construct, 
it is then administered to the appropriate subject, delivering its “cargo,” or the 
gene of interest, to the cell (37). Transduction may address a defect by providing 
genetic material or raising expression levels of an existing gene (37).  
The most important criterion for successful implementation of gene 
therapy is the selection of the viral vector, as it is the vehicle used to deliver the 
gene of interest into the host. The viral vector construct must contain the desired 
gene and the essential viral sequences needed for the assembly of viral particles, 
with dispensable viral genes eliminated to reduce patho- and immunogenicity 
(38). The ideal construct fulfills the following six parameters for safe and 
effective delivery of the transgene (38):  
 
1) Adequate production: Many viral particles are needed for sufficient 




2) Safety: The viral vector should not elicit an immune response that 
would harm the target cells or host subject. Some known viruses can 
integrate their genetic material into the host’s genome. Such insertions 
have been shown to cause cancer. 
 
3) Sustained and regulated expression of the gene of interest: The gene of 
interest should be expressed for a long period of time. Brief expression of 
the newly introduced transgene would thus be inefficient.  
 
4) Targeting of the viral vectors: Because the transduction efficiency of a 
particular tissue can vary dramatically among different viral vectors, it is 
necessary to choose one specific for the tissue to be affected.  
 
5) Infection of dividing and nondividing cells: If the target organ is in a 
postmitotic, nondividing state, viral vectors must be capable of targeting 
these somatic cells. 
 
6) Site-specific integration: Integration into the host genome at specific 
sites could enable the repair of specific mutations without random 




Discussed below are a variety of available viral vectors and the associated 
advantages and disadvantages of their use in gene therapy trials. The 
characteristics of these vectors are compared in Table 1. 
 
2.3.2.1 Herpes Simplex Virus Type 1 
Herpes simplex virus type 1 (HSV-1), currently the most extensively 
engineered herpes virus, is highly infectious and can be applied in a wide range of 
animal models. The virus has been classified as a feasible candidate for gene 
transfer in vivo because it remains viable after initial infection in humans and is 
able to stably and latently transduce non-dividing cells (39). Additionally, the 
large genomes of HSVs allow for the insertion of 30-40 kb of foreign genetic 
material, whereas other viruses such as adeno-associated viruses (AAVs) and 
SV40s have a maximum transgene capacity of only 4.7 kb in most cases (39). 
This comparatively large size allows HSV to hold at least 30 kb of non-HSV 
sequences representing large single genes or multiple transgenes that may be 
expressed simultaneously (39). Further, more than 80 HSV genes can be removed 
without compromising infectivity; thus, the virus is convenient for both gene 
deletion and replacement (40, 41). However, HSVs are unable to induce long-
term expression in certain tissues, and the complexity of HSV attachment and 
entry causes several problems in targeting of a vector to a particular tissue (39). 
Currently, more clinical testing must be completed to measure the true safety and 
effectiveness of HSV for gene therapy. Drawbacks of HSV also include its 





Retroviruses are enveloped 8-12 kb RNA viruses carrying two identical 
copies of genomic RNA that resemble cellular mRNA. The virus infects host cells 
by entering the cytoplasm by receptor-mediated endocytosis. Reverse 
transcriptase is then activated to transcribe the retroviral genome into DNA, 
which is then inserted into the cell’s chromosomes by viral integrase in order to 
form the provirus. The newly created viral DNA may randomly integrate into the 
host DNA at various locations; however, some retroviruses “prefer” certain sites 
for integration. This process allows for stable long-term expression, but the direct 
insertion of the virus’ genetic information into the host chromosomes may result 
in oncogenesis. This type of insertion may occur in the middle of an oncogene, 
triggering cancer. Additionally, retroviruses other than lentiviruses require 
dividing cells for infectivity. The only retroviruses that have been extensively 
explored for gene therapy applications are lentiviruses (42).  
 
2.3.2.2.1 Lentivirus 
Lentiviruses are uniquely able to integrate their genome into the 
chromosomes of non-dividing cells such as neurons. They are able to infect both 
dividing and non-dividing cells by relying on active transport of the preintegration 
complex to enter the nucleus through the nuclear pores (43, 44). Lentiviruses such 
as human immunodeficiency virus type 1 (HIV-1) and animal lentiviruses have 
been studied as potential gene therapy vectors because they are less tumerogenic 
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than other retroviruses and tend to not insert their genetic material into promoters, 
but into the bodies of genes themselves (42, 43). Because they rarely integrate 
into transcriptional start sites, lentiviral vectors are less likely to cause cancerous 
cells than other retroviruses. Other advantages of lentivirus viral vectors include 
stable expression, transgene capacity up to approximately 8 kb, and low 
immunogenicity (43). However, similarly to HSV, lentiviruses have yet to be 
established as safe and effective to treat genetic disease in animal species. The 
possibility of insertional mutagenesis and pathogenic vector mutation remain 
obstacles to the widespread use of this vector (42, 43). 
                        
2.3.2.3 Adenovirus 
Adenovirus is a non-enveloped, double-stranded DNA virus with over 50 
distinct variations, divided into six subclasses. Adenovirus serotypes in subclass C 
have a very efficient mechanism for nuclear entry, making them popular choices 
for the transduction of a variety of cell types (45). Immunogenicity may prevent 
them from being used clinically as a viral vector. Previous trials have reported 
strong and even fatal immune responses to recombinant adenoviral vectors, 
limiting the longevity of transgene expression as well as threatening the health of 
the host (46). Adenoviruses have high worldwide prevalence. As a result, many 
humans have preexisting immunity so the potential for an immune response may 





2.3.2.4 Adeno-Associated Virus  
 
Adeno-associated viruses (AAVs) are non-pathogenic, single-stranded 
DNA viruses of the parvovirus family, which require co-infection with an 
adenovirus helper virus (48). The AAV genome includes two ORFs. The left ORF 
codes for Rep proteins for DNA replication; two promoters, p5 and p19, regulate 
expression of the rep gene, which generates four replication proteins - Rep 78 and 
Rep 68 from p5, and Rep 52 and Rep 40 from p19 (48). The right ORF contains 
the cap genes, which code for structural capsid proteins. Promoter p40 regulates 
expression of the cap gene, which generates three structural proteins - VP1, VP2, 











Figure 1: Transcriptional map of AAV genome. Map showing location of genes and 




Although various viral vector choices exist for gene therapy, clinical trials 
have shown AAV to be the most viable option for several reasons. AAV is the 
only viral vector that has been used to induce long-term expression safely in large 
animals, including primates both human and non-human. In the absence of 
significant immune responses in mammalian species, AAV effectiveness and gene 
expression can last several years (37). Compared to other viruses, AAV elicits 
less of a host immune response and provides few alterations in host gene 
expression during infection (49). 
Additionally, AAV’s non-pathogenicity, non-immunogenicity, heat 
stability, and resistance to changes in pH make the virus ideal for a lab setting 
(50). This particular virus has been shown to be safer than other viruses in that it 
is unable to integrate DNA into the host genome. Additionally, rAAV used in 
gene therapy will not become pathogenic due to its inability to replicate. Although 
wild type AAV may replicate in the presence of an adenovirus helper virus, rAAV 
lacking the rep and cap genes will not (49).  
 
2.3.2.4.1 Adeno-Associated Virus Serotypes 
Over the past few decades, at least twelve serotypes of AAV have been 
discovered and commonly used in research (51). Of these twelve, eight are able to 
infect primates. Tissue specificity varies with serotype; for example, different 
serotypes have been shown to target skeletal and cardiac muscle, lung, liver, 
retina, and brain tissues (48, 51).  AAV2, the first and most popular serotype used 
in research, presents natural specificity for hepatocytes, neurons, and skeletal and 
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smooth muscle cells (52, 53). AAVs can be selected based on general tissue 
tropism, or engineered to have the desired tissue tropism based on the capsid 
serotype (54). For example, studies have shown that AAV8 vectors have been 
successful in transducing murine liver cells 100 times more efficiently than 
AAV2 vectors (55, 56). AAV6 is similar to AAV1 and AAV2, but has lower 
immunogencity than AAV2 and has shown proficient transduction of muscle, 
lung, and liver in vivo (57, 58). Therefore, AAV6 and AAV8 show promise as 
viral vectors for targeting and transducing the liver. 
Viral Vector Advantages Disadvantages 
- Large transgene capacity (30- 
  40 kb) 
- Difficulty maintaining long-term  
  expression 
- Transduces non-dividing 
   cells stably and latently 
- Complexity causes problems in  
  vector targeting 
HSV-1 
- Allows for both gene 
  deletion and repacement   
- Stable expression 
- Require dividing cells for  
  infectivity 
- Low immunogenicity 
- Random integration 
   into host DNA 
Retrovirus 
  
- High likelihood of mutagenesis 
   and oncogenesis 
- Infect both dividing and 
   non-dividing cells - Possibility of mutagenesis 
- Stable expression - Lack of safe usage in animal models Lentivirus 
- Transgene capacity of 
   approximately 8 kb   
- Efficient mechanism for nuclear entry - High immunogenicity 
- Broad host range - Inflammatory response 
    
Adenovirus 
    
- Broad tropism - Small transgene capacity (4.7 kb) 
- Non-pathogenic   
- Low immunogenicity   
- Resistant to changes in heat, pH, and 
   solvent   
AAV 
- Stable, prolonged, transgene 
expression   




2.4 Methods of Production of rAAV 
Four rAAV production systems have been reported (59):  
 
1) Production of rAAV in adherent HEK293 cells via expression of rep, 
cap, vg (viral genome), and helper adenovirus plasmids by transient 
transfection;  
 
2)  Production of rAAV in suspension-adapted mammalian cells infected 
with recombinant HSV-1 from which the rep, cap, and vg, are expressed; 
 
3) Production of rAAV on a large scale in packaging cells infected with an 
adenovirus helper virus; and  
 
4) Production in suspension-grown Sf9 via expression of rep, cap, rAAV 
genome from baculoviruses with which the Sf9 are infected.  
  
 The aforementioned production systems, 1, 2, and 3, suffer from one or 
more disadvantages. Production in adherent mammalian cells is not easily 
scalable. Production from a recombinant HSV is difficult due to the genomic 
instability of HSV. Production with an adenovirus helper virus creates the risk of 
contamination of AAV with toxic adenovirus. In contrast, the fourth production 
system described does not have these disadvantages, and can be scaled up to 
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produce large quantities needed for in vivo studies in higher mammals and 
humans. The recently approved Glybera was made using baculovirus technology 
(60). Thus, the baculovirus system may be the best reported system for large-scale 
production of rAAV at a good manufacturing practice level. 
 
2.4.1 Production of rAAV in Adherent Cells 
 Transfection of adherent mammalian cells with a plasmid encoding the rep 
and cap genes, a plasmid encoding helper virus genes, and a plasmid encoding the 
rAAV genome is useful for the production of rAAV on the scale used for the 
transduction of cultured cells. In contrast, clinical applications, especially those 
that entail the transduction of large numbers of cells, require a much larger 
amount of rAAV (61). Since the number of passages transfected mammalian cells 
can undergo while the transfection efficiency persists is limited, increasing the 
amount of rAAV produced requires increasing the number of cells transfected. 
Thus, clinical scale production via transient transfection requires high transfection 
efficiency and the cumbersome technology of growing mammalian cells on a 
large scale. While some mammalian cell lines, such as HEK293, can be 
transfected efficiently, these cells are adherent, so the number of transfected cells 
is limited by plate area. Because the amount of transfection reagent needed 
increases proportionally with the number of cells to be transfected, this process 
may be too expensive to be used in the clinical scale production of rAAV (61). 
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 Another difficulty in rAAV production in mammalian cells is the need for 
cotransfection of multiple plasmids. Even if each individual transfection is 
efficient, the efficiency of the cotransfection may be low. To improve 
cotransfection efficiency, the plasmid encoding helper virus genes can be replaced 
with an adenovirus helper virus (59). This approach, however, creates the risk of 
contamination of rAAV with adenovirus. Due to the toxicity of adenovirus, this 
risk may preclude clinical applications. 
For small-scale production of rAAV, cultured mammalian cells can be 
transiently cotransfected with a helper plasmid containing the rep and cap genes 
and with a plasmid containing the recombinant genome to be included. 
Cotransfection of mammalian cells, however, is inefficient in that it uses only 
adherent cells (61). Therefore, although this mammalian expression system is 
widely used for production of small amounts of rAAV, it cannot be feasibly 
scaled up to produce the amounts of rAAV that will be required for studies in 
large mammals or clinical studies in humans.  
Recently, a baculovirus/insect cell culture system has been developed by 
Dr. Kotin’s group at NIH. Because it does not require large quantities of 
transfection reagents, does not rely on cotransfection of mammalian cells, entails 
purification by column chromatography rather than CsCl gradient centrifugation, 
and is amenable to automation, this system allows semi-industrial or large-





2.4.2 Required Levels of Viral Particles for Rabbits 
Based on a rabbit’s size, large quantities of rAAV are needed to 
adequately infect hepatocytes. Normally, ten to one thousand viral particles are 
required to infect a single cell because the particle-to-infectivity ratio of AAV 
vector preparation usually ranges from 10:1 to 1000:1 (49). The frequency of 
incomplete or empty viral particles, defective particles, and host cell susceptibility 
lends to the high ratios required for effective transduction (49). In addition, during 
trafficking from an endocytoplasmic vesicle to the nucleus, the vector particle 
may become ubiquitinated and directed to a proteasome for degradation instead of 
being directed to the nucleus for transgene expression (49).  
A rabbit liver has approximately 1010 cells. Therefore, at least 1011 to 1013 
viral particles, with the LDL-R cassette, would be needed to infect a large number 
of hepatocytes to attempt to lower LDL-cholesterol blood levels. To safely ensure 
an adequate number of functioning viral particles (1013) reach the liver, about 1014 
viral particles should be delivered in each rabbit. For quick and efficient large-
scale production of the rAAV particles, a technique using baculoviruses can be 
implemented in order to attempt to achieve an observable level of expression of 
the LDL-R gene in the rabbits. 
 
2.4.3 Production in Suspension-Grown Cells 
 Production of rAAV in suspension cells is more scalable than production 
in adherent cells because the number of cells can be increased proportionally to 
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the volume of the culture rather than to plate area (61). Two such examples 
include HSV-1 infection of mammalian cells and baculovirus infection of Sf9 
cells.  
 
2.4.3.1 HSV-1 Infection of Mammalian Cells   
 Production of rAAV from suspension-grown mammalian cells infected 
with a recombinant HSV containing rAAV genome is scalable but suffers from 
the risk of contamination of rAAV with HSV and HSV proteins. Because HSV is 
pathogenic and immunogenic, this risk may preclude the production of clinical 
grade rAAV with this system. Moreover, HSV suffers from genomic and physical 
instability, thus producing and storing intact recombinant HSV may be difficult 
(60). 
 
2.4.3.2 Baculovirus Infection of Sf9 Cells 
Alternatively, clinical-grade rAAV has been produced on a semi-industrial 
scale in baculovirus-infected suspension grown Sf9 cells (61). In this system, rep 
proteins, cap proteins, and viral genome are expressed from recombinant 
baculoviruses with which the Sf9 cells are infected. Originally, the rep genes, the 
cap genes, and the viral genome were each expressed from a separate baculovirus, 
but more recently rep and cap genes have been consolidated into one baculovirus 
so that rAAV can be produced by infection of Sf9 cells with only two 
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baculoviruses (61). Since a baculovirus infection can propagate throughout an 
insect cell culture from even a small number of initially infected cells, scaling the 
amount of rAAV produced in insect cells does not require a change in the amount 
of transfection reagent used to produce the initial baculovirus stock. Further, the 
baculovirus provides the helper functions needed for rAAV production, so neither 
an adenovirus helper virus nor a recombinant DNA construct from which helper 
genes are expressed is needed. Because no adenovirus helper is necessary, rAAV 
can be purified from the Sf9 without the risk of adenovirus contamination. 
Moreover, purification of rAAV from infected insect cells can be automated (61). 
  Infecting Sf9 cells with purified baculovirus may be difficult because of 
damage that the viral particles sustain due to the instability of purified 
baculovirus. In contrast, baculovirus is stable in living insect cells. For this 
reason, the baculovirus system uses titerless infected-cells preservation and scale-
up (TIPS) to produce the rep and cap proteins. This system entails preserving cells 
infected with a baculovirus by freezing and introducing them into the culture to be 
infected with that baculovirus. The use of TIPS is preferable to the exposure of 
the suspension culture to purified baculovirus because it enables long-term 
preservation of the baculovirus stock and eliminates the need for determining 
viral titer. Because TIPS entails preserving baculovirus in frozen infected cells, it 
eliminates the difficulty of preserving purified baculovirus (61). 
  The optimal ratio of cells infected with baculovirus with the rep and cap 
genes to cells in the culture has already been established for existing stocks of 
frozen Sf9 containing this recombinant baculovirus. The ratio of the expression of 
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rep and cap proteins to the expression of rAAV genomes can affect the quality of 
the virus produced. Specifically, overproduction of rep and cap proteins relative 
to rAAV genomes will increase the fraction of empty viral particles. Since the use 
of frozen Sf9 infected with baculovirus with the rep and cap genes ensures that 
the optimal ratio of rep and cap genes to viral genomes will be produced in the 
suspension Sf9, TIPS eliminates the need to titer baculovirus with rep and cap 
genes and ensures that a large fraction of the physical rAAV particles produced in 
the suspension culture will contain rAAV genome (61). 
  Although the baculovirus genome is more stable than the HSV genome, 
the genomic instability of the recombinant baculovirus may make production of 
baculovirus with intact rAAV genome difficult. Since the recombinant 
baculovirus may suffer random deletions, it is important to sequence the 
recombinant baculovirus DNA and to verify the integrity of inverted terminal 
repeats (ITRs) in the recombinant baculovirus containing the rAAV genome. 
Because the secondary structure of the ITRs prevents PCR amplification and 
sequencing, a rescue assay is used to verify the integrity of the ITRs. This assay 
requires coinfection of Sf9 with the recombinant baculovirus containing the 
rAAV genome and with a bac-rep, from which two rep proteins but no cap 
proteins are expressed. The rep proteins produced from the bac-rep will replicate 
sequences flanked by functional ITRs. Thus, cells with recombinant baculovirus 
DNA containing a rAAV cassette with intact ITRs will accumulate copies of the 




In summary, the use of baculovirus-infected Sf9 cells for the production of 
rAAV at levels required for clinical trials is cost effective, reliable, non-
pathogenic, and scalable. Production of rAAV in 200 liter Sf9 suspension cultures 
with consistently high yield has already been reported (62). 
 
2.4.3.3 Purification of rAAV Produced Using the Baculovirus System  
In order to administer the rAAV produced in insect cells to the rabbits, the 
rAAV must be purified from the insect cell lysate. In CsCl gradient purification, 
particles are separated by density in a solution of varying CsCl concentration. 
While this method is slow and cumbersome, it allows for separation of empty 
viral particles from full viral particles. Although CsCl gradient purification can be 
used to purify rAAV for some research applications, this technique may not be 
optimal for purification of rAAV for animal models or clinical applications (63). 
Generally, centrifugation techniques cannot be easily scaled up. rAAV can also be 
purified by affinity chromatography on a heparin column (58, 64). Purification 
using a heparin column, while fast, can suffer from low yield. Additionally, not 
all serotypes can bind to heparin. For the purification of some serotypes, 
immunochromatography may be used. For instance, if an anti-AAV6 antibody is 
available, it can be bound to sepharose and used for the purification of AAV6 by 






2.5 Animal Models of FH 
 
2.5.1 Presence of FH in Animal Species  
The causes and effects of FH have been studied in few animal species, 
including rabbit, feline, and murine models. The feline model, in which cats 
inherit primary hyperchylomicronaemia, mimics many symptoms of FH in 
humans and is a possible candidate for FH research (65). However, some 
significant differences limit the applicability of this research to human FH. In 
particular, human FH primarily consists of LDL-cholesterol elevation in the 
bloodstream, while this cat model has elevated levels of triglyceride and 
cholesterol present in chylomicrons (66). Additionally, the genetics of the 
diseases differ: human FH is an autosomal dominant trait while the disorder in 
cats is autosomal recessive (67). These differences indicate that another animal 
model, such as mice or rabbits, may be more suitable for FH research. 
Furthermore, the use of companion animals such as cats and dogs for research is 
prohibited at the University of Maryland, thus making cats not an option for this 
project. 
Murine models are commonly used for many types of research, including 
studies of heritable hypercholesterolemia and other diseases similar to FH (68). 
Although research involving most vertebrate animals must be approved by the 
University of Maryland Institutional Animal Care and Use Committee (IACUC), 
the Animal Welfare Act exempts rats and mice from this regulation (69). Due to 
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this exemption, murine models are commonly used for research, including studies 
of heritable hypercholesterolemia and other diseases similar to FH (68). This 
model, however, is not an ideal analog of FH in humans because of intrinsic 
differences in the metabolic characteristics in both species (68).  
One specific murine model induces hypercholesterolemia by imposing 
dietary changes in the subjects to include foods high in cholesterol, saturated fats, 
and bile acids (68). However, this diet-induced method is not the most effective, 
because the mice must be continuously fed this diet in order to sustain high levels 
of plasma LDL- cholesterol. If the diet changes, normal levels of LDL-cholesterol 
will promptly return in the mice subjects. For this reason, this model cannot 
accurately represent FH in humans, as the mice still possess the gene responsible 
for producing fully functional LDL-R. The hyperlipidemia is transient and self-
correcting when the specialized diet is replaced with a standard diet (68).  
Another form of a murine model that has been studied is the LDL-R -/- 
mouse, in which the mice were homozygous for the deletion of the LDL-R gene. 
These mice are frequently referred to as “knock-out” mice because the gene of 
interest has been deleted from the genome (70). Studies have shown that FH in 
humans causes premature atherosclerosis and highly elevated plasma levels of 
LDL-cholesterol, while LDL-R -/- mice have only slightly elevated LDL-
cholesterol levels and little atherosclerosis. This can be attributed to the difference 
in the metabolism of LDL in the two species, specifically in the editing of 
apolipoprotein B, which transports cholesterol to tissues within the body (70). In 
an improved model of these LDL-R -/- mice, by additionally knocking out the 
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gene for the apolipoprotein B mRNA editing catalytic peptide-1 (APOBEC-1), 
mice have been bred with a lipoprotein profile that faithfully mimics that of 
humans with FH.  
Figure 2 below provides a graphical comparison of lipid levels in mice of 
different genotypes.  
Figure 2: Plasma cholesterol distribution in knock-out mice. The measurements were found 
using fast performance liquid chromatography and the measurements are in OD units / fraction, 
with the downward pointing arrows representing the elution peak for each of the lipoprotein 




Although this LDL-R -/-, Apobec -/- knock-out method induced 
spontaneously elevated lipid concentrations, premature atherosclerosis, and other 
clinical and metabolic signs similar to FH in humans, it is still not the most 
suitable model for studying FH (70). The knock-out mouse adequately mimics the 
symptoms, but not the pathology of FH because it does not possess the disease 
and thus LDL receptors are not synthesized at all. As previously described, 
humans with FH can still produce the LDL-R protein, but often times these 
individual’s receptors insufficiently operate and cannot remove enough LDL from 
the bloodstream (70). Therefore, mice are not the most accurate animal model for 
human FH.  
In comparison to the non-USDA regulated murine model, rabbits are a 
USDA-regulated species.  Additional benefits of using rabbits as the model 
include their docility, non-aggression, and short vital cycles, making rabbits easy 
to handle and observe (71). Their size also proves advantageous in that rabbits are 
big enough to provide sufficient tissue samples for experimental work and small 
enough to be economical for studies (72) Furthermore, because the rabbit liver, at 
1010 cells, is comparable in size to that of a human liver at 1011 cells, a similarly 
large number of viral particles is needed for adequate transduction. The WHHL 
rabbit strain, in particular, possesses the disease and exhibits symptoms of 
myocardial infarction, valvular diseases, and xanthomas. Both the phenotype and 




Discussed below are two different rabbit species that have been selected as 
the animal model and the justification for their use in studies related to FH.      
 
2.5.2 The Watanabe Heritable Hyperlipidemic Rabbit Model               
           The ideal animal model for FH displays genetic characteristics that are 
found throughout different stages of the human disease, ranging from fatty streaks 
in the early stages to plaques in advanced stages of disease (73). Lesions that 
occur in cholesterol-fed rabbits, one popular model, are different from those in 
humans, resembling more of a lipid-storage disorder rather than atherosclerosis 
(73). Such models involving induced diet changes are not optimal. Instead, the 
WHHL rabbit strain, which is similar both genetically and clinically to humans 
with FH, is the most characteristic animal model for FH. 
WHHL rabbits possess a twelve-base frameshift deletion, or a deletion of 
four amino acids, within the cysteine-rich ligand-binding domain in the gene that 
encodes LDL-R (74). This specific mutation results in the production of a 
receptor that is the approximate molecular weight of a functional LDL-R; 
however, the receptor is transported to the cell surface at one-tenth the rate of the 
WT LDL-R. Such retardation of the transportation of the LDL-R from the 
endoplasmic reticulum, where the protein is made, to the Golgi, where it is 
modified post-translationally and sent to the plasma membrane, is due to the 
improper formation of disulfide bonds in the protein, leading to misfolding of the 
protein (74). In addition, the frameshift deletion reduces the affinity of LDL-
cholesterol to its receptors so that the receptors, already few in number, that are 
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successfully transported to the cell’s surface are less effective at removing LDL-
cholesterol from the bloodstream (74). Ultimately, the cell is unable to internalize 
LDL-cholesterol, leading to high blood plasma LDL-cholesterol levels (75).  
A similar mutation that causes 95% fewer LDL-R proteins in an individual 
with FH was observed in human FH patients and confirmed via S1 nuclease 
mapping of their LDL-R RNA (74). On a genetic level, WHHL rabbits and 
humans with FH are comparable. Both still produce the defective LDL-R, unlike 
knockouts, which do not produce the receptor protein at all. 
Phenotypically, the reduction of LDL-R functionality in WHHL rabbits 
results in an atherosclerotic process starting in utero, with lesions in the aortic 
arch, deposition of cholesteryl esters in intimal and medial smooth muscle cells, 
and frequency of atherosclerotic plaques progressing with age (73, 76). 
 Homozygous WHHL rabbits have plasma cholesterol levels reaching 900 mg/dL, 
the majority of which is LDL-cholesterol, and have a lifespan of two to four years 
compared to six years in NZW rabbits (73).  
Though there are several phenotypic differences between humans with FH 
and WHHL rabbits, such as early distribution of lesions and involvement of the 
aortic valve with aortic stenosis, there are similarities as well (73). These 
similarities include the narrowing of the coronary ostia, with the progression of 
FH throughout the coronary arterial system, increased LDL-cholesterol levels in 
the bloodstream, and the presence of extensive tissue cholesterol deposits (73). 
Table 2 outlines the morphologic characteristics of homozygous and heterozygous 




1 NZW regression = NZW rabbits fed 2% cholesterol for 8 weeks, followed by 5 months of normal diet (age at time of 
sacrifice, 12 months). 
2 Associated with pulmonary hypertension in elderly patients 
3 Not examined 
4 From Atschul R: Selected Studies on Atherosclerosis, Springfield, IL, Charles C. Thomas, 1950. 
5 Kjaernes et al. (Acta Pathol Microbiol Scand (A) 1981, 89:35) have noted a difference between human and cholesterol-
fed animals for the localizationof 
   lipid at arterial branches. 
6 Aorta. 
7 Transmural infarction was found in 8 of 67 hearts from WHHL homozygotes examined by Hatanaka et al. 
8 Homozygous familial hypercholesterolemia. 
NZW rabbits were fed 0.5% cholesterol and 2% penut oil for 24 weeks and were 7 months of age at the time of sacrifice. 
WHHL homozygous rabbits were 12 months of age. 
 
Table 2: Summary of morphologic findings in homozygous WHHL rabbits compared with cholesterol-fed 
 WHHL heterozygous and cholesterol-fed control (New Zealand White, NZW) rabbits and humans 








Distribution of atherosclerosis      
    Proximal aorta + + + + + + + + 
+ + + 
+ + + + + + + 
    Distal aorta + + + + + + + + + + + + + + + + 
    Pulmonary artery  + + + + + + 
+ + + 
+ + + + +2 
    Cerebral artery + + NE3 +4 + + + + 
    Coronary artery      
        Epicardial + + + + + + + + + + + + + + 
        Intramyocardial + + + + + + + + + + + + 
    Involvement at flow dividers + + + + + + + + + + + + + + +5 
      
Lesion types      
    Fatty streaks + + + + + 0 + + 
    Fibrous plaques + + + + + + + + + 
    Fatty plaques + + + + + 0 + + 
    Complicated lesions + + + + + + + + + + + + + + + + + 
      
Lesion histology7      
    Foam cells + + + + 
+ + + 
+ + + 
    Cholesterol clefts + + + + + + + + + + + + + + 
    Fibrous caps + + + + + + + + + + + + + 
    Calcification + + + + + + + + + + + + 
    Necrosis + + + + + + + + + + + 
    Ground substance + + + + + + + + + + + + + + 
    Smooth muscle + + + + + + + + + 
    Collagen + + + + + + + + + + + + 
      
Myocardium      
    Focal fibrosis + + + + + + + + + + + 
    Healed infarction      
        Subendocardial + + + + + + + + + + + + + 
        Transmural +8 0 0 0 + + + 
      
Extravascular lipid + + + + + + + + +3 
Xanthomas + + + 0 0 + + +3 
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WHHL rabbits and individuals with FH share both genetic and phenotypic 
characteristics, making WHHL rabbits the best representation of this disorder in 
humans.  
 
2.5.3 Pathophysiology of WHHL Rabbits 
WHHL rabbits are a fitting model for human FH because of the 
similarities between the pathophysiologies of the two organisms. In WHHL 
rabbits, different levels of LDL-cholesterol plasma concentration indicate 
differing amounts and functionalities of LDL-R since they are responsible for 
internalizing LDL-cholesterol. In order to determine what caused the specific 
effect, previous experiments involving WHHL rabbits and LDL-cholesterol have 
included Western blotting of hepatocytes in order to determine if proper protein 
expression was achieved (77). WHHL rabbits, which develop 
hypercholesterolemia and atherosclerosis spontaneously due to genetic and 
functional deficiencies of the LDL-R, present with higher concentrations of LDL-
cholesterol in the blood than standard NZW rabbits.  
According to a 1982 study by Havel, et al.,  involving autoanalyzation of 
lipoprotein, triglyceride, and total cholesterol concentrations, female WHHL 
rabbits typically exhibit an LDL-cholesterol plasma concentration of 338 mg/dL 
as compared to the average of 11.9 mg/dL in NZW females - approximately a 30-
fold increase. A 20-fold increase is observed in males with respect to LDL-
cholesterol, while WHHL rabbits of both sexes have slightly lower plasma 
concentrations of high-density lipoprotein (HDL). Various other measurements, 
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including very low-density lipoprotein (VLDL) and intermediate-density 
lipoprotein (IDL) concentrations, are displayed in Table 3 below. (78) 
 
Concentration of total cholesterol and triglycerides in plasma 
and lipoprotein fractions of normal and WHHL rabbits (mg/dL) 
  Serum VLDL IDL LDL HDL 
Total cholesterol      
   Control Japanese males 38.3 ± 12.6 9.0 ± 7.8 6.7 ± 3.5 12.0 ± 3.5 7.0 ± 2.7 
   WHHL males 731.3 ± 53.2 91.7 ± 10.1 46.7 ± 20.0 451.3 ± 16.5 6.0 ± 2.7 
      
   Control NZW males 58.5 ± 1.9 17.0 ± 7.2 7.8 ± 3.5 11.5 ± 3.3 22.3 ± 4.4 
   WHHL males 487.5 ± 75.8 110.3 ± 41.5 116.3 ± 26.4 218.0 ± 68.1 8.3 ± 2.9 
      
   Control NZW females 46.8 ± 4.0 15.5 ± 4.4 8.5 ± 1.7 11.8 ± 1.3 18.0 ± 2.5 
   WHHL females 582.0 ± 143.3 106.0 ± 23.8 110.7 ± 21.1 338.0 ± 100.5 12.3 ± 2.5 
      
Triglycerides      
   Control Japanese males 64.3 ± 37.8 37.3 ± 30.4 7.0 ± 3.0 12.7 ± 4.0 5.0 ± 2.7 
   WHHL males 288.3 ± 106.1 57.0 ± 18.5 23.3 ± 12.9 162.0 ± 39.9 1.7 ± 1.1 
      
   Control NZW males 213.3 ± 27.4 128.5 ± 37.0 14.0 ± 5.8 15.5 ± 3.9 24.8 ± 4.9 
   WHHL males 435.0 ± 94.7 153.5 ± 48.0 78.3 ± 26.0 146.0 ± 32.8 4.8 ± 2.8 
      
   Control NZW females 108.0 ± 43.5 62.5 ± 32.5 11.8 ± 1.9 11.8 ± 1.7 24.7 ± 6.5 
   WHHL females 308.7 ± 128.8 124.0 ± 80.7 47.0 ± 21.7 129.7 ± 19.5 8.7 ± 1.5 
Table 3. Comparison of lipid profiles between control and WHHL rabbits (2) 
 
High blood concentration of LDL-cholesterol can contribute to the 
formation of atheroma. Macrophages engulf LDL-cholesterol, die, and become 
part of the atheroma. Advanced atheroma can result in infarction, ischemia, and 
aneurysms. While both alanine aminotransferase and alkaline phosphatase are 
found in various tissues throughout the body, elevated levels in the blood could be 
indicative of liver damage (79). Typically, alanine aminotransferase is found in 
very small concentrations in the rabbit liver. In rabbits, the normal range is 25-
65IU/L (80). Significantly high levels are associated with hepatic damage and 
necrosis (79). However, the severity of the increase is not correlated with the 
severity of the disease (80). Alkaline phosphatase is expressed in the plasma 
membrane of hepatocyte cells that border the bile canaliculus, a structure 
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associated with the collection of bile. Normal levels are 10-70IU/, however its 
range varies widely among healthy rabbits (80). Increased levels of this enzyme 
can be associated with conditions of biliary stasis in which there is limited bile 
flow out of the liver (79).  
 
2.6 Liver-Targeted Vector Delivery  
     The delivery route of the chosen vector to the targeted cells or organ can 
effect transduction. Several methods for gene delivery include ex vivo, in vivo, in 
utero, and surgical procedure; however, for the purpose of this study, only two 
methods that focus on delivering genes specifically to the liver will be discussed, 
hepatic portal vein injection (surgical) and peripheral ear vein injection (in vivo). 
 
2.6.1 Hepatic Portal Vein Injection 
     The liver is one of the most complex organs for mammalian species, as it 
performs nearly 500 different functions including the regulation of cholesterol by 
synthesizing and exporting cholesterol to other cells and removing cholesterol and 
converting it into bile. Approximately 1.5 liters of blood/minute circulates 
through the liver, and the organ can hold nearly 10% of the body’s total blood 
volume. Of the blood that passes through the liver, nearly 75% is derived from the 
hepatic portal vein, the blood vessel responsible for moving blood from the 
gastrointestinal tract to the liver. Unlike most veins, the hepatic portal vein does 
not deliver blood directly to the heart (81,82).  
      Gene delivery by hepatic venous injection occurs by first accessing and 
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installing ligatures, or sutures, around the jugular vein to prevent any blood flow 
to the area. An angiocatheter, later replaced by a balloon catheter, is then inserted 
into the vein and a guide wire penetrates the hepatic vein with a fluroscopic 
control. After gaining access to the hepatic vein, a volume of solution containing 
the viral vector is then injected directly into the vein (83). 
      Delivering a viral vector solution into the hepatic vein allows for the virus 
to directly target the liver without affecting numerous other organs and cells. The 
biggest risk with this procedure is the possibility of complications during surgery 
including blood loss, hepatic injury, and hemorrhage due to the force of injected 
fluid. A surgical procedure of this nature also requires highly skilled and trained 
surgeons with the appropriate lab equipment to avoid complications.  
 
2.6.2 Ear Vein Injection 
     Injection of a viral vector via a peripheral vein may be the simplest 
method of delivering a virus to host cells. Peripheral veins are the most common 
access point for intravenous therapy in hospitals and paramedic services (84). If 
the virus has high specificity for the target organ, viral injections through 
peripheral veins may be appropriate as the injected serum will preferentially 
target the tissue of interest even though such an injection would lead this virus to 
pass through several organs on the way to the liver (85). Because AAV6 and 
AAV8 show high liver specificity, injection through a peripheral vein may be an 
adequate method for gene delivery to the liver (55-58). Research into the injection 
of vectors through the rodent tail vein causes a large volume of the injected 
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solution to be forced into the vena cava, creating a backup of fluid that ultimately 
ends up in the liver. Reports have found transgene expression levels 
approximately 100-fold lower in the heart, spleen, and kidney than in the liver 
after viral injection in rodents (85).  
For rabbits in particular, the marginal ear vein, a peripheral vein, is commonly 
used for the removal of blood and intravenous injections (84). Preliminary 
research of marginal ear vein injections in rabbits has shown similar results as tail 
vein injections in rodents.  Injections through the marginal vein are a safe and 
effective method of obtaining high levels of gene transfer in the liver without 
















Chapter 3: Isolation, Cloning, and Sequencing of the Rabbit LDL-R 
3.1 Total RNA Isolation 
The full-length rabbit LDL-R mRNA was isolated from liver tissue. A 
NZW rabbit was sacrificed after deep anesthesia, then pieces of liver tissue were 
collected, snap-frozen in liquid nitrogen, and stored at -80°C until further 
processing. To isolate total RNA, approximately 1 g of frozen rabbit liver tissue 
was initially ground in liquid nitrogen using a mortar and a pestle, and 
subsequently dissolved in 10 mL of Trizol reagent (Invitrogen, Carlsbad, CA), an 
acidic solution of phenol and guanidine isothiocyanate. RNA isolation was 
completed using the Trizol reagent and the Chomczynski and Sacchi method for 
the single-step RNA isolation by acid guanidinium thiocyanate-phenol-
chloroform extraction (86). The quality and concentration of the isolated total 
RNA was determined by UV spectrophotometry (A260/A280) using a NanoDrop 
spectrophotometer. An A260/A280 ratio greater than 1.8 was considered 
acceptable for downstream applications. 
 
3.2 Isolation of mRNA from Total RNA 
In mammalian cells, mRNA comprises approximately 2% of total RNA. 
Generally, successful 5’ and 3’ RACE procedures require a sample enriched with 
mRNA. The low mRNA concentrations in the sample necessitate isolation of 
mRNA from total RNA. Eukaryotic mRNA has a poly-A tail whereas other 
eukaryotic RNAs do not. Based on this property, mRNA was separated from total 
RNA using an illumina Oligo(dT)-cellulose column (GE Healthcare, Carlsbad, 
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CA). mRNA molecules containing poly-A tails hybridize to the oligo(dT) 
cellulose column whereas other RNA molecules pass through the column. For 
every 1.2 mg of total RNA or approximately 31 A260 units, 50 µg of a mRNA-
enriched sample was obtained after single passage through a column. A second 
passage through a column resulted in isolation of approximately 25 µg of mRNA 
with a purity greater than 90%.  
 
3.3 RLM-RACE 
RNA-ligase mediated rapid amplification of cDNA ends (RLM-RACE) 
was used to amplify the NZW LDL-R cDNA for sequencing. The ExactSTART 
Eukaryotic mRNA 5’ & 3’ RACE Kit was used (Epicentre, Madison, WI). 
START stands for “Selective Tagging and Amplification of RNA Transcripts.” 
The kit uses a series of RNA-modifying enzymes and oligonucleotide adaptors to 
isolate and amplify a specific cDNA product through the following steps: 1) DNA 
synthesis by reverse transcription, 2) non-selective cDNA amplification, and 3) 
primer-specific cDNA amplification. This procedure allows for isolation and 




3.3.1 mRNA Enzyme Treatment and Adaptor Ligation 
Initially, RNA was treated with a series of enzymes to ensure that only 
full-length mRNAs with intact 5’ and 3’ ends will undergo reverse transcription. 
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Full-length mRNAs have a cap structure at the 5’ end and a poly-A tail at the 3’ 
end. The first enzyme, heat-labile alkaline phosphatase, was used to remove the 
phosphate group at the 5’ end of every uncapped mRNA strand. Alkaline 
phosphatase replaces this phosphate group with a hydroxyl group, preventing 
degraded mRNAs from participating in subsequent adaptor ligation steps. 
Tobacco acid pyrophosphatase was then used to remove the 5’ cap from the intact 
mRNAs, facilitating adaptor ligation at the 5’ end. After removal of the cap, RNA 
ligase was used to ligate an oligonucleotide adaptor to the 5’ end of the RNA. 
 
3.3.2 Reverse Transcription of mRNA and Non-selective cDNA Amplification 
The reverse transcription reaction used an extended oligo-dT primer 
consisting of an oligo(dT) sequence appended with a PCR priming site sequence 
at its 5′ end. The full-length cDNA molecules resulting from this reverse 
transcription reaction were amplified non-selectively to form a cDNA library 
using:  
 




2) a reverse primer located within the previously described PCR priming 





3.3.3 Selective Amplification of the LDL-R cDNA 
The amplified cDNA library from the previous reaction was used to 
selectively amplify parts of the LDL-R cDNA in three separate PCR reactions 
using three sets of primers: 
 
A) The 5’ end of the LDL-R mRNA was selectively amplified using the 
forward primer within the sequence of the 5’ RACE oligonucleotide 
adaptor and an internal LDL-R gene-specific reverse primer  
(5’-AGACGTGCTCCCAGGACGAGT-3’), designed from a partial 
sequence of the rabbit LDL-R mRNA previously reported on Genbank.  
 
B) The 3’ end of the LDL-R mRNA was selectively amplified using the 
reverse primer within the sequence of the extended oligo-dT primer and an 
internal LDL-R gene-specific forward primer  
(5’-CACTGGAAATGCGACGGCCAG-3’) designed from a partial 
sequence of the rabbit LDL-R mRNA previously reported on Genbank. 
The gene-specific forward primer in this reaction was upstream of the 
reverse primer used in the previous reaction to ensure complete coverage 
of the full-length LDL-R mRNA. 
 
C) The full-length LDL-R ORF from the initiation codon to the 
termination codon was amplified using the forward primer  
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(5’-ACCGGTGCCACCATGAGGACGGCGCGCTGGGT-3’) and the 
reverse primer (5’-TGGAGGACGACGTGGCCTGATAACTCGAG-3’) 
designed after sequencing the 5’ and 3’ RACE products described above. 
These primers also contained a Kozak sequence, as indicated by italics, 
and unique restrictions sites, as indicated by underlining, for convenient 
subsequent cloning in an expression vector. This amplification product 
was cloned into a pPCR-Script plasmid to verify the sequence before 
further downstream applications.  
 
After purification, the amplified cDNA products from the 5’ and 3’ RACE 
procedures, using primer sets A and B as listed above, were cloned individually 
into the pPCR-script cloning vector via the process described in section 3.3.4. The 
sequence of the complete 5’ UTR of the LDL-R mRNA, as well as part of the 
ORF that was previously unknown, was obtained by sequencing the pPCR-script 
cloning vector containing the product from the 5’ RACE reaction. The sequence 
of the complete 3’UTR of the LDL-R mRNA was obtained by sequencing the 
pPCR-script cloning vector containing the product from the 3’ RACE reaction. 
All non-selective and selective amplifications described above were performed 
using the proof-reading polymerase pHusion (New England Biolabs, Ipswich, 
MA) instead of Taq polymerase, which introduces mutations at a higher rate. In 
addition, the use of a polymerase with proof-reading activity allows for direct 
cloning of the PCR products in blunt-end ligations. The PCR products from the 
selective amplifications were purified using a StrataPrep PCR Purification Kit 
53 
 
(Agilent Technologies, Santa Clara, CA) before cloning, and the integrity and 
quality of the PCR products were evaluated by gel electrophoresis. 
 
3.3.4 pPCR Script Cloning 
The PCR-Script Amp Cloning Kit (Stratagene, La Jolla, CA) was used to 
clone the LDL-R cDNA products described in section 3.3.3. The kit permits the 
efficient cloning of PCR fragments with a high yield and a low rate of false 
positives. The kit provides a linearized vector with a rare SrfI (nucleotide 
sequence accession #: U46017) restriction site. In the ligation reaction, the 
predigested vector and the PCR product are mixed at an insert-to-vector ratio of 
100:1 with a ligase and the SrfI enzyme. If the vector self-ligates without the 
insert, it recreates the SrfI restriction site, allowing it to be redigested until it 
contains the insert. If the insert is ligated into the vector, the SrfI site is destroyed, 
and the vector can no longer be digested by the SrfI enzyme. This enhances 
cloning efficiency, especially with large inserts. The ligation reactions were then 
transformed to XL10-Gold ultracompetent bacterial cells using the heat-shock 
method. The transformation reactions were then plated in LB ampicillin agar 
plates that also contained X-Gal and isopropyl β-D-1-thiogalactopyranoside 
(IPTG) for blue-white screening. After overnight incubation for colony formation, 
several white colonies were picked and grown in 5 mL of LB broth supplemented 
with 100 mg/mL ampicillin overnight at 37°C. Plasmid minipreps were performed 
using the alkaline lysis method and Qiagen prep columns (Qiagen, Valencia, CA). 
The insert cloned in the pPCR-Script plasmid was sequenced using M13 forward 
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and M13 reverse primers via DyeDeoxy terminator cycle sequencing with an ABI 
3730 sequencer.  
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Chapter 4: In Vivo Study to Determine Optimal rAAV Serotype for Rabbit 
Liver Transduction 
Prior to production of a recombinant virus containing the LDL-R ORF, the 
most efficient rAAV serotype for hepatocyte transduction and gene expression 
was determined in healthy NZW rabbits. Rabbits were treated with either 
recombinant AAV6 or AAV8, containing LacZ ORF downstream of a CMV 
promoter. Liver samples were then analyzed for transduction ability using qPCR 
and gene expression using β-galactosidase assays. The serotype that caused 
greatest expression levels was then chosen for mass-production. rAAV6-LacZ and 
rAAV8-LacZ were provided as a generous gift from Dr. Robert Kotin from the 
NIH. 
 
4.1 Rabbit Care 
All group members completed online BioSafety Level 2 training through 
the Department of Environmental Safety at the University of Maryland, as well as 
online rabbit care training through the American Association of Laboratory 
Animal Science. Group members were also trained in person on proper animal 
care and handling techniques by Dr. Doug Powell, Dr. Ioannis Bossis, and 
research specialist Yonas Araya. Animal Study Protocol #R-11-38 was submitted 
to the UMCP Institutional Animal Care and Use Committee and approved on 
August 26, 2011. Twelve 3-month-old female NZW rabbits were obtained from 
Charles River Laboratories in November 2011. 
Rabbits were housed in room 1420S/1420T of the Gudelsky Building 
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(795), Department of Veterinary Medicine, University of Maryland. The rabbits 
were housed one per cage for the duration of the study. Rabbits were acclimated 
for a period of several weeks with food and water provided ad libidum. Fresh 
food and water were replenished once daily. Bedding, water, and food containers 
were changed weekly. Temperature, humidity, and health status were recorded 
daily. Rabbits were given enrichment in the form of plastic toys. 
 
4.2 Baseline Data Collection and Analysis 
Upon acclimation, rabbits were weighed to determine the amount of 
anesthesia necessary for surgical procedures. Initial blood samples were drawn 
from each rabbit before injection via the marginal ear vein and stored at -80°C, as 
taken from the submitted animal protocol. 
 
4.3 Injection of rAAV6-LacZ and rAAV8-LacZ 
Rabbits were randomly assigned a number 1-12 and grouped by viral 
serotype. Five rabbits were placed into each of two groups for rAAV6 and rAAV8 
serotypes, respectively. Two rabbits were intended to be used as controls, but one 
died before the study began. Within each experimental group, three rabbits were 
sacrificed 10 days post-injection, and the remaining two were sacrificed 28 days 













NZW Rabbit Group Assignments 
    
Rabbit number AAV serotype 10-day sacrifice 28-day sacrifice 
1 none (control) died prematurely  
2 none (control)  x 
3 8  x 
4 8  x 
5 6  x 
6 6  x 
7 6 x  
8 6 x  
9 6 x  
10 8 x  
11 8 x  
12 8 x   
Table 4. NZW rabbit group assignment. Rabbits were randomly assigned into five groups: two 
control, three rAAV6 10-day sacrifice, two rAAV6 28-day sacrifice, three rAAV8 10-day 
sacrifice, and two rAAV8 28-day sacrifice. Rabbit 1, designated as a control, died before the study 
began. 
 
After an acclimation period of several weeks, each experimental rabbit 
was injected through the ear vein with 2x1013 particles of either rAAV6-LacZ or 
rAAV8-LacZ in 5 mL of saline. The control rabbit was injected with saline only.  
 
4.4 Experimental Data Collection 
Blood samples were taken after one week and three weeks post-injection 
and stored at -80°C. After the designated time period (10 or 28 days), rabbits were 
sacrificed. High dose anesthesia, 50 mg/kg ketamine and 15 mg/kg xylazine, was 
administered into the thigh muscle of the rabbit. Rabbits were then observed for 
movement. Once movement ceased, pupils were examined for light reactivity. 
Once the rabbit was confirmed to be unconscious, it was exsanguinated and then 
asphyxiated in a CO2 chamber. 
The liver, gall bladder, lungs, heart, ovaries, and pancreas were isolated. 
Each organ (except for the liver) was stored individually in 50 mL conical tubes 
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and frozen at -80°C immediately following removal. Carcasses were double-
bagged in autoclaved bags and incinerated. 
 
4.5 Qualitative Analysis of β-galactosidase Activity in Liver Samples 
 
Representative liver samples from each lobe were frozen in 1.5 mL tubes 
for the determination of rAAV genome copy numbers and quantification of β-
galactosidase expression. In addition, fresh liver samples were processed for the 
qualitative evaluation and visualization of LacZ staining in liver tissues. For that 
purpose, fresh liver from different areas of the tissue was sectioned into 1 mm 
slices using a tissue slicer, washed in cold phosphate buffered saline (PBS) to 
remove excess blood, and fixed in β-galactosidase fixative (0.5% glutaraldehyde, 
2% paraformaldehyde, 0.1M phosphate buffer pH=7.3, 3mM MgCl2, 3mM 
EGTA, 0.01% sodium deoxycholate, 0.02% NP-40) for one hour at room 
temperature. Subsequently, the tissue slices were washed with a washing buffer 
several times for a duration of 60 minutes and finally incubated in β-galactosidase 
staining solution (0.1M phosphate buffer pH=7.3, 3mM MgCl2, and 0.01% 
sodium deoxycholate, 0.02% NP-40, 5mM ferricyanide, 5mM ferrocyanide, 
1mg/mL X-gal). Pictures were taken of each sample the day after staining. The 
colors of liver samples treated with rAAV6-LacZ vs. rAAV8-LacZ were 
compared to determine which had a greater rate of viral gene expression. 
 
4.6 Quantitative Analysis of β-galactosidase Activity in Liver Samples 
 
Liver tissue from sacrificed animals was cut in pieces, flash frozen in 
liquid nitrogen, and stored at -80°C until analyzed. For the β-galactosidase assay, 
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liver tissue pieces were cracked with a liquid nitrogen-chilled mortar and pestle, 
and pieces weighing approximately 50 mg were collected for extraction. Tissue 
pieces were extracted with 1mL of extraction buffer (100 mM potassium 
phosphate buffer, 0.2% Triton X-100, 1 mM dithiothreitol, 0.2 mM PMSF, 5 
µg/mL leupeptin) using a dounce homogenizer (87). The homogenized samples 
were then clarified by centrifugation at 10,000 x g for 10 minutes. The clarified 
supernatant was collected and heated at 48°C for 60 minutes to inactivate 
endogenous β-galactosidase activity. Total protein concentration in the samples 
was measured using the bicinchoninic acid (BCA) assay against a bovine serum 
albumin (BSA) standard (Pierce, Rockford IL). β-galactosidase activity in the 
samples was measured using the Galacto-Light Plus™ kit (Applied Biosystems, 
Bedford, MA). Galacton-Plus® is a modified X-gal molecule; when β-
galactosidase cleaves the molecule, it emits light in the form of 
chemiluminescence, which is measured with a luminometer (Turner, Sunnyvale, 
CA). As the amount of β-galactosidase in the sample increases, more light will be 
emitted. Therefore, relative amount of chemiluminescence indicates relative 
amount of β-galactosidase activity in the tissues. Data were normalized based on 
total protein concentration and presented as relative luminescence units (RLU) per 
milligram of protein. 
 
4.7 qPCR of Liver Samples 
 
Total genomic DNA were isolated from liver samples using an 
autonomated Maxwell 16 DNA isolation system and Maxwell 16 purification 
DNA cartridges (Promega, Madison, WI). The samples were analyzed by qPCR 
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using spectrophotometry of cyber green dye. Four samples from different lobes of 
each rabbit liver were analyzed and 2 by 2 ANOVA with nested design was 
performed on the results. Log10, log2, inverse, and square root transformations 
were performed on the data and log10 transformation was found to best normalize 
the variance. 
qPCR was performed on a LightCycler 2.0 (Roche Applied Science, 
Indianapolis, IN ) using 30 ng of genomic DNA in duplicates. All reactions were 
performed in a 20 µl final volume containing 5 µL of template DNA, 10 µL of 
Premix Ex Taq (TaKaRa, Otsu, Japan), 0.4 µL of ROX Reference Dye (TaKaRa), 
0.2 µmol/L of each primer, and 0.1 µmol/L of probe. rAAV copy numbers were 
determined using primers and a probe designed to specifically amplify part of the 
CMV promoter from cytomegalovirus. Genomic DNA copy numbers were 
determined using primers and a probe designed to amplify part of the rabbit b-
actin gene. For each sample, Ct values were compared with those obtained with 
standard dilutions of plasmid containing either the CMV promoter or the rabbit b-
actin sequence. The thermal profile for qPCR was identical for all reactions: 5 





Chapter 5: Construction and Mass-Production of rAAV8-LSP-LDL-R 
 
5.1 Production of pFBVG-LSP-LDL-R Plasmid 
  
Following the cloning of the full length rabbit LDL-R described earlier, an 
XhoI restriction enzyme site was found within the ORF. In order to subclone the 
LDL-R ORF from the pPCR-Script plasmid (Figure 3) to a baculovirus transfer 
vector, an XhoI restriction enzyme digestion was required. As such, the XhoI site 
within the ORF needed to be removed without changing the amino acid to 
maintain the integrity of the ORF upon restriction enzyme digestion. Thus, site-
directed mutagenesis was performed resulting in a mutant plasmid pPCR-Script.  
 
Figure 3. pPCR-Script Plasmid. This plasmid contains the LDL-R ORF with appropriate 
restriction sites post-site-directed mutagenesis. 
 
To create a rAAV, the gene of interest must be inserted into a shuttle 
plasmid containing ITRs, a promoter, and a SV40 polyadenylation site. As such, 
the cytomegalovirus (CMV) promoter and LDL-R gene were subcloned into the 
digested pFBGR plasmid (Figure 4), creating pFBVG-CMV-LDL-R (Figure 5), 
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which contained all the necessary elements for the rAAV viral genome. In 
addition, pFBGR is a polyhedrin-based baculovirus transfer vector plasmid that 


















Figure 5. pFBVG-CMV-LDL-R plasmid. This plasmid contains the LDL-R ORF flanked by 
XhoI/AgeI restriction sites along with the CMV promoter from the pFBGR backbone. 
 
For the purpose of creating pFBVG-CMV-LDL-R, pPCR-LDL-R and 
pFBGR were digested with XhoI/AgeI. The digested plasmids were then run 
through gel electrophoresis in order to separate the LDL-R ORF from the linear 
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pPCR-Script DNA, and linear pFB from the GFP ORF. The components 
corresponding to the cDNA of the LDL-R and the linear pFB DNA were observed 
under UV light from a transilluminator. The LDL-R cDNA was isolated using a 
QIAGEN gel extraction kit (QIAGEN, Valencia CA). 
After purification, the LDL-R insert and linear pFB were ligated to create 
the circular pFBVG-CMV-LDL-R plasmid. In order to amplify this plasmid, 
bacterial cells were transformed with the ligated, circular pFBVG-CMV-LDL-R. 
After transformation and overnight plating in ampicillin LB-agar plates, several 
colonies were isolated and grown overnight in 5 mL LB broth for preparation of 
plasmid minipreps. Plasmid minipreps were digested again with XhoI/AgeI to 
confirm insertion of the LDL-R ORF in the linearized pFBGR. 
Following confirmation of successful insertion of the LDL-R ORF into the 
linearized pFBGR, a maxi-prep of the plasmid was prepared using a QIAGEN 
HiSpeed Plasmid Maxi-Kit (QIAGEN, Valencia CA). Integrity of the ITRs was 
confirmed by DNA sequencing. Expression of the LDL-R protein was confirmed 
by transfection of the pFBVG-CMV-LDL-R plasmid in mammalian cells 
(HEK293) using the FuGene HD reagent (Roche Applied Science, Indianapolis, 
IN). FuGene 6 is a transfection reagent composed of a blend of lipids in 80% 
ethanol. When mixed with DNA, FuGene HD forms a complex, which assists in 
transporting the DNA into mammalian cells. Two days post-transfection, total cell 
lysates were prepared and subjected to sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) and western blotting using a rabbit polyclonal 
antibody raised against human LDL-R (Abnova, Walnut, CA). The initial strategy 
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was to use this plasmid for large-scale production of rAAV-LDL-R. However, it 
was determined in the NZW rabbit study that expression using the CMV promoter 
was largely silenced 10 days post-injection and even more so 28 days post-
injection. Therefore, the CMV promoter was replaced with a liver-specific 
promoter that is known to induce long-term expression when used within a rAAV 
vector (88).  
 
5.2 Production of rAAV Via Recombinant Baculovirus/Insect Cell System 
The protocol described in the following sections was performed in Dr. 
Robert Kotin’s lab at the NIH. 
 
5.2.1 Insertion of the rAAV-LDL-R Expression Cassette into Bacmid 
In order to insert the rAAV-LDL-R expression cassette (LITR-LSP-LDL-
R-polyA-RITR) construct into a bacmid, the Bac-to-Bac system was used 
(Invitrogen, Carlsbad, CA). Specifically, competent Bac-DH10 cells were 
transformed with pFBVG-LSP-LDL-R. These cells are pre-transformed with a 
bacmid that has a mini-attTn7 target site and a helper plasmid from which 
transposition helper proteins are produced. Insertion of the rAAV cassette by 
homologous recombination occurred by transposition between this mini-attTn7 
site and the mini-Tn7 sites flanking the rAAV-LDL-R expression cassette in 
pFBVG-LSP-LDL-R. Following transformation, the Bac-DH10 cells were 
incubated on an agar plate with 50 μg/mL kanamycin, 7 μg/mL gentamicin, 10 
μg/mL tetracycline, 100 μg/mL X-gal, and 50 μg/mL IPTG for 72 hours at 37°C. 
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Because the helper plasmid, the bacmid, and pFBVG-LSP-LDL-R confer 
resistance to kanamycin, gentamicin, and tetracycline, these antibiotics ensure that 
only the transformed Bac-DH10 cells with the helper plasmid, the bacmid, and 
pFBVG-LSP-LDL-R can grow. Importantly, the bacmid contains a β-
galactosidase ORF that is disrupted upon insertion of the construct by 
transposition. For this reason, only Bac-DH10 cells containing bacmid without 
insert had β-galactosidase expression. Because the agar plate contains X-gal and 
IPTG, which triggers the transcription of the β-galactosidase ORF, disruption of 
the β-galactosidase ORF was screened by examining colonies for color. 
Specifically, because β-galactosidase catalyzes the formation of a blue product 
from X-gal, blue colonies had bacmid that contained the intact β-galactosidase 
ORF and, therefore, lacked the insert. For this reason, only white colonies were 
picked. 
 
5.2.2 Purification of Bacmid 
Five white Bac-DH10 colonies were picked and each was grown 
separately overnight in 9 mL LB with kanamycin, gentamicin, and tetracycline 
with agitation at 37°C. Bacmid from each of these overnight cultures was purified 
by miniprep and screened for insert by PCR with LSP-specific primers. 
 
5.2.3 Verification of ITR Function by Rescue Assay 
In order to determine whether the ITRs were intact after transposition into 
the bacmid, a rescue assay was performed. Sf9 cells were cotransfected with 
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bacmid containing the construct and superinfected with bac-rep (recombinant 
baculovirus expressing rep). The resulting cells expressed the two AAV rep 
proteins, which, in the absence of cap proteins, replicated DNA flanked by intact 
ITRs without packaging.  48,72, 96 and120 hours post-infection a fraction of 
sample was collected and the DNA contained in the Sf9 cells was purified and run 
on gel electrophoresis. A band of approximately 4.2 kb composed of the amplified 
construct (LITR-LSP-LDL-R-RITR) was observed, indicating that the ITRs were 
functional. In contrast, if the ITRs were defective, the rep proteins would not have 
replicated the construct, so a band with the mass of the construct would not have 
been observed. 
 
5.2.4 Transformation of Sf9 Cells for Production of P1 Baculovirus 
In order to produce P1 baculovirus containing the rAAV-LDL-R 
construct, Sf9 cells were transfected with one of the bacmids determined to have 
rAAV-LDL-R inserted genome. To prepare Sf9 cells for transfection, 106 cells in 
2 mL Sf9 media were allowed to attach to a well of a 6-well plate during a 30 
minute incubation at 27°C. Solution A and Solution B were prepared the day of 
the transfection. Solution A consisted of 600 μL Grace’s medium without 
supplement and 30 μg miniprep-purified bacmid. Solution B consisted of 600 μL 
Grace’s medium without supplement and 30 μL CellFECTIN. Solutions A and B 
were mixed and incubated for 30 minutes at room temperature. Immediately 
before transfection, the supernatant was removed from the attached Sf9 cells, and 
4.8 mL of Grace’s medium were added to the mixture of Solutions A and B. 1 mL 
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of the resulting mixture was added dropwise to each well with attached Sf9 cells. 
Sf9 cells were incubated in this mixture for 5 hours at 27°C. After incubation, this 
mixture was removed by aspiration; the Sf9 cells were incubated in complete 
medium for 96 hours at 27°C. By the end of this incubation, baculovirus 
containing the construct was present in the supernatant. 
 
5.2.5 Determination of Viral Titer 
Since production of P2 virus requires viral titer of about 107 particles per 
mL, it was necessary to determine the titer of the P1 baculovirus in the 
supernatant of the Sf9 cells via a plaque assay. Serial dilutions of the P1 
supernatant were placed over attached Sf9 cells that were nearly confluent. These 
cells were incubated for 1 hour at 27°C, and the supernatant was then removed. 
To prevent the diffusion of viral particles produced during the plaque assay, an 
agarose overlay was applied containing Sf9 medium. The Sf9 cells were 
incubated for 6-10 days at 27°C to allow plaque formation. To determine viral 
titer, the plaques were counted. 
 
5.2.6 Titerless Infected-cells Preservation and Scale-up (TIPS) 
100 mL of Sf9 culture (at 2x106 per mL density) was infected with 2x106 
PFU of recombinant baculovirus for 72 hours at 27°C. When the diameter of the 
infected Sf9 cells (TIPS) reached 17-18 microns with viability 90-95% as 
determined using a cell-counter, they were frozen at 2x107/mL. The viral titer in 
the TIPS was determined by plaque assay as described above, and was ensured to 
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be at least 108 PFU/mL before it was used to infect Sf9 suspension cells for rAAV 
production.  
 
5.2.7 Production of rAAV from Sf9 Suspension Cells 
For small-scale production of rAAV, 500 mL of Sf9 cells were infected 
with the baculovirus containing the rAAV-LDL-R construct and with a 
baculovirus containing rep and cap genes. The ratio of rep and cap proteins to 
rAAV genomes must be sufficiently low to minimize production of empty viral 
particles. In order to avoid overproduction of rep and cap proteins relative to 
recombinant genomes, a stock of TIPS was used with baculovirus with the genes 
for rep and cap that had already been optimized for rAAV production (61). The 
optimal ratio of Sf9 cells to TIPS had been determined to be 1:10,000. The same 
ratio of Bac-rep-cap TIPS was used. For this reason, 0.050 mL from both TIPS 
were used to infect 20 L of Sf9 culture (2x106/mL cells). The cells were grown for 
72 hours at 27°C with agitation. Infected cells were monitored for diameter and 
viability.  
To assess the quality of the rAAV produced from Sf9 cells, a small 
amount of virus was purified by CsCl gradient centrifugation and inspected by 
TEM and SDS-PAGE followed by silver stain for viral proteins. The lysate was 
incubated with 4% PEG8000 (polyethylene glycol) overnight with shaking at 4°C 
and centrifuged at 4000 rpm for 30 minutes in Sorvall GSA rotor. To purify 
rAAV by CsCl gradient centrifugation, the pellet was resuspended in 12 mL CsCl 
solution and centrifuged at 45000 rpm for 40 hours at 15°C in a T150 rotor. To 
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detect rAAV, the refractive index of 0.5 mL fractions of the CsCl gradient was 
measured. To remove CsCl from the fractions containing rAAV, these fractions 
were dialyzed with PBS with 2 mM MgCl2. A diluted sample of recovered rAAV 
was then adsorbed during a 1-minute incubation to a 300-mesh formvar/carbon-
coated grid (Electron Microscopy Sciences, Hatfield, PA), negatively stained with 
2% pH 7.0 phosphotungstic acid, and visualized by negative stain transmission 
electron microscopy (TEM).  
In order to mass-produce rAAV with the construct, 20 L of Sf9 cells were 
infected with the baculovirus containing the rAAV-LDL-R construct and with a 
baculovirus containing rep and cap genes. The stock of TIPS used for small-scale 
production was used with the same ratio of Sf9 cells to TIPS, namely 1:10,000. 
Thus, 2.0 mL from both TIPS were used to infect 20 L of Sf9 culture (2x106/mL 
cells). The cells were grown for 72 hours at 27°C with agitation in a 25 L rocking 
platform bioreactor (WAVE Bioreactor System 20/50; GE Healthcare Life 
Sciences, Piscataway, NJ). Infected cells were monitored for diameter and 
viability. Five days post-infection, the cells were lysed using 1% triton x-100 for 
2 to 4 hours. Both intra- and extracellular rAAV particles were recovered by 
processing the entire contents. Further disruption of cells was achieved by 
homogenization with a microfluidizer. A dual-piston mechanical cell disrupter 
(deBEE 1000; BEE International, South Easton, MA) operating at 15,000 psi and 
a 1-mm orifice reaction chamber with a flow rate of approximately 0.9 L/min 
solubilized the biomass and effectively lysed the cells with a single pass. 
Following homogenization, the lysate was returned to the bioreactor for nuclease 
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treatment (TurboNuclease; Acelagen, Inc., San Diego, CA) to reduce viscosity 
and degrade RNA, genomic DNA, baculovirus DNA, and unencapsidated vector 
DNA (5 U/ml at 37°C for approximately 2 hours). At the same time, PEG8000 
(1.5% total) were also added for 2 hours. Following nuclease and PEG-8000 
treatment, depth filtration was used for clarification (Sartopure GF + Maxicaps, 
1.2 µm; Sartorius Stedim North America, Bohemia, NY) and then microfiltration 
using a 0.2-µm capsule filter (Sartopore 2XLG). The filtrate was collected in a 
sterile bioprocessing bag for further processing. 
To purify the mass-produced rAAV8-LDL-R, immunoaffinity 
chromatography was used. The immunoaffinity medium, AVB-Sepharose (GE 
Life Sciences Healthcare) specifically binds several AAV serotypes, including 
serotypes 1, 2, 6, and 8. The filtered cell lysate containing rAAV8-LDL-R was 
passed through the column. The column was washed with phosphate-buffered 
saline (PBS) until the ultraviolet (UV) absorbance curve returned to baseline and 
stabilized. The adsorbed rAAV particles were eluted in acidic medium (50 mM 
sodium citrate adjusted with HCl to pH 3.0), and the column eluate was adjusted 
immediately with 1/10 volume of 1 M Tris-Cl (pH 8.0). Virus was removed from 
the column by three consecutive elutions in order to ensure maximum recovery. 
The neutralized eluate was concentrated and diafiltrated against PBS using 
tangential flow filtration, TFF (100 kDa NMWCO). The final vector product was 






5.2.8 Characterization of rAAV8-LSP-LDL-R 
 
The total particle concentration was assessed by protein concentration 
assays, and the filled particle number, i.e., particles that contain vector genomes 
(vg), was determined using two independent methods: 1) qPCR using vector-
specific primers and 2) directly determining the amount of DNA extracted from 
the particles using SYBR Gold nucleic acid dye. After dialyzing the vector 
samples against PBS with 2 mM MgCl2, aliquots (70 µl) were treated with 
proteinase K (40 µg) (Invitrogen, Carlsbad, CA) and incubated for 30 min at 
56°C. The proteinase K was heat inactivated (95°C for 5 min) and the samples 
were slowly equilibrated to ambient temperature to allow time for annealing the 
complementary single-stranded vector genomes. Using a black bottom 96 wells 
plate, samples were diluted and added to a final volume of 200 µL of SYBR Gold 
solution (3 µL of SYBR Gold [Invitrogen, Carlsbad, CA], in 30 mL of fluorescent 
buffer—10 mM HEPES and 1 mM EDTA, pH 8.0). The fluorescent signal, 
proportional to the amount of DNA, was read in a Costar black bottom, 96 well 
plate (Corning Inc., Corning, NY) and fluorescent plate reader (485 nm/535 nm, 1
s) (VICTOR 2, Perkin Elmer, Waltham, MA). DNA reference standards were 
produced using dilutions of a commercially available DNA ladder (Fermantas, 
Glen Burnie, MD). 
Real-time PCR (q-RT-PCR) was used for quantitative analysis of 
encapsidated vector genomes using vector specific forward and reverse primers. 
The primers used, forward 5'-GCCCATCTGATAGGGAATGA-3' and reverse 5'-
CAAGGTCACCCCAGTTATCG-3', amplified a 150 bp product, using the 
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following reaction conditions: initial denaturation 95°C (10 min) and 30 cycles of: 
95°C (15 sec), 58°C (30 sec), 72°C (30 sec). PCR copy number standards were 
prepared from the pFBVG-LSP-LDL-R plasmid. All qPCR reactions were 
performed with a real-time, thermocycler (ICycler, BioRad, Hercules, CA) using 
SYBR green PCR master mix (RT2 SYBR Green/Fluorescein Mastermix, 
SABiosciences, Frederick, MD). Standard curves and melting temperature curves 
for q-RT-PCR of rAAV8-LSP-LDL-R can be seen in appendices E.3 and E.4, 
respectively. SYBR 
 
5.2.8.1 Sodium Dodecyl Sulfate–Polyacrylamide Gel Electrophoresis (SDS-
PAGE) and Western Blot Analyses  
Following fractionation and SDS-PAGE, proteins were electrophoretically 
transferred to nitrocellulose membranes. Silver staining and western blotting were 
then performed. Membranes were incubated for 30 minutes at room temperature 
in blocking solution (5% fat-free milk powder diluted in PBS with Tween 20 
[PBS-T] buffer). Rabbit polyclonal antiserum raised against recombinant VP1 
was used at a final 1:5,000 dilution. After an hour of incubation at room 
temperature, the solution was removed, and the membrane was washed in PBS-T 
buffer (3 × 15 minutes at room temperature). The secondary antibody, horseradish 
peroxidase (HRP)-conjugated goat anti-rabbit IgG (Sigma-Aldrich, St. Louis, 
MO), was diluted 1:5,000 and added to the solution. Following an hour of 
incubation, the solution was removed, and the membrane was washed 3 times for 
15 minutes with PBS-T at room temperature. Light is emitted from the HRP-
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catalyzed reaction with SuperSignal West Dura Extended Duration Substrate 
(Thermo Scientific Pierce Protein Research Products, Rockford, IL). Images were 
captured using a cooled CCD camera and quantitatively analyzed using the 
software package provided in the G:BOX Chemi system (Syngene USA, 
Frederick, MD). (89) 
 
5.2.8.2 Transmission Electron Microscopy (TEM) of AAV Particles  
A diluted sample of recovered rAAV was then adsorbed during a 1 minute 
incubation to a 300-mesh Formvar and carbon-coated grid (Electron Microscopy 
Sciences, Hatfield, PA), washed with distilled water, negatively stained with 2% 
pH 7.0 phosphotungstic acid, air-dried, and visualized by negative stain 
transmission electron microscopy (TEM)  with the JEM 1200EX II (JEOL, 
Tokyo, Japan) (90). 
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Chapter 6: Results and Discussion 
6.1 Isolation and Sequencing of LDL-R Gene 
6.1.1 RLM-RACE  
When the protocol for the 5’ RLM-RACE procedure was designed, it was 
expected that the 5’ end of the rabbit LDL-R mRNA would be similar in GC 
content and size to the LDL-R mRNAs of other species. However, the 5’ UTR of 
rabbit LDL-R mRNA was found to be only 87 bp and 75% GC rich, while those 
of other species are approximately 200 bp and less GC rich. In addition, the N-
terminal portion of the rabbit LDL-R protein is shorter in length than that of other 
species. Prior to this study, these properties had prevented the complete 5’ UTR 
from being isolated and sequenced. In order to circumvent these obstacles, it was 
necessary to use many different combinations of primers to get a complete and 
accurate amplification product for sequencing. These primers as well as those 
used for the 3’ RLM-RACE procedure and the final amplification of the full-
length LDL-R mRNA are outlined in Table 5 below. 
 
Table 5. RLM-RACE Primer Table 
 
  
Primer # Primer Name  Primer Sequence  
1   5' RACE Forward Primer  5’ ATACACATACGATTTAGGTGACACTATAG 3' 
2   5' RACE LDL-R Specific Reverse Primer 5’ AGACGTGCTCCCAGGACGAGT 3’ 
3   3' RACE Reverse Primer 5' CTAGACTTAGAAATTAATACGACTCACTATAG 3' 
4   3' RACE LDL-R Specific Forward         Primer 5’ CACTGGAAATGCGACGGCCAG 3’ 
5   Full Length LDL-R ORF Forward    Primer  5’ ACCGGTGCCACCATGAGGACGGCGCGCTGGGT 3’ 
6   Full Length LDL-R ORF Reverse    Primer  5’ TGGAGGACGACGTGGCCTGATAACTCGAG 3’ 
75 
 
Primers 2 and 4 were obtained from a partially sequenced LDL-R mRNA found 
on GenBank. Primers 1 and 2 were used to determine the sequence from the 5’ 
RACE oligo acceptor to the 5' LDL-R Specific Reverse Primer. Primers 3 and 4 
were used to determine the sequence from the 3’ LDL-R Specific Forward Primer 
to the 3’ RACE adaptor. Following reverse transcription and amplification using 
the above primers, the final amplification products were isolated and visualized 
using gel electrophoresis on an agarose gel under UV light using an ethidium 
bromide stain (see Figure 6). Figure 6A shows the 5’ RACE amplification 
product. Less prominent bands may have been the result of variation of the 5’ 
start site and the 3’ ends. 
Based on the position of the 
prominent band on this gel 
relative to the ladder, this 
portion of the rabbit LDL-R 
cDNA is approximately 460 
bp. Figure 6B shows the 3’ 
RACE amplification 
product. Based on the 
position of the prominent 
band on this gel relative to 
the ladder, this portion of the 
rabbit LDL-R cDNA is 
approximately 680 bp. Both 
Figure 6. Isolation and sequence of the full-length 
rabbit LDL-R mRNA. A) 5’ RACE amplification 
product. B) 3’ RACE amplification product. C) Full-
length LDL-R ORF amplification product. RACE 
was designed based on a partial sequence of the LDL-R 
mRNA deposited in GenBank. 1A shows the 
amplification product to be approximately 460 bp. 1B 
shows the amplification product to be 680 bp. 1C shows 
the full ORF amplification product to be 2.5 kb.  
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of these values were verified to be accurate using sequence analysis. These 
products were cloned into a pPCR-Script cloning vector and then sequenced. This  
preliminary sequence was used to construct primers 5 and 6 for PCR 
amplification and cloning of the full ORF. Figure 6C shows the full-length ORF 
using these two primers. Based on the position of the prominent band on this gel 
relative to the ladder, the full-length ORF amplification product is approximately 
2.5 kb.  
Table 6. Primers used for Sequencing of the rabbit LDL-R 
 
6.1.2 Sequencing and Gene Alignment 
The rabbit LDL-R was sequenced using a set of primers outlined in Table 6. 
 
 
Using the primers listed in table 6, the complete sequence of the rabbit 
LDLR mRNA was obtained (GenBank accession number: JX679211). See 
appendix E.1 for the complete sequence of the full length LDLR mRNA. 
After sequencing the full length MRNA, nucleotide and protein sequence 
alignments were performed via the ClustalW algorithm with the LDL-R mRNA 
    














sequences of other mammalian species to evaluate for conservation. These 
alignments were done using the mRNA sequences for the human, mouse, ovine 
and bovine LDL-R reported on Genbank. Alignments were completed using 
Multalin software (91). See appendix E.2 for the nucleotide sequence alignment. 
In this alignment, text in red indicates areas of complete consensus. Blue text 
indicates an area of low consensus or discrepancy between sequences. Black text 
represents an area of neutral consensus. From this alignment, it is apparent that 
despite the wide range of species, there are several areas in this alignment of high 
consensus. Percent identity was calculated by dividing the number of pairs in the 
alignment comprised of identical nucleotides by the length of the alignment. 
Percent identities for pairwise alignments between species ranged from 26.6% 
(mouse and rabbit) to 95.5% (ovine and bovine). This indicates a moderate level 
of conservation at the nucleotide level for this gene among several mammalian 
species. For the interest of the study, the rabbit and the human LDL-R mRNA 
display 46.6% identity. The human full length mRNA is substantially larger than 
the rabbit mRNA (approximately 5.3 kb versus 3.2 kb respectively). At the ORF 
level (initiation to termination codon) the two sequences are 75.5% identical. The 
5’ UTR is smaller in the rabbit compared to other species including humans (87 
bp versus 187 bp for the rabbit and human respectively). However, the 5’ UTR of 
the rabbit gene is similar in length to the 5’ UTR of both the bovine and ovine 
LDL-R mRNA. Additionally, the 5’ UTR in the rabbit LDL-R mRNA has a 
75.9% GC content compared to what is found in other species (approximately 
60% GC on average). The high GC content region also extends in the N-terminal 
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portion of the ORF.  This may explain the failure in previous attempts to clone 
and sequence the full length rabbit LDL-R mRNA. In total, the rabbit LDL-R 
mRNA is 66.9% GC, whereas the human LDL-R mRNA is 54.4% GC. The 3’ 
UTR is considerably larger in humans compared to other mammalian species 
including the rabbit (534 bp vs 2.5 kb for the rabbit and human respectively). 
These observations are expected due to the low degree of conservation usually 
displayed in the 5’ UTR and 3’ UTRs among species. 
A protein alignment using the clustalW algorithm was also performed 
using the rabbit, human, mouse, ovine, and bovine LDL-R amino acid sequences. 
This alignment (Figure 7) indicates several areas of high consensus and 
conservation. Percent identities for pairwise alignments between species ranged 
from 73.1% (mouse and rabbit) to 96.4% (ovine and bovine). Percent similarities 
for pairwise alignments between species ranged from 83.0% (mouse and rabbit) to 
97.9% (ovine and bovine). Percent similarity was calculated by dividing the 
number of pairs of aligned amino acid residues that are comprised of two residues 
similar to each other by the number of residues in the alignment. Similar residues 
may not be identical, but any difference would not be expected to have a large 
effect on the overall function of the protein. For the interest of the current study, 
the alignment of the rabbit and human LDL-R amino acid sequences indicated 
75.6 % identity and 84.4 % similarity. Portions of this alignment have been 
highlighted to indicate their functional importance in the rabbit LDL-R protein. 
Yellow highlighted text represents the ligand-binding domain of the LDL-R 
including the seven cysteine rich repeats. The alignment of the ligand-binding 
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domains of the human and rabbit LDL-R indicates 74.8% identity and 84.4% 
similarity. Turquoise highlighted text represents the Epidermal Growth Factor 
(EGF) homology domain. The alignment of the EGF homology domain of the 
human and rabbit LDL-R indicates 84.0% identity and 91.2% similarity. Green 
highlighted text and gray highlighted text represent the O-linked sugar domain 
and the trans-membrane domain respectively. However, these portions of the 
alignment are too short to yield any significant information from an in-depth 
analysis of the identity and similarity percentages. The portion of the alignment 
corresponding to the site of the twelve-base deletion responsible for the WHHL 
phenotype is double underlined. 
Figure 7. Protein alignment for the rabbit, human, mouse, ovine, and cow 
LDL-R 
           1                                                              60 
rabbitLDLR      MRTARW VLGLLLAAAA GAAAGDKCGR NEFQCRNGKC ISYKWVCDGS SECQDGSDEW 
 humanLDLR  MGPWGWKLRW TVALLLAAA- GTAVGDRCER NEFQCQDGKC ISYKWVCDGS AECQDGSDES 
 ovineLDLR  MRLAGWGLRW AIALLIAAG- EAAVEDNCAR NEFQCRDGKC ISYKWVCDGT AECQDGSDES 
bovineLDLR  MRLAGWGLRW AIALLIAVG- EAAVEDNCGR NEFQCQDGKC ISYKWVCDGT AECQDGSDES 
 mouseLDLR  MSTADLMRRW VIALLLAAA- GVAAEDSCSR NEFQCRDGKC IASKWVCDGS PECPDGSDES 
 Consensus  m..agw.lRW .iaLLlAaa. gaAveD.C.R NEFQCr#GKC IsyKWVCDGs aECqDGSDEs 
 
            61                                                            120 
rabbitLDLR  EQTCMSLTCK SDDFSCGGRL NRCIPGHWKC DGQQDCEDGS DELGCAPKTC SQDEFRCAEG 
 humanLDLR  QETCLSVTCK SGDFSCGGRV NRCIPQFWRC DGQVDCDNGS DEQGCPPKTC SQDEFRCHDG 
 ovineLDLR  QETCKSVTCK MGDFSCGGRV NRCISESWRC DGQKDCENGS DEEGCPPKTC SQDEFRCNDG 
bovineLDLR  QETCKSVTCK MGDFSCGGRV NRCISGSWRC DGQVDCENGS DEEGCSPKTC SQDEFRCNDG 
 mouseLDLR  PETCMSVTCQ SNQFSCGGRV SRCIPDSWRC DGQVDCENDS DEQGCPPKTC SQDDFRCQDG 
 Consensus  q#TC.SvTCk sg#FSCGGRv nRCIp.sWrC DGQvDC##gS DE.GCpPKTC SQD#FRC.#G 
 
            121                                                           180 
rabbitLDLR  ACISRLFACD GEPDCPDGSD EASCAPSTCG PAHFRCNSSS CVPALWACDG EPDCDDGSDE 
 humanLDLR  KCISRQFVCD SDRDCLDGSD EASCPVLTCG PASFQCNSST CIPQLWACDN DPDCEDGSDE 
 ovineLDLR  KCIAPKFVCD LDLDCLDGSD EASCPMPTCS PANFQCNSSM CIPQLWACDG DPDCDDGSDE 
bovineLDLR  KCIAPKFVCD LDLDCLDGSD EASCPMPTCG PANFQCNSSM CIPQLWACDG DPDCDDGSDE 
 mouseLDLR  KCISPQFVCD GDRDCLDGSD EAHCQATTCG PAHFRCNSSI CIPSLWACDG DVDCVDGSDE 
 Consensus  kCIsp.FvCD .#.DClDGSD EAsCp..TCg PA.FqCNSS. C!PqLWACDg #pDCdDGSDE 
 
            181                                                           240 
rabbitLDLR  WPARCGAR-- PSPQPGRGPC SRHEFHCGSG ECVHASWRCD GDADCRDGSD ERDCAAATCR 
 humanLDLR  WPQRCRGLYV F--QGDSSPC SAFEFHCLSG ECIHSSWRCD GGPDCKDKSD EENCAVATCR 
 ovineLDLR  WPKHCGSPHP SGPPKDDNPC SALEFHCGSG ECIHSSWRCD SDPDCKDKSD EENCAVATCR 
bovineLDLR  WPKHCGTPHP SGPLQDNNPC SALEFHCGSG ECIHSSWHCD HDPDCKDKSD EENCAVATCR 
 mouseLDLR  WPQNCQGRDT AS-KGVSSPC SSLEFHCGSS ECIHRSWVCD GEADCKDKSD EEHCAVATCR 
 Consensus  WP..Cg.... ..p..d..PC SalEFHCgSg EC!HsSWrCD gdpDCkDkSD EenCAvATCR 
 
            241                                                           300 
rabbitLDLR  PDEFQCSDGT CIHGSRQCDQ QQDCGDMSDE VGCVNVTLCE GPDKFKCHSG ECISLDKVCN 
 humanLDLR  PDEFQCSDGN CIHGSRQCDR EYDCKDMSDE VGCVNVTLCE GPNKFKCHSG ECITLDKVCN 
 ovineLDLR  PDEFQCSDGT CIHGSRQCDR EPDCKDLSDE LGCVNVTLCE GPNKFKCHSG ECISLDKVCN 
bovineLDLR  PDEFQCSDGT CIHGSRQCDR EPDCKDLSDE LGCVNVTLCE GPNKFKCQSG ECISLDKVCN 
 mouseLDLR  PDEFQCADGS CIHGSRQCDR EHDCKDMSDE LGCVNVTQCD GPNKFKCHSG ECISLDKVCD 
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 Consensus  PDEFQCsDGt CIHGSRQCDr #.DCkD$SDE lGCVNVTlC# GP#KFKChSG ECIsLDKVC# 
 
            301                                                           360 
rabbitLDLR  SARDCQDWSD EPIKECATNE CMRGNGGCSH TCFDLRIGHE CHCPKGYRLV DQRRCEDINE 
 humanLDLR  MARDCRDWSD EPIKECGTNE CLDNNGGCSH VCNDLKIGYE CLCPDGFQLV AQRRCEDIDE 
 ovineLDLR  SIRDCRDWSD EPLKDCGTNE CLDNKSGCSH ICNDLKIGYE CLCPEGFQLV DKHRCEDIDE 
bovineLDLR  SVRDCRDWSD EPLKDCGTNE CLDNKGGCSH ICNDLKIGYE CLCPEGFQLV GKHRCEDIDE 
 mouseLDLR  SARDCQDWSD EPIKECKTNE CLDNNGGCSH ICKDLKIGSE CLCPSGFRLV DLHRCEDIDE 
 Consensus  saRDCrDWSD EPiK#CgTNE C$dnngGCSH iCnDLkIGyE ClCP.G%qLV d.hRCEDI#E 
 
            361                                                           420 
rabbitLDLR  CEDPDICSQL CVNLAGSYKC ECRAGFQLDP HSQACKAVDS IAYLFFTNRH EVRKMTLDRS 
 humanLDLR  CQDPDTCSQL CVNLEGGYKC QCEEGFQLDP HTKACKAVGS IAYLFFTNRH EVRKMTLDRS 
 ovineLDLR  CQNPDTCSQL CVNLEGSYKC ECEEGFRLEP LTKACKAVGT IAYLFFTNRH EVRKMTLDRS 
bovineLDLR  CQNPDTCSQL CVNLEGSYKC ECEEGFRLEP LTKACKAVGT IAYLFFTNRH EVRKMTLDRS 
 mouseLDLR  CQEPDTCSQL CVNLEGSYKC ECQAGFHMDP HTRVCKAVGS IGYLLFTNRH EVRKMTLDRS 
 Consensus  C##PDtCSQL CVNLeGsYKC #CeeGF.$#P htkaCKAVgs IaYLfFTNRH EVRKMTLDRS 
 
            421                                                           480 
rabbitLDLR  EYTSLIANLK NVVALDAEVA SNRIYWSDLS QRKIYSAQID GAHGFPAYDT VISSDLQAPD 
 humanLDLR  EYTSLIPNLR NVVALDTEVA SNRIYWSDLS QRMICSTQLD RAHGVSSYDT VISRDIQAPD 
 ovineLDLR  EYTSLIPNLK NVVALDTEVA SNRIYWSDLS QRKIYSAQID DAPGFSSYDT VIGENLQAPD 
bovineLDLR  EYTSLIPNLK NVVALDTEVA SNRIYWSDLS QRKIYSAQID GAPGFSSYDT VIGEDLQAPD 
 mouseLDLR  EYTSLLPNLK NVVALDTEVT NNRIYWSDLS QKKIYSALMD QAPNLS-YDT IISEDLHAPD 
 Consensus  EYTSLipNLk NVVALDtEVa sNRIYWSDLS QrkIySaqiD .ApgfssYDT !Ise#lqAPD 
 
            481                                                           540 
rabbitLDLR  GLAVDWIHGH IYWTDSVLGT VSVADTRGFR RKTLFRQEGS KPRAIVVDPA HGFMYWTDWG 
 humanLDLR  GLAVDWIHSN IYWTDSVLGT VSVADTKGVK RKTLFRENGS KPRAIVVDPV HGFMYWTDWG 
 ovineLDLR  GLAVDWIHSN IYWTDSILGT VSVADTKGVK RKTLFQEEGS KPRAIVVDPV HGFMYWTDWG 
bovineLDLR  GLAVDWIHSN IYWTDSILGT VSVADTKGVK RKTLFQEEGS KPRAIVVDPV HGFMYWTDWG 
 mouseLDLR  GLAVDWIHRN IYWTDSVPGS VSVADTKGVK RRTLFQEAGS RPRAIVVDPV HGFMYWTDWG 
 Consensus  GLAVDWIHsn IYWTDS!lGt VSVADTkGvk RkTLFq#eGS kPRAIVVDPv HGFMYWTDWG 
 
            541                                                           600 
rabbitLDLR  VPAKIEKGGL NGVDVYSLVT EDIQWPNGIT LDLSSGRLYW VDSKLHSISS IDVNGGNRKT 
 humanLDLR  TPAKIKKGGL NGVDIYSLVT ENIQWPNGIT LDLLSGRLYW VDSKLHSISS IDVNGGNRKT 
 ovineLDLR  TPAEIKKGGL NGVDVYSLVT EDIQWPNGIT LDLSGGRLYW VDSKLHSISS IDVNGGNRKT 
bovineLDLR  APAEIKKGGL NGVDVYSLVT EDIQWPNGIT LDLSGGRLYW VDSKLHSISS IDVNGGNRKT 
 mouseLDLR  TPAKIKKGGL NGVDIHSLVT ENIQWPNGIT LDLSSGRLYW VDSKLHSISS IDVNGGNRKT 
 Consensus  tPAkIkKGGL NGVD!ySLVT E#IQWPNGIT LDLssGRLYW VDSKLHSISS IDVNGGNRKT 
 
            601                                                           660 
rabbitLDLR  VLEDEQRLAH PFSLAIFEDK VFWTDVINEA IFSANRLTGS DVHLVAENLL SPEDIVLFHN 
 humanLDLR  ILEDEKRLAH PFSLAVFEDK VFWTDIINEA IFSANRLTGS DVNLLAENLL SPEDMVLFHN 
 ovineLDLR  VLEDKKKLAH PFSLAIFEDK VFWTDIINEA IFSANRLTGS DISLMAENLL SPEDIVLFHN 
bovineLDLR  VLEDKKKLAH PFSLAIFEDK VFWTDVINEA IFSANRLTGS DISLMAENLL SPEDIVLFHN 
 mouseLDLR  ILEDENRLAH PFSLAIYEDK VYWTDVINEA IFSANRLTGS DVNLVAENLL SPEDIVLFHK 
 Consensus  !LEDekrLAH PFSLA!%EDK V%WTD!INEA IFSANRLTGS D!.L.AENLL SPEDiVLFHn 
 
            661                                                           720 
rabbitLDLR  LTQPRGVNWC EKTAL-PNGG CQYLCLPAPQ INSHSPKFTC ACPDGTLLAA DMRSCRTEAD 
 humanLDLR  LTQPRGVNWC ERTTL-SNGG CQYLCLPAPQ INPHSPKFTC ACPDGMLLAR DMRSCLTEAE 
 ovineLDLR  LTQPRGVNWC ERTSL-RNGG CQYLCLPAPQ INPRSPKFTC ACPDGMLLAK DMRSCLTESE 
bovineLDLR  LTQPRGVNWC ERTAL-RNGG CQYLCLPAPQ INPRSPKFTC ACPDGMLLAK DMRSCLTESE 
 mouseLDLR  VTQPRGVNWC ETTALLPNGG CQYLCLPAPQ IGPHSPKFTC ACPDGMLLAK DMRSCLTEVD 
 Consensus  lTQPRGVNWC ErTaL..NGG CQYLCLPAPQ InphSPKFTC ACPDGmLLAk DMRSClTE.# 
 
            721                                                           780 
rabbitLDLR  VILSTQRAST AARPQLTGSP AGTTQE---- --------PL TEPTLSTLET ATTSQQALHN 
 humanLDLR  AAVATQETST V-RLKVSSTA VRT-QHTTTR PVPDTSRLPG ATPGLTTVEI VTMSHQALGD 
 ovineLDLR  SAVTTRGPST V-----SSTA VGP-KRT--- ---------- SSPELTTAES VTMSQQALGD 
bovineLDLR  SAVTTRGPST V-----SSTA VGP-KRT--- ---------- ASPELTTAES VTMSQQGQGD 
 mouseLDLR  TVLTTQGTSA V-RPVVTASA TRPPKHSEDL SAPSTPRQPV DTPGLSTVAS VTVSHQVQGD 
 Consensus  .avtTqg.St v.r...ssta vgp.k.t... ........p. ..P.LtT.es vTmSqQalg# 
 
            781                                                           840 
rabbitLDLR  ADGRGSEGTP RSVGALSVVL PIALLGLLCL GALVLWKNWR LRSVHSINFD NPVYQKTTED 
 humanLDLR  VAGRGNEKKP SSVRALSIVL PIVLLVFLCL GVFLLWKNWR LKNINSINFD NPVYQKTTED 
 ovineLDLR  VAGRADTERP GSVGALYIVL PIALLILLAF GTFLVWKNWR LKSINSINFD NPVYQKTTED 
bovineLDLR  IASQADTERP GSVGALYIVL PIALLILLAF GTFLLWKNWR LKSINSINFD NPVYQKTTED 
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 mouseLDLR  MAGRGNEEQP HGMRFLSIFF PIALVALLVL GAVLLWRNWR LKNINSINFD NPVYQKTTED 
 Consensus  .agrg.ee.P .svgaLs!vl PIaLl.lL.l G.fllWkNWR Lks!nSINFD NPVYQKTTED 
 
            841                                              888 
rabbitLDLR  EVHICRSQDG YTYPSRQMVS LEDDVA                         
 humanLDLR  EVHICHNQDG YSYPSRQMVS LEDDVAALSI VLPIVLLVFL CLGVFLLW 
 ovineLDLR  EVHICRSQDG YTYPSRQMVS LEDDAA                         
bovineLDLR  EVHICRSQDG YTYPSRQMVS LEDDVA                         
 mouseLDLR  ELHICRSQDG YTYPSRQMVS LEDDVA                         
 Consensus  EvHICrsQDG YtYPSRQMVS LEDDvA.... .......... ........ 
 
The percent identity for the nucleotide alignment was significantly lower 
than that of the protein alignment. However, this is expected in genes that are 
constantly selected for or in genes in which a homozygous mutation is lethal. If 
mutations result in a lethal protein product, then most surviving mutations would 
be expected to be synonymous. Though the EGF homology domain was the 
portion that showed the most similarity between the two sequences, the ligand-
binding region and, more specifically, the site of the deletion for WHHL rabbits 
were highly similar between the two species, lending merit to the use of the 
WHHL rabbit as an animal model for FH. Despite a relatively high degree of 
conservation, the human and the rabbit protein display significant variation. 
Therefore using the rabbit as a model for FH and gene therapy likely requires the 
use of the rabbit sequence in the recombinant viral vector choice, rather than the 
human sequence or a chimeric sequence.  
 
6.2 Data from in vivo Studies 
 In order to determine the most effective serotype for transduction and 
expression in rabbit hepatocytes, qualitative and quantitative assays were 
performed. Liver samples isolated from NZW rabbits injected with either rAAV6-
LacZ or rAAV8-LacZ were used for these assays. First, to qualitatively show 
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observable differences in functionality of each serotype, a β-galactosidase staining 
assay was performed. Once these differences were confirmed, an assay measuring 
relative expression of β-galactosidase was performed in order to quantitatively 
show differences in functionality. qPCR was also performed in order to show the 
transduction efficiency of each virus and the maintenance of viral DNA in liver 
cells over time. 
 
6.2.1 β-galactosidase Staining Assay 
 Liver sections from transfected rabbits were fixed and incubated in a β-
galactosidase staining solution containing 1 mg/mL X-gal.  Intensity of blue color 
produced by cleavage of X-gal is proportional to the concentration of β-
galactosidase, and therefore the expression levels of the viral LacZ gene. The 
samples shown below are representative of rAAV8-LacZ and rAAV6-LacZ 
treatment after 10 days. Qualitatively, there was distinctly higher β-galactosidase 
activity with rAAV8-LacZ treatment as displayed by the accumulation of the blue 
X-gal substrate (Figure X). This observation suggests that rAAV8 is a more 
efficient viral vector in targeting rabbit liver than rAAV6. No visual development 
of β-galactosidase was seen in rabbits treated with rAAV8-LacZ or rAAV6-LacZ 





Figure 8: β-galactosidase staining of liver sections. The samples shown in the figure above 
represent liver slices isolated from three different rabbits. (A) shows representative liver samples 
after 10 days from rabbits injected with the rAAV8-LacZ, and (B) is representative of liver 
samples after 10 days from rabbits injected with rAAV6-LacZ. (C) is from the control rabbit after 
28 days with no viral injection. Results shown are after overnight incubation in β-galactosidase 
staining solution. 
 
6.2.2 Quantitative Detection of β-galactosidase Activity 
A quantitative assay was performed to measure β-galactosidase 
expression. Samples were taken from five lobes of each rabbit liver. Assays were 
performed twice on each sample and the mean was taken to obtain the data shown 
in Tables 7 and 8. After performing the BCA assay to determine total protein 
concentration in each sample, 10 µL of sample was used for each luminescence 
reading. This resulted in a total protein mass of 10-20 µg per sample, which was 
in the targeted linear range based on standard curves. Based on the measured 
volume, total protein concentration per sample, and luminescence data, we 
obtained data in relative luminescence units per mg of protein, which is 
representative of relative β-galactosidase activity in each tissue sample. 
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Table 7: β-galactosidase assay of NZW rabbits treated with rAAV8-LacZ. 5 NZW rabbits 
were injected with rAAV8-LacZ. Rabbits were sacrificed after 10 or 28 days. Galacto-light Plus 
assay was performed on samples from five lobes of each liver. Samples were run in duplicates and 
the numbers shown are the average of the two outputs. Data shown represents the relative 
luminescence units per mg of total protein (total protein concentration was determined from the 
BCA assay). 
 
Table 8: β-galactosidase assay of NZW rabbits treated with rAAV6-LacZ. 5 NZW rabbits 
were injected with rAAV6-LacZ. Rabbits were sacrificed after 10 or 28 days. Galacto-light Plus 
assay was performed on samples from five lobes of each liver. Samples were run in duplicates and 
the numbers shown are the average of the two outputs. Data shown represents the relative 
luminescence units per mg of total protein (total protein concentration was determined from the 
BCA assay). 
 
 For the purpose of statistical analysis, data was divided into four groups: 
AAV6 sacrificed after 10 days (rabbits 7, 8, and 9), AAV6 sacrificed after 28 
days (rabbits 5 and 6), AAV8 sacrificed after 10 days (rabbits 10, 11, and 12), and 
AAV8 sacrificed after 28 days (rabbits 3 and 4). Preliminary analysis on raw data 
with Bartlett’s test for equal variance yielded a significant result, which meant the 
untransformed data was not homogeneous in variance. After log10 transformation, 






Time Relative Luminescence Units per mg of Total Protein 
   Lobe 1 Lobe 2 Lobe 3 Lobe 4 Lobe 5 
10 AAV8 10 days 98457 54478 115642 39724 63245 
11 AAV8 10 days 124693 87426 103071 61301 109117 
12 AAV8 10 days 28415 74516 93476 64512 33419 
3 AAV8 28 days 3014 1742 2104 3451 1076 
4 AAV8 28 days 784 1428 1911 845 741 






Time Lobe 1 Lobe 2 Lobe 3 Lobe 4 Lobe 5 
7 AAV6 10 days 14076 9652 16102 4129 7415 
8 AAV6 10 days 2489 9651 4187 3258 6145 
9 AAV6 10 days 1784 2105 3014 1784 2479 
5 AAV6 28 days 184 196 321 85 142 
6 AAV6 28 days 78 112 154 104 118 
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transformed data were homogeneous, which allowed for ANOVA to be 
performed. The following Figure 9 and Table 9 show the distribution of the raw 
and transformed data and the statistical analysis performed (Newman-Keuls 
Multiple Comparison Test). 
 
 
Figure 9. β-galactosidase assay of liver 
tissue post-infection. Raw and log-transformed β-galactosidase assay data post-infection with 
AAV6 and AAV8 serotypes. Samples were collected at either 10 or 28 days after treatment. 
 
 
Compared Serotypes  q Significant?  P< 0.05 
AAV6 10 days  AAV6 28 days 21.18 Yes 
AAV8 10 days  AAV8 28 days 23.33 Yes 
AAV6 10 days  AAV8 10 days 18.57 Yes 
AAV6 28 days  AAV8 28 days 13.21 Yes 
 
Table 9. Newan-Keuls Multiple Comparison Test on β-Galactosidase Assay Data. ANOVA 
was performed on log-transformed data. Further analysis shows significant differences between all 
experimental groups. 
 
ANOVA was performed on the transformed data and indicated a 
significant difference between groups. Further analysis by Newman-Keuls 
Multiple Comparison Test showed significant differences between all groups, 
including AAV6 at 10 days and AAV8 at 10 days; AAV6 at 28 days and AAV8 at 
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28 days; AAV6 at 10 days and AAV6 at 28 days; and AAV8 at 10 days and 
AAV8 at 28 days. 
Luminescence per mg of liver tissue in rabbits exposed to AAV8 was 
significantly greater than in rabbits exposed to AAV6 at both time points. This 
indicates that AAV8 had greater viral expression in liver tissue than AAV6. A 
significant decrease in luminescence data between 10 days and 28 days for rabbits 
treated with both serotypes indicates that viral expression decreased over time. 
This suggests that the host cell silenced transgene expression between 10 and 28 
days for both serotypes.  
 
6.2.3 qPCR Analysis of Liver 
To quantify the degree of transduction and maintenance of the viral 
transgene in the liver, qPCR was performed on liver samples. Samples were taken 
from four different lobes of the liver of each rabbit. qPCR was performed twice 
on each sample and the average was taken to obtain the data shown in Tables 10 
and 11. qPCR was used with a primer specific to the CMV promoter, a viral 
promoter not otherwise present in mammalian cells. The data in the tables 
therefore represent the number of AAV genomes per diploid rabbit genome. The 














Time  Lobe 1 Lobe 2 Lobe 3 Lobe 4 
10 AAV8 10 days  21.4 3.45 6.78 11.8 
11 AAV8 10 days  7.45 0.92 5.21 1.47 
12 AAV8 10 days  1.93 17.1 9.45 2.75 
3 AAV8 28 days  0.85 1.75 16.2 4.23 
4 AAV8 28 days  3.15 0.45 7.56 11.47 
2 CONTROL 28 days  <0.01 <0.01 <0.01 <0.01 
       
Table 10: qPCR of NZW rabbits treated with rAAV8-LacZ. 5 NZW rabbits were injected with 
rAAV8-LacZ and 1 with saline solution only (control). Rabbits were sacrificed after 10 or 28 
days. qPCR was performed on samples from four lobes of each liver using a CMV promoter-
specific primer. Samples were run in duplicates and the numbers shown are the average of the two 
outputs. Data shown represents the number of CMV promoters per diploid rabbit genome. 




Table 11: qPCR of NZW rabbits treated with rAAV6-LacZ. 5 NZW rabbits were injected with 
rAAV6-LacZ and 1 with saline solution only (control). Rabbits were sacrificed after 10 or 28 
days. qPCR was performed on samples from four lobes of each liver using a CMV promoter-
specific primer. Samples were run in duplicates and the numbers shown are the average of the two 
outputs. Data shown represents the number of CMV promoters per diploid rabbit genome. 
Sensitivity of the assay was 0.01 copies per diploid genome. 
 
For the purpose of statistical analysis, data was divided into four 
groups: AAV6 sacrificed after 10 days (rabbits 7, 8, and 9), AAV6 sacrificed after 
28 days (rabbits 5 and 6), AAV8 sacrificed after 10 days (rabbits 10, 11, and 12), 
and AAV8 sacrificed after 28 days (rabbits 3 and 4). Preliminary analysis on raw 
data with Bartlett’s test for equal variance yielded a significant result, which 
meant the untransformed data was not homogeneous in variance. After log10 





Time Lobe 1 Lobe 2 Lobe 3 Lobe 4 
7 AAV6 10 days 0.06 0.09 0.19 0.24 
8 AAV6 10 days 0.27 <0.01 0.13 0.05 
9 AAV6 10 days 0.57 0.17 0.06 0.42 
5 AAV6 28 days 0.14 0.07 0.41 0.26 
6 AAV6 28 days 0.25 0.03 <0.01 0.34 
2 CONTROL 28 days <0.01 <0.01 <0.01 <0.01 
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transformation, Bartlett’s test yielded a non-significant result, indicating that the 
variances for the transformed data were homogeneous, which allowed for 
ANOVA to be performed. The following Figure 10 and Table 12 show the 
distribution of the raw and transformed data and the statistical analysis performed 
(Newman-Keuls Multiple Comparison Test). 
 
Figure 10. qPCR of liver tissue post-infection. Raw and log-transformed qPCR data post-




Compared Serotypes q Significant? P<0.05 
AAV6 10 days AAV6 28 days 0.0002958 No 
AAV8 10 days AAV8 28 days 1.255 No 
AAV6 10 days AAV8 10 Days 5.784 Yes 
AAV6 28 days AAV8 28 days 3.576 Yes 
Table 12. Newan-Keuls Multiple Comparison Test on qPCR Data. ANOVA was performed on 
log-transformed data. Further analysis shows significant differences between AAV6 and AAV8 at 
both time points. 
 
ANOVA was performed on the transformed data and indicated a 
significant difference between groups. Further analysis by Newman-Keuls 
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Multiple Comparison Test showed significant differences between all groups, 
including AAV6 at 10 days and AAV8 at 10 days; and AAV6 at 28 days and 
AAV8 at 28 days. No significant difference was found between AAV6 at 10 days 
and AAV6 at 28 days; or between AAV8 at 10 days and AAV8 at 28 days.  
The number of viral genomes per diploid rabbit genome in liver of 
rabbits exposed to AAV8 was significantly greater than that of rabbits exposed to 
AAV6 at both time points. This indicates that AAV8 had greater viral 
transduction in liver tissue than AAV6. No significant change in the number of 
viral genomes between time points for both serotypes indicates that viral DNA 
was maintained over time. This suggests that viral genomes were not destroyed by 
host immune response between 10 and 28 days. 
 
 
6.3 Production of pFBVG-LSP-LDL-R Plasmid 
Prior to restriction enzyme digestion with XhoI/AgeI for ligation of the 
LDL-R ORF into pFB, site directed mutagenesis was performed to destroy a XhoI 
site within the LDL-R ORF between nucleotides 2505 and 2510. Below is a 
segment from nucleotides 2478 to 2429 containing the XhoI site. 
CAGGAGCCAGGACGGCTACACCTACC CCT CGA GAC AGATGGT CAGCCTGGAG 
                                                                          P       R      D 
CTCGAG = XhoI site 
A = site directed mutagenesis 
 
  
 A/C site directed mutagenesis at nucleotide 2509 destroyed the XhoI site, 
but maintained the arginine residue and the integrity of the amino acid sequence. 
The following forward and reverse A/C primers were synthesized with a 5’ 
phosphor group (Integrated DNA Technologies, Coraville, IA): 
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 Figure 11: Gel electrophoresis of digested 
pPCR-Script plasmid, containing the LDL-R 
ORF. The resulting fragments were nearly 
identical in size, creating one thick band. LDL-R 
ORF: 2.7 kB, pPCR-Script backbone: 2.6 kB. 
The bottom portion was used for downstream 
procedures  
  
5’ CGA CAG ATG GTC AGC CTG GAG 3’ (Forward primer A/C) 
3’ CGA GGG GTA GGT GTA GCC G 5’ (Reverse primer A/C) 
  
 
 The pPCR-Script-LDL-R plasmid was used as the 
template in the PCR with these primers. After running the 
PCR reaction, the solution was treated with the DpnI 
restriction enzyme to degrade the template plasmid, leaving 
the linear mutant PCR product. After purification of the 
product, the DNA was self-ligated at the open 5’ phosphate 
ends with DNA ligase to obtain mutant pPCR-Script-LDL-R 
without the XhoI restriction site. The cloning vector 
containing the LDL-R insert, pPCR- Script, was digested 
with AgeI/XhoI to remove the LDL-R insert for ligation into 
pFB. Although two bands were expected, only one thick 
band was observed in the gel (Figure 11) due to 
insufficient resolution. The size of the LDL-R insert 
and that of the pPCR-Script plasmid backbone 
differed by only 100 bp. Since the LDL-R insert was 
2.6 kb compared to the plasmid backbone of 2.7 kb, the bottom portion of the 
observed band was hypothesized to be the insert. The bottom portion of the band 
was, therefore, excised, and the DNA was extracted and ligated into digested pFB. 






and LDL-R ORF 
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Figure 13: Gel 
electrophoresis of purified 
plasmids taken from 
bacterial colonies. 6 of 7 
bacterial colonies 
confirmed the presence of 











This new plasmid was identical to 
pFBGR with the viral genome insert 
replacing the GFP ORF. In order to 
exclude the possibility that the 
subcloning plasmid backbone was 
inserted into pFB, the plasmid was 
screened for insert by restriction 
digestion following bacterial 
transformation and purification. Six of 
the 7 miniprep products showed the expected restriction pattern (Figure 13). 
Subsequently, two miniprep products that showed the expected restriction pattern 
were screened by PCR with primers specific for the insert (Figure 14).  
 Figure 12: pFBVG-CMV-LDL-R plasmid, 
containing the LDL-ORF, flanked by AgeI and 
XhoI restriction sites, and CMV promoter. This 
plasmid was constructed via ligation of LDL-ORF 















Expression of LDL-R was confirmed by transfection of HEK293 cells 
with pFBVG-CMV-LDL-R and Western blot (Figure 15).  
Since β-galactosidase expression diminished significantly after 10 days 
and was non-existent 28 days post-infection due to CMV silencing, a liver-
specific promoter was chosen that would not be silenced in hepatocytes for long-
term expression of LDL-R. To replace the CMV promoter in pFBVG-CMV-LDL-
R with the liver-specific promoter HCR-ApoE-hAAT (hepatic control region 
apolipoprotein enhancer/alpha1-antitrypsin), a DNA cassette was first synthesized 
containing the liver-specific promoter flanked by AgeI and SpeI sites (GenScript, 
Piscataway, NJ). The synthesized construct was provided in a pUC57 vector 
(pUC57-LSP). Double digestion of this plasmid with AgeI/SpeI and ligation to 
3 kb 
2.5 kb 
 Figure 15: Western blot of 
HEK 293 transfection by 
pFBVG-CMV-LDL-R . HEK293 
cells expressed LDL-R gene 
Figure 14: Gel electrophoresis of 
purified PCR product taken from 
bacterial colony. The presence of the 
correct insert was confirmed by the 
observation of a 2750 bp band, 
corresponding to the LDL-R ORF. 
s Amplified LDL-
R ORF: 2750 bp 
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Expression of LDL-R was confirmed by transfection of pFBVG-LSP-
LDL-R into two human cell lines, namely HEP2G and HEP3B, and Western blot 









Figure ?: pFBVG-LSP-LDL-R plasmid, 
containing the LDL-ORF, flanked by 
AgeI and XhoI restriction sites, and 
HCR-hAAT promoter..   
Figure 17: Western blot of 
HEP3B and HEP2G  
transfection by  
pFBVG-LSP-LDL-R .  
HEK3B and HEK2G cells 
expressed LDL-R gene. 
Figure 16: pFBVG-LSP-LDL-R plasmid. 
The CMV promoter was replaced with the 
liver-specific HCR-ApoE-hAAT promoter by 
ligation of pFBVG-CMV-LDL-R and 
pUC57-LSP.   
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Shown below (Figure 18) is the sequence of the artificially synthesized cassette 
containing the convenient restriction sites and various promoter elements. As 
shown, the p10 promoter is enclosed within the region between the AgeI and 
XhoI restriction sites. Upon digestion at those sites and insertion of the LDL-R 
ORF to pFB, this p10 promoter was removed. As an insect cell promoter, p10 is 
responsible for expression of LDL-R upon transfection of Sf9 insect cells with the 
pFBVG-LSP-LDL-R plasmid. Prior to mass production of rAAV-LDL-R, 
expression of LDL-R needed to be confirmed in insect cells to verify the integrity 
of the ORF. Therefore, it was necessary to reinsert this promoter into the pFBVG-
LSP-LDL-R. To that end, the plasmid containing the HCR-ApoE-hAAT promoter 

















Figure 18: HCR-ApoE-hAAT and p10 promoters. Red: HCR and SV40 intron. Italics: hAAT 
and p10* promoters. Underline: unique AgeI and SpeI restriction sites 
 
 
6.4 Rescue Assay 
Coinfection of Sf9 cells with baculovirus containing rAAV genome and 
with bac-rep resulted in the production of a 4.3 kb single stranded DNA, which 
was visualized by 1% agarose gel electrophoresis (Figure 19). Because rep 
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proteins replicate sequences flanked by ITRs, the presence of this DNA is 
evidence that the ITRs of the rAAV are functional and resulted in the rep protein-
mediated replication of the rAAV genome. Moreover, the fact that the size of the 
replicated DNA is the size of the rAAV genome further supports the conclusion 
that the rAAV genome was replicated. Since the rAAV genome can be replicated 
by the rep proteins only if its ITRs are intact, the production of a 4.3 kb DNA is 
evidence that the ITRs are intact. 
 
 
6.5 Examination of Fractions Eluted from AVB Column by Silver Staining, 
qPCR, and Direct DNA Binding 
In order to detect rAAV eluted from AVB column, the absorbance at 280 
nm of eluted material from three consecutive elutions was monitored (Figure 20). 
Additionally, viral proteins from the fraction with highest Abs<280> were 







Figure 19. Rescue assay to verify ITR 
integrity. Sf9 were coinfected with 
recombinant baculovirus with rAAV 
genome and with a recombinant baculovirus 
from which AAV rep proteins were 
expressed. DNA from Sf9 was purified 72 
hours after infection and visualized on a 1% 




detected by SDS-PAGE followed by silver stain (Figure 21). The most intense 
bands detected by silver stain had the molecular weights of VP1, VP2, and VP3. 
For this reason, the fraction was concluded to contain purified rAAV. 
 
Figure 20. Absorbance profiles of three consecutive elutions from AVB column. Sf9 cultures 
were homogenized, filtered, and passed over an AVB column. Abs<280> of three consecutive 




To quantitatively assess the DNA content of the 
vector particles, qPCR and DNA direct 
flourscent binding assays were performed. Both 
assays yielded similar results. According to 
qPCR analysis, 1.5X1014 viral particles 
contained the 150bp sequence amplified by 
Figure 21. SDS-
PAGE and silver 
stain of eluted 
fraction with 
greatest Abs<280>. 
Material eluted from 
AVB column was 
separated by size by 
SDS-PAGE and 





PCR. This analysis was corroborated by measurement of relative fluorescence 
from the binding of DNA to SYBR Gold nucleic acid dye indicated that 9.7X1013 
viral particles contained nucleic acid. The similarity between the number of viral 
genomes calcuted from qPCR data and  from DNA direct binding data indicates 
that a sufficient quantity of vector particles containing viral genome were mass-
produced (see Appendix E.5).  
 
6.6 Examination of Purified rAAV by TEM 
Examination of purified rAAV by TEM shows that the physical particles 
have the size and shape of AAV and that a large fraction of these particles contain 










Figure 22. TEM image of purified rAAV. Diluted rAAV purified by CsCl 
gradient was mounted onto 300-mesh formvar/carbon-coated grids, negatively 







Chapter 7: Conclusions and Future Directions 
 
7.1 Significance of Sequencing the Complete NZW Rabbit LDL-R mRNA 
 
 Although expression of the human LDL-R has been induced in WHHL 
rabbits by a viral vector in order to treat the rabbit’s hypercholesterolemia, the 
immunogenicity of the human LDL-R in rabbits may have prevented the long-
term effects of this expression from reflecting the effects of expression of LDL-R 
in humans (92). Thus, the use of the WHHL rabbit as an animal model for 
exploring the treatment of FH by transfer of an LDL-R ORF may require the 
expression of the rabbit LDL-R rather than the human LDL-R. Since the WHHL 
rabbit is an excellent animal model for FH, the safety and effectiveness of transfer 
of the LDL-R ORF to rabbit hepatocytes may be useful in developing gene 
therapy as a possible treatment for FH in humans.   
Prior to this study, the 5’ UTR of the NZW LDL-R mRNA was unknown. 
With the complete structure of the fully functional NZW LDL-R mRNA, any 
significant differences occurring between the NZW and WHHL genomes in the 5’ 
UTR can be investigated and evolutionary relationships can be assessed. 
Additionally, research involving the NZW rabbit LDL-R mRNA can be more 
effective due to the enhanced ability to predict structure, make primers, and 
identify mutants.  
 
7.2 Significance of Determining AAV Specificity of Rabbit Liver 
 
Determining liver-specificity of AAV serotypes is important for assessing 
the feasibility of rAAV-mediated gene transfer in rabbit hepatocytes. Because 
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rAAV8 transduced the liver more efficiently and caused greater transgene 
expression levels than rAAV6, rAAV8 should be considered for future gene 
transfer into rabbit hepatocytes in vivo. Since many cases of FH result from a 
defect in the LDL-R, this disease may be amenable to treatment by transfer of the 
LDL-R ORF to hepatocytes. AAVs may be useful for gene therapy in humans 
because they are non-immunogenic non-pathogenic and because they can be 
mass-produced. For these reasons, exploring liver-specificity of AAV may be 
useful for developing a treatment for humans suffering from FH. Since previous 
literature does not address CMV silencing in rabbit hepatocytes, the observed 
silencing indicates that future in vivo studies should involve mammalian tissue-
specific promoters rather than viral promoters. 
 
7.3 Significance rAAV8-LSP-LDL-R Mass Production 
 The livers of large mammals, including humans, contain trillions of cells. 
For this reason, even with a high transduction efficiency, transfer of LDL-R ORF 
via a rAAV to a large fraction of liver cells requires semi-industrial production of 
rAAV. Moreover, the clinical use of rAAV requires preparation of rAAV without 
the risk of contamination with toxins or pathogens. Production of rAAV with an 
adenovirus helper virus or with a recombinant HSV creates the risk of 
contamination with pathogens, and purification by CsCl creates the risk of 
contamination with CsCl, which is toxic. Inspection of rAAV8-LSP-LDL-R by 
TEM and western blot shows that the large-scale production of rAAV8 by the 
baculovirus system and the subsequent purification by affinity chromatography is 
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feasible. Because it does not create the risk of contamination, this system for 
rAAV production may allow the production of quantities of rAAV-LSP-LDL-R 
sufficient for treatment of FH by transfer of the LDL-R ORF to human liver cells. 
 
7.4 Future Studies  
The rAAV8-LSP-LDL-R particles will be injected into WHHL rabbits 
in order to evaluate the effects of viral-mediated transfer of the LDL-R ORF into 
hepatocytes on blood LDL levels. In order to assess the safety and effectiveness 
of this treatment for FH in WHHL rabbits, the blood concentrations of HDL, 
LDL, alkaline phosphatase, and alanine aminotransferase will be measured at 
multiple time points post-exposure to rAAV. Additionally, liver samples will be 
observed under a fluorescent microscope to phenotypically analyze its 
morphology. Specifically, the degree of inflammation of the tissue sample will 
first be determined in order to evaluate the presence or severity of necrosis and 
possible tissue changes. To detect cholestasis, the hepatocytes will be observed 
for any foamy swelling or pigment changes, while potential scarring will be 
observed to determine if fibrosis has occurred (93). The duration of the infection 
and of transgene expression will be determined by qPCR with primers specific to 
the rAAV genome and by western blot with an anti-LDL-R antibody, 
respectively.   
Transfer of the LDL-R ORF into WHHL rabbit hepatocytes may decrease 
blood LDL-cholesterol levels via expression of functional LDL-R. Because the 
phenotype of FH in the WHHL rabbit is similar to that of FH in humans, 
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successful treatment of WHHL rabbits with rAAV8-LSP-LDL-R would provide 
evidence that viral-mediated transfer of the LDL-R ORF may be a feasible 
treatment for FH in humans.  
Because intracellular cholesterol homeostasis is necessary for the survival 
of hepatocytes, maintaining physiological LDL-R expression levels may be 
necessary for long-term infection. Regulatory elements that induce abnormally 
high LDL-R expression or that are not sensitive to intracellular cholesterol 
concentration may cause pathological accumulation of cholesterol in infected 
cells. Transfer of the LDL-R gene to hepatocytes may induce physiological and 
cholesterol-sensitive expression of LDL-R and, for this reason, may be more 
effective than transfer of the LDL-R ORF with a liver-specific promoter in long-
term treatment of hypercholesterolemia resulting from LDL-R deficiency. 
However, at present there are no widely used viral-mediated gene therapy 
approaches that can deliver pieces of genomic DNA as large as the human LDL-R 
gene (~44 kb). 
 Finally, the immunological response to a gene therapy treatment must be 
considered. The introduction of any foreign protein, particularly the mass of 
protein present in 1013 viral particles as generated in this study (0.1 mg), is certain 
to pose immunological risks to the host as well as to the success of the treatment. 
Rabbits are known to be highly immunocompetent, making studies of immune 
response especially important. Successful completion of these studies in rabbits 
would contribute to transition of this gene therapy approach as a potential 






Appendix A: Isolation and Sequencing of LDL-R Gene 
 
 
A.1 Total RNA Isolation 
 
The following protocol was performed with TRIzol Reagent Kit (cat# 15596-026), 
purchased from Invitrogen 
 
1. Store 1g of rabbit tissue at -80°C 
 
2. Homogenize sample by adding 10ml of Trizol reagent (Invitrogen, 
 Carlsbad, CA)  and grinding tissue with mortar and pestle  
 
3. Transfer tissue sample to a 2ml low-retention tube and pass sample 
 through a sterile, disposable needle 10 times in order to fragment 
 high-molecular components such as DNA 
 
4. Let homogenate sit at room temperature for 5 minutes 
 
5. Add 200µL chloroform and vortex vigorously for 15 seconds 
 
6. Let homogenate sit at room temperature for 3 minutes 
 
7. Centrifuge sample at 12,000 x g for 15 minutes at 4°C 
 
8. Transfer upper aqueous phase to new 1.5mL RNase-free tube 
 
9. Add 5mL isopropanol to isolated aqueous phase 
 
10. Incubate at room temperature for 10 minutes 
 
11. Centrifuge at 12,000 x g for 10 minutes at 4°C 
 
12. Remove supernatant from tube, leaving only the RNA pellet 
 
13. Wash pellet with 10mL of 75% ethanol 
 
14. Centrifuge sample at 7500 x g for 5 minutes at 4°C and discard the wash 
 
15. Resuspend RNA pellet in RNase-free water by passing solution up and  




16. Incubate in heat block at 60°C for 10 minutes 
 
A.2 mRNA Isolation from Total RNA 
 
The following protocol was performed with an Illumina oligo(dT)-cellulose 
column (cat# 27-5543-02), purchased from GE Healthcare 
 
1. Load 1mL 0.1M NaOH onto assembled columns and let it drain completely 
 
2. Equilibrate the column with 4mL of binding buffer (10mM Tris-HCl, 1mM 
 EDTA, 0.3M NaCl at room temperature) in 1mL aliquots 
 
3. Load 1mL of binding buffer onto column and allow 0.5mL to pass through.  
 
4. Add 3mL of binding buffer to isolated total RNA pellet 
 
5. Heat RNA solution in a 70°C water bath for 5 minutes and chill on ice for 5 
 minutes 
 
6. Load dissolved RNA solution into column under gravity flow and wash with 
 4mL of binding buffer 
 
7. Elute mRNA with 1.5mL elution buffer (10mM Tris-HCl, 1mM EDTA) and 
 collect the eluate in a 15mL sterile centrifuge tube 
 
8. Equilibrate the column with 4mL binding buffer 
 
9. Heat the sample from step 8 in a 70°C water bath for 5 minutes and then chill 
 on ice for 5 minutes 
 
10. Incubate RNA sample at room temperature for 20 minutes, then add 90µL of 
 5M NaCl. 
 
11. Immediately load RNA into column and was with 4mL binding buffer 
 
12. Repeat Step 8 
 
13. Add 90µL of 5M NaCl and 3mL of ethanol to RNA 
 
14. Centrifuge sample at 7,000 x g for 2 minutes at 4°C 
 
15. Add 1mL of 75% ethanol to sample and repeat step 15 
 
16. Remove supernatant and dry pellet at room temperature 
 





A.3 Isolation and Amplification of cDNA 
 
The following protocol was performed with the ExactSTART Eukaryotic mRNA 
5’-&3’-RACE Kit (cat# ES80910), purchased from Epicentre. 
 
 
A.3.1 Alkaline Phosphatase Treatment 
 
1. Combine 10µL APex reaction buffer, 5µL APex heat-labile alkaline 
 phosphatase, nuclease-free water, and RNA sample to achieve a total 
 reaction volume of 100µL 
 
2. Incubate reaction at 37°C for 15 minutes 
 
3. Add 1µL of glycogen, 100µL of 1:1 phenol: chloroform 
 
4. Centrifuge mixture at 10,000 x g for 1 minute. Collect and save the aqueous 
 phase in a new tube 
 
5. Add 100µL of nuclease-free water and repeat step 4, and combine aqueous 
 phase with that of step 4 
 
6. Add 200µL of 24:1 chloroform: isoamyl alcohol to combined aqueous phases 
 and repeat step 4 
 
7. Add 20µL of 3M sodium acetate and 100µL of isopropyl alcohol to the tube 
 containing the combined aqueous phases and repeat step 4 
 
8. Incubate tube on ice for 20 minutes 
 
9. Centrifuge sample at 10,000 x g for 15 minutes at 4°C 
 
10. Remove and discard the supernatant 
 
11. Wash pellet with cold 80% ethanol and repeat steps 9 and 10 
 
12. Dry pellet and Resuspend RNA in 7.5µL nuclease free-water  
 
 
A.3.2 Tobacco Acid Pyrophosphatase Treatment 
 
1. Mix the following in a PCR tube and place on ice: 1µL TAP buffer, 0.5µL 




2. Incubate mixture at 37°C for 30 minutes 
 
3. After incubation period, keep mixture at room temperature and proceed 
immediately to Part C 
 
 
A.3.3  5’-RACE Acceptor Oligo Ligation 
 
1. Assemble the following reagents in the order given: 10µL TAP-treated RNA 
 from Part B Step 3, 4µL nuclease-free water, 2µL RNA ligase buffer, 1µL 
 TAP STOP buffer, 1µL 5’-RACE acceptor oligo, 1µL 2mM ATP solution, 
 and 1µL T4 RNA ligase 
 
2. Incubate reaction at 37°C for 30 minutes and proceed immediately to Part D 
 
 
A.3.4  First-Strand cDNA Synthesis 
 
1. Add the following reagents in a reaction tube at room temperature: 20µL of 
 mixture from Part B Step 2, 14µL nuclease-free water, 1µL cDNA 
 synthesis primer, 2µL dNTP Premix, 2µL MMLV RT buffer, and 1µL 
 MMLV reverse transcriptase 
 
2. Incubate reaction at 37°C for 1 hour 
 
3. Incubate reaction at 85°C for 10 minutes 
 
4. Add 1µL of RNase solution to reaction and incubate at 55°C for 5 minutes 
 
5. Store reaction tube at 55°C until PCR amplification in Part E 
 
 
A.3.5  Second-Strand cDNA Synthesis and PCR Amplification 
 
1. Add the following reagents to reaction tube at 55°C: 41µL of mixture from 
 Part D Step 4, 18µL nuclease-free water, 5µL PCR primer 1, 5µL PCR 
 primer 2, 30µL FailSafe PCR premix E, 1µL pHusion (New England 
 Biolabs, Ipswich, MA) DNA polymerase 
 
2. Cycle the sample in a thermocycler under the following conditions: 95°C for 
 30 seconds, followed by 20 cycles of: 95°C for 20 seconds, 60°C for 20 













A.4 Purification of PCR Product 
 
The following protocol was performed with a StrataPrep PCR Purification Kit 
(cat#211188) purchased from Agilgent Technologies 
 
1. Add a volume of DNA-binding solution equal to the volume of the aqueous 
 portion of the PCR product to a microcentrifuge tube and mix solution 
 
2. Transfer mixture to the microspin cup that is seatd in a 2mL receptacle tube 
 
3. Microcentrifuge the mixture at maximum speed for 30 seconds 
 
4. Remove and retain the microspin cup and discard DNA-binding solution 
 
5. Mix 20mL of 100% ethanol with 5X PCR buffer 
 
6. Add 750µL of mixture from step 5 to microspin cup 
 
7. Repeat step 3 and discard the wash buffer 
 
8. Transfer microspin cup to a new 1.5mL microcentrifuge tube and discard 
 receptacle tube 
 
9. Add 50µL elution buffer directly onto top of fiber matrix located at the bottom 
 of the microspin cup 
 
10. Incubate at room temperature for 5 minutes 
 
11. Repeat step 3 and discard the microspin cup 
 
 
A.5 1% Agarose Gel Electrophoresis 
 
1. Mix 400ml TAE buffer with 4g agarose in a flask 
 
2. Microwave mixture for 5 minutes, while stirring occasionally 
 
3. Assemble gel tray while the mixture cools down 
 
4. Pour mixture into gel tray 
 
5. Add 4 µL ethidium bromide and let mixture sit for approximately 1 hour 
 
6. Load samples into gel 
 a) Combine 20µL of sample with 4µl 5X buffer 
 b) Add 20µL into each well of gel using fine tipped pipettes 
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 c) Add 12µL of marker/ladder 
 
7. Run the gel at 110 volts for 25 minutes 
 
8. View gel in transilluminator 
 
 
A.6 Cloning of LDL-R cDNA products 
 
The following protocol was performed with the PCR-Script Amp Cloning Kit 
(cat#400771) purchased from Stratagene 
 
1. To prepare the ligation reaction, add the following components in order in a 
 0.5mL microcentrifuge tube: 1µL of pPCR-Script AMP SK(+) cloning 
 vector, 1µL PCR-Script 10x reaction buffer, 0.5µL of 10mM rATP, 4µL 
 of blunt-ended PCR product, 1µL of Srf I restriction enzyme, 1µL of T4 
 DNA ligase, 1.5µL distilled water 
 
2. Gently mix ligation reaction and incubate at room temperature for 1 hour 
 
3. Heat mixture at 65°C for 10 minutes 
 
4. Store mixture on ice until ready to perform the transofration into the XL10-
 Gold Kan ultracompetent cells 
 
5. Thaw the ultracompetent cells on ice 
 
6. Gently mix the cells and  aliquot 40µL of cells into each of 3 chilled 14mL 
 round-bottom tubes 
 
7. Add 1.6µL of XL10-Gold β-mercaptoethanol mix to 40µL of competent cells 
 
8. Gently swirl the contents of the tube and incubate the cells on ice for 10 
 minutes 
 
9. Add 2µL of mixture from step 4 to the tube from step 8 and gently swirl 
 
10. Incubate tube on ice for 30 minutes 
 
11. Preheat NZY+ broth in a 42°C water bath for later use 
 
12. Heat tubes in a 42°C water bath for 30 seconds 
 




14. Add 0.45mL of broth from step 11 to each tube and incubate tubes at 37°C for 
 1 hour with shaking at 225-250 rpm 
 
15. Spread 100µL of 2% X-gal and 100µL of 10mM IPTG on LB-ampicillin agar 
 plates 30 minutes prior to plating the transformations 
 
16. Plate 200µL of the transformation reactions and the transformation reactions 
 containing the pUC18 control plasmid using a sterile spreader 
 
17. Incubate plates overnight at 37°C. Colonies containing plasmids with inserts 
 will be white. 
 
18. Extract white colonies for examination 
 
 
A.7 Plasmid Miniprep 
 
The following protocol was performed using the QIAprep Spin Miniprep Kit  
(cat# 27104) purchased from QIAGEN 
 
1. Centrifuge 3mL of overnight bacterial culture sample at 8000rpm for 3 
 minutes at room temperature 
 
2. Resuspend bacterial cells in 250µL resuspension buffer (P1) and transfer to a    
 microcentrifuge tube 
 
3. Add 250µL lysis buffer (P2) to solution and mix thoroughly for no more than 
 5 minutes 
 
4. Add 350µL neutralization buffer (N3) to solution and mix thoroughly 
 
5. Centrifuge mixture for 10 minutes at 13,000rpm 
 
6. Extract the supernatant from step 5 by decanting or pipetting into the QIAprep 
 spin column 
 
7. Wash the spin column with 0.5mL binding buffer (PB), centrifuge for 1 
 minute, and discard the flow-through 
 
8. Wash the spin column with 0.75mL wash buffer (PE), centrifuge for 1 minute, 
 and discard the flow-through 
 
9. Transfer spin column to a 1.5mL microcentrifuge tube and add 50µL elution 
 buffer (EB) to center of spin column 
 
10. Let sample stand for 1 minute and centrifuge for 1 minute 
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Appendix B: Production of pFVG-lacZ and pFBVG-CMV-LDL-R plasmids 
 
 
B.1 Site-Directed Mutagenesis of XhoI within LDL-R ORF 
 
The reagents used in the following protocol were purchased from Integrated DNA 
Technologies 
 
1. Combine the following at room temperature: 0.5µL forward primer, 0.5µL 
 reverse primer, 0.25µL of 40mM dNTP mix, 1.25µL of 10x Pfu DNA 
 polymerase buffer, 1µL of LDL-R ORF, 0.25µL of Pfu DNA polymerase, 
 and 8.75µL of distilled water. 
 
2. Run the following PCR program: a) 5 minutes at 95°C    b) Repeat 18x: 50   
  seconds at 95°C, 50 seconds at 60°C, and 1 minute at 68°C    
  c) 7 minutes at 68°C 
 
3. Add 0.25µL of DpnI to reaction mixture and incubate for 1 hour at 37°C 
 
 
B.2 Double Digestion of pPCR-LDL-R and pFBGR 
 
1. Combine the following elements: Total 20 µL 
 a)  9µL H20 
 b)  2µL 10X buffer 
 c)  2µL BSA 
 d)  5µL DNA sample 
 e) 1µL XhoI restriction enzyme  
 f) 1µL AgeI restriction enzyme   
 
2. Incubate mixture for 3 hours at 37°C 
 
 
B.3 Extraction of LDL-ORF and pFBGR DNA sample from Gel 
 
The following protocol was performed with a QIAquick Gel Extraction Kit 
(cat#28704), purchased from QIAGEN 
 
1. Excise DNA fragment from agarose gel with a scalpel 
 
2. Weigh the gel in a tube. Add 3 volumes of Buffer QG to 1 volume of gel 
 
3. Incubate at 50°C for 10 minutes and vortex the tube every 2 minutes\ 
 
4. After the gel has dissolved completely, add 10µL 3M sodium acetate until the 




5. Add 1 gel volume of isopropanol to sample and mix 
 
6. Place the QIAquick spin column in the provided 2mL collection tube 
 
7. Apply sample to the spin column and centrifuge for 1 minute 
 
8. Discard the flow-through 
 
9. Add 0.5mL Buffer QG to spin column and centrifuge for 1 minute 
 
10. Repeat step 8 and add 0.75mL Buffer PE to spin column 
 
11. Centrifuge the spin column for 1 minute at 17,000 x g 
 
12. Place QIAquick spin column into a clean 1.5mL microcentrifuge tube 
 




B.4 DNA Ligation of pFB and LDL-R ORF 
 
1. Combine the following in an eppendorf tube: 
  a) 1µL DNA ligase buffer 
  b) 1µL T4 DNA ligase 
  c) 1µL of pFB linear DNA 
       d) 7µL of LDL-R ORF 
 
2. Store in 16°C environment overnight 
 
3. The following day, combine 4µL of ligation sample with 60µL E. coli 
 competent cells 
 
4. Put sample on ice for 30 minutes 
 
5. Heat-shock bacteria in 42°C heat block for 40 seconds 
 
6. Put sample on ice for 2 minutes 
 
7. Add 350mL of SOC recovery media to bacterial mixture 
 
8. Put on agitator for 1 hour at 37C 
 




B.5 Plasmid Maxiprep 
 
This protocol was performed with a QIAGEN Plasmid Plus Maxi Kit (cat#12963) 
purchased from QIAGEN 
 
1. Centrifuge 250mL of overnight LB culture at 6000 x g for 15 minutes at 4°C 
 
2. Resuspend the bacterial pellet in 10mL resuspension buffer (P1) 
 
3. Add 10mL lysis buffer (P2) to sample, mix, and incubate at room temperature 
 for 5 minutes 
 
4. During incubation, screw the cap onto the nozzle of the QIAfilter cartridge 
 
5. Add 10mL neutralization buffer (P3) to the mixture, and mix thoroughly 
 
6. Pour lysate into the barrel of the QIAfilter cartridge and incubate at room  
 temperature for 5 minutes 
 
7. Equilibrate a HiSpeed tip with 10mL equilibration buffer 
 
8. Remove cap from QIAfilter cartridge nozzle and insert plunger into cartridge 
 
9. Filter cell lysate into equilibrated HiSpeed tip 
 
10. Wash the HiSpeed tip with 60ml wash buffer (QC) 
 
11. Elute DNA with 15mL elution buffer (QF) 
 
12. Add 10.5mL isopropanol to lysate, mix, and incubate for 5 minutes 
 
13. During incubation, remove plunger and attach QIAprecipitator Module onto 
 cartridge nozzle 
 
14. Transfer the eluate-isopropanol mixture into the syringe and insert the plunger 
 
15. Filter the mixture through the QIAprecipitator using constant pressure 
 
16. Remove QIAprecipitator from syringe and take out the plunger. Reattach the    
 QIAprecipitator and add 2mL 70% ethanol to syringe 
 
17. Remove QIAprecipitator from syringe and take out the plunger. Reattach the 
 QIAprecipitator, insert the plunger, and dry the membrane by forcefully 
 pressing air through the QIAprecipitator 
 




19. Remove the plunger from a new 5mL syringe, attach the QIAprecipitator and 
hold it over a 1.5mL collection tube 
 a) Add 1mL buffer TE to syringe 
 b) Insert plunger and elute DNA into collection tube using constant  
       pressure 
 
20. Remove QIAprecipitator from syringe, pull out plunger, and reattach 
 QIAprecipitator to the 5mL syringe 
 
21. Transfer the eluate from step 19 to the 5mL syringe and elute a second time 
 into the 1.5mL collection tube 
 
 
B.6 Transfection of HeLa Cells 
 
1. Seed 5 x 104 cells/35mm dish in 3mL complete medium 24 hours prior to 
 transfection 
 
2. Add 97µL serum-free medium into bottom of 7mL Bijou tube 
 
3. Pipette 3µL of FuGene 6 reagent into medium without allowing any contact 
 with walls of plastic tube 
 
4. Gently flick the tube to mix the solution and incubate for 15 minutes at room 
 temperature 
 
5. Add 1µg DNA to diluted FuGene reagent 
 
6. Gently flick the tube to mix the solution and incubate for 30 minutes at room 
 temperature 
 
7. Add solution to HeLa cells in a dropwise manner. Gently swirl the wells to 
 ensure even distribution over the entire plate surface 
 
8. Incubate cells at 37°C for 2 hours 
 
 
B.7 Western Blot 
 
1. Obtain protein lysate 
 a) Keep cells on ice 
 b) Resuspend cell pellets in extraction buffer 
 c) Sonocate cells with decontaminated sonocator tip  




2. Add 100µL blue buffer and 5µL mercaptoethanol to samples 
 
3. Heat samples in 95°C heat block for 5 minutes 
 
4. During heating, prepare 10% Tris-glycine gel 
 a) Wash wells with distilled water 
 b) Fill gel cartridge with tris-glycine buffer 
 
5. Load wells with either 7µL of marker, 7µL of control, and 7µL of each 
 sample 
 
6. Run the gel at 30amps for 1 hour 
 
7. Prepare membrane and sponges for blotting 
 a) Place sponges and a membrane in two separate beakers, each     
          containing 1400mL transfer buffer 
 b) Squeeze sponges inside buffer to remove any air bubbles 
 c) Pour buffer into a large plastic container 
 
8.  Place the cartridge with the gel still on it into transfer buffer and gently rock 
 it to see if the gel will come off of the cartridge on its own. Allow it to 
 sit in buffer for 10 minutes. 
 
9. Assemble the transfer apparatus 
 a) Position one sheet of filter paper underneath the gel, while still in  
       the buffer 
 b) Gently lift the gel and filter paper and place them on top of 3  
       sponges 
 c) Place soaked membrane on top of the gel and use pipet to   
            remove air bubbles 
 d) Place second piece of filter paper on top of membrane and   
           remove air bubbles 
 e) Place 3 more sponges on top of filter paper 
 f) Place apparatus into vertical gel cartridge 
 
10.  Add transfer buffer to gel cartridge and run the gel at 25 volts in 4°C 
 
11.  Apply primary antibody Anti-LDLr pAb (Abnova cat#PAB8804) 
 a) Wash with western blot buffer and rock apparatus gently 
 
12. Apply secondary antibody Bovine anti-rabbit igG-HRP (Santa Cruz 
 Biotechnology cat# sc-2370) 






B.8 Enhanced Chemiluminscence 
 
1. Cut a piece of sheet protector to the proper size and place it in the metal 
 developing cartridge 
 
2. Dry membrane from western blot apparatus 
 
3. Place membrane inside sheet protector 
 
4. Put minimal amount of signing reagent (developing peroxide solution) onto 
 membrane until the entire membrane is covered 
 
5. Let membrane sit for 2 minutes and pipette any excess liquid 
 
6. Close sheet protector and tape it into the x-ray film cartridge 
 
7. Take cartridge to the dark room and activate the developing machine 
 
8.  Cut a corner of the film to distinguish which way the samples are oriented on  





























Appendix C: In vivo Study to Determine Optimal rAAV Serotype for Rabbit 
Liver Transduction 
 
C.1 Guidelines of Ethical Treatment and Euthanasia 
 
All research conducted using animal models must meet clear and strict and 
specific guidelines outlined by the American Veterinary Medical Association 
(AVMA), including proper and humane euthanasia. As described by the AVMA, 
it is the duty of every veterinarian to show the highest level of respect to animals 
and ensure that their death’s for research be as painless and distress free as 
possible. While it is not always possible to euthanize an animal with complete 
absence of pain or discomfort, the AVMA requires that euthanasia techniques 
result in a rapid loss of consciousness, followed by cardiac arrest, and then 
ultimately a loss of brain function (29).  
In its latest report on euthanasia guidelines, the AVMA describes two 
different categories for euthanasia methods: acceptable and conditionally 
acceptable. As described in the 2007 report, “acceptable methods are those that 
consistently produce a humane death when used as the sole means of euthanasia; 
conditionally acceptable methods are those techniques that by the nature of the 
technique or because of greater potential for operator error or safety hazards 
might not consistently produce humane death or are methods not well 
documented in the scientific literature” (29). 
For the purpose of study, the following acceptable methods, in regards to 
rabbit models, were examined (28, 29). 
1) Barbiturate Overdose - Barbiturates are drugs that are able to depress 
the central nervous system (CNS) and slowly can induce euthanasia by 
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shutting down the cerebral cortex and creating a loss of consciousness in 
animal species. An overdose of these drugs create deep anesthesia, 
followed by apnea, loss of control of the respiratory system, and finally 
cardiac arrest. Barbiturates are best administered intravenously and can be 
an effective method of euthanasia because of the minimal pain 
experienced by animals, as well as their cheap expense compared to other 
methods. 
2) Inhalent Anesthetic Overdose - Several inhalent anesthetics exist to 
euthanize animal species including ether, halothane, methoxylfurane, 
desflurane, and isoflurane; however, studies have shown that halothane 
has been found to be the most effective and safe inhalent anesthetic when 
trying to induce anesthesia quickly. In order for inhalent anesthetics to 
function, animals must be placed in a closed container with either a gauze 
soaked in the chosen anesthetic or the anethesthic transferred into the 
container by a vaporizer. Of the two available options, vaporizing is the 
least preferred method because of the longer induction time and the 
commonality of animals struggling and becoming irritated and anxious 
during vaporization. Inhalent anesthetics are an effective agent for smaller 
animals (typically 7 kilograms or less) and are considered safe in 
laboratory settings as most available inhalent anesthetics are both 
nonflammable and nonexplosive.  
3) Carbon Dioxide (compressed tanks only) When used with the right 
equipment, carbon dioxide (CO2) can be an effective method of 
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euthanizing small laboratory animals such as rats, mice, chickens, and 
rabbits. However, small burrowing animals such as rabbits of the species 
Oryctolagus experience some complications during exposure to CO2, as 
these animals have the physiologic mechanisms for dealing with 
hypercapnia, or loss of consciousness due to too much carbon dioxide in 
the bloodstream. Thus, researchers must use a sufficient concentration of 
carbon dioxide to kill the animal by hypoxemia. The only allowable 
technique of administering carbon dioxide to animals is through gas 
cylinders, as the chambers allow the exchange of the gas to be accurately 
regulated. CO2 is also a popular euthanasia method because of the gas is 
inexpensive, nonexplosive, nonflammable, and nearly harmless to 
personnel staff. 
4) Carbon Monoxide - A colorless, odorless gas, carbon monoxide (CO) 
can block the uptake of oxygen by binding to hemoglobin and cause fatal 
hypoxemia. CO remains both nonflammable and nonexplosive as long as 
the gas concentration remains below 10%. However, regardless of the 
gas’s concentration it can still be extremely dangerous for personnel 
working with it due to its toxicity and difficult to detect. An exhaust 
system is required to prevent humans from exposure that can create a 
health hazard. The gas itself creates a loss of consciousness in animals 
with minimal discomfort and an absences of pain. Concentrations between 
four to six percent are often used to ensure that death occurs quickly. 
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5) Potassium Chloride in Conjunction with General Anesthesia - 
Intravenously or intracardially injecting a supersaturated solution of 
potassium chloride into animals has been deemed an appropriate method 
of creating cardiac arrest and ultimately death. AVMA does note however 
that it is unacceptable to apply this method to an unanaesthetized animal. 
Animals must be under anesthesia and have a loss of consciousness, reflex 
muscle response, and response to noxious stimuli. The injection of the 
cardiotoxic potassium ions (administered 1 to 2 mmol/kg of body weight) 
will cause cardiac arrest in the subjects. Although potassium chloride is 
not a controlled substance and thus easy to obtain in research facilities, 
personnel must be trained and knowledgeable inanesthetic techniques to 
be able to appropriately administer the substance. Often times potassium 
chloride in conjunction with general anesthesia is not a chosen method for 
euthanasia because of the substance’s ability to create rippling of muscle 



















C.2 Approved IACUC protocol detailing rabbit care, blood withdrawal, viral 










































































C.3 Qualitative Analysis of β-galactosidase   
 
1. Dissect liver out from rabbit and section into several 1mm slices using a tissue 
 slicer 
 
2. Wash tissue samples in 1L of cold PBS solution (80g NaCl, 2g KCl, 11.5g 
 Na2HPO4, 2g KH2PO4) 
 
3. Fix the thin sections in β-galactosidase fixative (0.5% glutaraldehyde, 2.0% 
 paraformaldehyde in 0.1M phosphate buffer  containing  3mM Mgcl2 and 
 3mM EGTA) on ice for 30-60min 
 
4. Wash three times in β-galactosidase wash buffer (2 mM MgCl2 and 0.01% 
 sodium deoxycholate in 0.1M phosphate buffer) for 15 minutes at  room 
 temperature, with gentle rocking  
 
5.     Incubate tissues in β-galactosidase staining solution (25 mg/ml Xgal in 
 dimethylformamide, 50 mM potassium ferrocyanide 0.1M sodium 
 phosphate buffer of pH 8.0, and 50 mM potassium ferricyanide in 0.1M 
 sodium phosphate buffer of pH 8.0) at 37°C overnight 
 
6.     Monitor staining and take pictures of tissue samples 
 
 
C.4 Quantitative Analysis of β-galactosidase 
 
 
C.4.1 Preparation of Samples 
 
1. Wash tissues in PBS 
 
2. Suspend samples in lysis solution (100mM potassium phosphate, 0.2% Triton 
 X-100, 1mM DTT, 0.2mM PMSF, and 5µg/mL leupeptin) for 5 minutes 
 on ice 
 
3. Collect supernatant in microtubes and incubate at 48°C for 60 minutes 
 
 
C.4.2 Determination of Total Protein Concentration 
 
The following protocol was performed with Peirce BCA Protein Assay Kit 
(cat#23225), purchased from Thermo Scientific 
 
1. Pipette 25µl of each standard or unknown sample into microplate well 
 
2. Add 200µL of the working reagent to each well and mix plate thoroughly on a 




3. Cover and incubate tubes at 37°C for 30 minutes 
 
4. Cool plates to room temperature 
 
5. Set the spectrophotometer to 562nm, and measure the absorbance of all the 
 samples within 10 minutes 
 
6. Subtract the average 562nm absorbance of the blank standard sample from the 
 562nm absorbance of all other individual standards and unknown samples 
 
7. Prepare a standard curve by plotting the average blank-corrected 562nm 
 measurement for each BSA standard vs. its concentration in µg/mL. Use 




C.4.3 Determination of β-galactosidase Concentration 
 
The following protocol was performed with Galacto-Light Plus Kit (part#T9003), 
purchased from Applied Biosystems 
 
1. Dillute Galacton-Plus substrate 1:100 with reaction buffer 
 
2. Transfer 5µL of extract to microplate wells 
 
3. Add 70µL of reaction buffer to wells and incubate for 1 hour 
 
4. Place plate in luminometer and inject 100µL of accelerator 
 
5. Read signal after a 2 second delay 
 
 
C.5 DNA Isolation from Liver Samples and Purification 
 
The following protocol was performed with the Maxwell 16 MDx DNA 
Purification Cartridge Kit (cat#AS3000), purchased from Promega 
 
1. Add 500µL of nuclease-free water to each tube of lyophilized proteinase K, 
 and gently swirl to dissolve 
 
2. Dispense solution into smaller aliquots and store at -20°C 
 
3. Scrape 5µm sections of sample of interest into microtubes 
 




5. Incubate samples overnight at 70°C 
 
6. Add 2 volumes of lysis buffer to each sample 
 
7. Vortex microtubes 
 
8. Turn on Maxwell 16 MDx Instrument 
 
9. Verify that the Home screen indicates “SEV”. Press “Run/Stop” to continue 
 
10.  Select “DNA” and “Tissue DNA” protocol 
 
11. Transfer cartridges containing samples and plungers from the preparation rack 
 onto Maxwell 16 platform 
 
12. Place 1 blue elution tube for each cartridge into elution tube slots  
 
13. Add 300µL of elution buffer to each elution tube 
 
14. Press “Run/Stop” button to begin purification 
 
15. Follow on-screen instructions to transfer data 
 
16. Press “Run/Stop” to stop process 
 
17. Remove elution tubes, cartridges, and plungers from platform 
 
 
C.6 qPCR of Liver Samples 
 
1. Combine the following: 5 µl of template DNA, 10 µl of Premix Ex Taq 
 (TaKaRa), 0.4 µl of ROX Reference Dye (TaKaRa), 0.2 µmol/l of each 
 primer, and 0.1 µmol/l of probe, and 4µL nuclease-free water 
 
2. Set the following thermal profile for all reactions with 30ng of genomic DNA 
 in duplicates using the Lightcycler 2.0 machine: 95°C for 5 minutes, 










Appendix D: Production of rAAV Via Recombinant Baculovirus/Insect   
 Cell System 
 
The following protocols were performed with the Bac-to-Bac Baculovirus 
Expression System (cat#10359-016), purchased from Invitrogen, and were 
conducted at the NIH under the guidance of Dr. Robert Kotin. 
 
 
D.1 Insertion of LITR-LP-LDLr-polyA-RITR into Bacmid 
 
1. Thaw on vial of DH10BAC competent cells on ice 
 
2. Dispense 50µL of cells into 15mL rounded polypropylene tubes 
 
3. Add 50ng of plasmid DNA to cells and gently mix 
 
4. Incubate on ice for 30 minutes 
 
5. Heat-shock cells for 45 seconds at 42°C 
 
6. Chill on ice for 2 minutes 
 
7. Add 450µL of S.O.C. medium and shake in 37°C incubator for 4 hours 
 
8. Plate 100µL of dilution mixture on LB agar plate containing 50µg/ml 
 kanamycin, 7µg/mL gentamicin, 10µg tetracycline, 100µg/ml Blou-gal, 
 and 40µg/m: IPTG 
 
9. Incubate for 72 hours at 37°C 
 
10. Streak a single white colony on a fresh plate containing the same components 
from step 8 and incubate overnight at 37°C 
 
 
D.2. Isolation of Recombinant DNA from Bacmid 
 
1. Harvest 1.5mL bacterial cells by centrifugation at 9,000 x g for 15 minutes 
 
2. Discard the supernatant and add 0.4mL resuspension buffer to pellet. Transfer 
cell suspension to centrifuge tube 
 
3. Add 1.5mL lysis buffer and invert tube 5x 
 
4. Add 2.1nL precipitation buffer, invert tube 5x and centrifuge mixture at 




5. Discard the supernatant and resuspend DNA in 70% ethanol 
 
6. Centrifuge sample at 8,000 rpm for 5 minutes at 4°C 
 
7. Discard the supernatant, air-dry pellet for 10 minutes 
 
8. Dissolve pellet in 200µL TE Buffer 
 
9. Store bacmid DNA at 4°C 
 
 
D.3 Isolation of P1 Baculovirus 
 
1. Seed 2mL of Sf9 cells (1x106) into each well of a 6-well plate 
 
2. Incubate for 30 minutes at room temperature 
 
3. Mix 600µL of Grace’s medium without supplement and 30µg Bacmid   
 DNA from protocol D.2  
 
4. Prepare a separate solution of 600µL of Grace’s medium without supplement 
 and 30µg CellFectin 
 
5. Combine the solutions from steps 3 and 4 and mix gently 
 
6. Incubate for 30 minutes at room temperature 
 
7. Add 4.8mL of Grace’s medium to combined mix and remove supernatant 
 from 6-well plate 
 
8. Add 1mL of mix into each will in a drop-wise manner 
 
9. Incubate 6-well plate for 5 hours at 27°C 
 
10. Remove lipid mix, add 2mL of complete medium, and incubate for 96 hours 
 at 27°C 
 








D.4 Production of P2 Baculovirus  
 
1. Plate 100mL of Sf9 suspension cells (2x106) and incubate at room 
 temperature for 1 hour 
 
2. Infect cells with 1mL P1 Baculovirus 
 
3. Incubate cells for 72 hours at 27°C 
 
4. Collect 2mL of medium containing virus and transfer to microtube 
 
5. Centrifuge sample at 500 x g for 5 minutes 
 
6. Harvest P2 Baculovirus supernatant and store in dark bottle at 4°C 
 
 
D.5 Double Infection and Viral Purification by Affinity Chromatography 
 
1. Dilute stock of TIPS to 1:10,000 
 
2. Infect 200mL of Sf9 cells (2x106) with diluted TIPS cells 
 
3. Place suspension culture on shaker for 5 days  at 135 rpm and 28°C 
 
4. Add 1% of triton and 0.075M final NaCl 
 
5. Homogenize sample with deBEE 1000 homogenizer using a D10 nozzle and 
 process pressure at 15Kpsi 
 
6. Centrifuge sample at 12,000 x g for 45minutes 
 
7. Filter 0.2µM of the supernatant 
 
8. Add 10µg/mL of turbonuclease (cat#N0103M, Accelagen) 
 
9. Incubate sample for 2 hours at 37°C   
 
10. Add 50% PEG to supernatant until the final concentration of cells is 4% 
 
11. Place sample on shaker overnight at 4°C 
 
12. Centrifuge sample at 4,000rpm for 30 minutes 
 





14.  Ultracentrifuge sample in TI50 rotor at 45,000rpm, at 15°C for 40 hours 
 
15. Harvest rAAV by fractionating the gradient with 0.5mL fractions 
 
16. Pool the fractions that have a reflective index around 1.372 
 
17. Dialyze the fractions containing rAAV with PBS and 2mM MgCl2 
 








































Appendix E: Data 
 
E.1 Oryctolagus cuniculus Low Density Lipoprotein Receptor mRNA, 
Complete cds 
 
     1 gtgcactcct cgaagcccga ccgcccgcac gcacgctacg gctgggctgc gggtcccgga 
       61 gcggcactga cggcggaggc tcccacgatg aggacggcgc gctgggtcct cggcctgctc 
      121 ctggccgccg ctgccggggc tgcagcaggg gacaagtgtg gccggaatga gttccaatgc 
      181 cggaacggga agtgtatctc ctacaagtgg gtgtgtgacg gcagctccga gtgtcaggac 
      241 ggctcggacg agtgggagca gacctgcatg tctctcacct gcaagtccga tgactttagc 
      301 tgcggcggcc gcctgaaccg ctgcatcccc gggcactgga aatgcgacgg ccagcaggac 
      361 tgcgaggacg gctccgacga gctgggctgc gcgcccaaga cgtgctccca ggacgagttc 
      421 cgctgcgccg agggcgcgtg catctcccgg ctgttcgcct gcgacgggga gccggactgc 
      481 cccgacggct cggacgaggc ctcgtgcgcg ccgtccacct gcggccccgc ccacttccgg 
      541 tgcaacagct cctcctgcgt ccccgcgctg tgggcctgcg acggcgagcc ggactgcgac 
      601 gatggctccg acgagtggcc ggcgcgctgc ggcgcccgcc ccagcccgca gcccggccgc 
      661 gggccctgct cccgccacga gttccactgt ggcagcggcg agtgcgtgca cgcgagctgg 
      721 cgctgcgacg gcgacgccga ctgcagggac ggctcggacg agcgcgactg cgccgcggcc 
      781 acgtgccgcc cggacgagtt ccagtgctcg gacgggacgt gcatccatgg cagccggcag 
      841 tgtgaccagc agcaggactg cggggacatg agcgacgagg tgggctgcgt caacgtgaca 
      901 ctgtgcgagg ggcccgacaa gttcaagtgc cacagcgggg agtgcatctc cctggacaaa 
      961 gtgtgcaact ccgccaggga ctgccaggat tggtcagacg agcccatcaa agagtgcgcg 
     1021 accaatgagt gcatgcgggg caacggaggc tgctcccaca cctgcttcga cctcagaatc 
     1081 ggccacgagt gtcattgtcc caaaggctac cggctggtgg accagcgacg ctgcgaagat 
     1141 atcaatgagt gtgaggaccc cgacatctgc agccagctgt gtgtgaacct ggcgggcagc 
     1201 tacaagtgcg agtgccgggc cggcttccag ctggaccccc acagccaggc ctgcaaggcc 
     1261 gtggactcca tcgcctacct cttcttcacc aaccggcacg aggtgcgcaa gatgaccctg 
     1321 gaccgtagcg agtacacaag cctcatcgcc aacctcaaga acgtggtggc cctggacgcg 
     1381 gaggtggcca gcaaccgcat ctactggtcg gacctgtccc agcgcaagat ctacagcgca 
     1441 cagatcgacg gggcgcacgg cttccccgcc tacgacaccg tcatcagcag cgacctgcag 
     1501 gcccccgatg ggctggctgt ggactggatc cacggccaca tctactggac agactccgtg 
     1561 ctgggcaccg tgtccgtggc cgacaccagg gggttcagga ggaagacact gttccggcag 
     1621 gaaggctcca agcccagggc catcgtggtg gaccccgcgc acggcttcat gtactggacc 
     1681 gactggggcg tccccgccaa gatcgagaaa gggggcctga acggcgtgga cgtctactcc 
     1741 ctggtgaccg aggacatcca gtggcccaat ggcatcaccc tggatctttc cagcggccgc 
     1801 ctctactggg tggactccaa gctgcactcc atctccagca tcgacgtcaa cgggggcaac 
     1861 cggaagacgg tgctggagga cgagcagcgg ctggcgcacc ccttctctct ggccatcttt 
     1921 gaggacaaag tgttctggac ggacgtcatc aacgaagcca tcttcagtgc caaccgcctc 
     1981 accggctccg acgtccacct ggtggccgag aacctgctgt ccccggagga catcgtcctg 
     2041 ttccacaacc tcacgcagcc cagaggggtg aactggtgcg agaagacggc cctccccaac 
     2101 ggcggctgcc aatacctgtg cctgccggcc ccacagatca atagccactc gcccaagttc 
     2161 acctgcgcct gccccgacgg cacgctgctg gccgcggaca tgcggagctg ccgcacagag 
     2221 gccgacgtga tcctgagcac ccagagggcg tcgacggccg ctcggccgca gctcacgggc 
     2281 agccctgccg gtaccacaca ggagcccctg accgagccca cgctcagcac cttggagacg 
     2341 gcgaccacgt cccagcaagc cctgcacaac gccgacggcc gaggcagcga ggggacgccc 
     2401 aggagcgtgg gggccctgtc cgtcgtcctg cccatcgcgc tgctgggcct gctctgcctc 
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     2461 ggcgccctgg tcctgtggaa gaactggcgg ctccgcagcg tccacagcat caacttcgac 
     2521 aacccggtct accagaagac cacggaggac gaggtgcaca tctgcaggag ccaggacggc 
     2581 tacacctacc cctcgagaca gatggtcagc ctggaggacg acgtggcctg agccgccgcc 
     2641 tggatctcgc cgccacccgc gggcctgagc cgccgccgcc gccgcctgcc cgggccgtgt 
     2701 tttatatatt tattcgcccg ggatggggcc ggctgctctc tggacagagg ggggcccggg 
     2761 cctccctgca ctgcgcccgc gctcatctca ggagctccgt gtttacctcg ccggttgccc 
     2821 ttaactgtcc gagaagtgcc tgcgcccgcc cacgccaggt ccctggtccc cggcagcgtg 
     2881 gggcgggggc tgggcggagc gcggcccggg cgtgcatggc gttttagctt tgcacctcgc 
     2941 aagccgcgcg agtctgtgac gacatttgca ctttgtgcgt ttctggagac gctgagcaca 
     3001 tgtatagaaa ttatttattt ttgctaacgc tggctgctgt gtgcagcggc gcggggccgc 
     3061 ccgtgggggg gtgggggagg gctccgtgcc gcctttgaac cactgtatag agagttttta 
     3121 tagcctgaag gggtccctgt ggttgattaa acttctttaa cgagt 
 
 
E.2 Nucleotide Alignment for the Rabbit, Human, Mouse, Ovine, and Bovine               
LDL-R mRNA 
Red: high consensus    Black: neutral consensus   Blue: low consensus 
 
           1                                                              60 
rabbitmRNA                                                                    
 humanmRNA  CTCTTGCAGT GAGGTGAAGA CATTTGAAAA TCACCCCACT GCAAACTCCT CCCCCTGCTA 
 mousemRNA                                              GCAGACTCCT CCCCCGCCTG 
 ovinemRNA  CGCGTCC--- ---------- ---------- ---------- ---------- ---------- 
bovinemRNA  CGCGTCC--- ---------- ---------- ---------- ---------- ---------- 
 Consensus  c.c.t.c... .......... .......... .......... .......... .......... 
 
         61                                                            120 
rabbitmRNA                                                                    
 humanmRNA  GAAACCTCAC ATTGAAATGC TGTAAATGAC GTGGGCCCCG AGTGCAATCG ---------- 
 mousemRNA  GAAACCTCGC CCCTAGTACT GGGAATGACT CTGGGCGTGC GGCGTAGTTT GCAGCCGGGA 
 ovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
bovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 Consensus  .......... .......... .......... .......... .......... .......... 
 
            121                                                           180 
rabbitmRNA                                               GTGCACTCC TCGAAGCCCG 
 humanmRNA  ---------- ---------- ---------- ---------- --------CG GGAAGCCAGG 
 mousemRNA  CACCGTGAGG CTTGCGAGCC CAGATTCGCA GCCGAGACAC CGTGGGGCCC GCGATCCAGT 
 ovinemRNA  ---------- ---------- ---------- ---------- --TGGCCGCG CGAAGCCGGG 
bovinemRNA  ---------- ---------- ---------- ---------- --GGGCCGCG CGAAGCCCGG 
 Consensus  .......... .......... .......... .......... ..tgg.c.Cg .gaAgcC.gg 
 
            181                                                           240 
rabbitmRNA  ACCGCCCGCA CGCACGCTAC GGCTGGGCTG CGGGTCCCGG AGCGGCACTG ACGGCGGAGG 
 humanmRNA  GTTTCCAGCT AGGACACAGC AGGTC--GTG ATCCGGGTCG GGACAC-TGC CTGGCAGAGG 
 mousemRNA  GTTTGCAGCG GGAACATTTC GGGGTCTGTG ATCCGAGTGA GGACGC-AAC GCAGAAGCTA 
 ovinemRNA  GGTGCCAGAG CGGTCACTGC CAGCGGACAG CGGCCTGTGC CGGGGCGTGA CAAGCGGAGG 
bovinemRNA  GTTTCCAGAG CGGTCACTGC GAGCGGACAG CGGCCTGGGC CGGGGCGTGA CAAGCGGAGG 
 Consensus  gtttcCaGcg cGgaCactgC ggg.gg.ctG cggc..gtg. .G.ggC.tg. c.aGcgGagg 
 
            241                                                           300 
rabbitmRNA  CTCCCACGAT GAGGACGGCG ---------- --CGCTGGGT CCTCGGCCTG CTCCTGGCCG 
 humanmRNA  CTGCGAGCAT GGGGCCCTGG GGCTGGAAAT TGCGCTGGAC CGTCGCCTTG CTCCT---CG 
 mousemRNA  -----AGGAT GAGCACCGCG GATCTGATGC GTCGCTGGGT CATCGCCCTG CTCCT---GG 
 ovinemRNA  CTGGGATCAT GAGGCTCGCG GGCTGGGGAC TGCGCTGGGC CATCGCCCTG CTCAT---CG 
bovinemRNA  CTGGGATCAT GAGGCTTGCG GGCTGGGGGC TGCGCTGGGC CATCGCCCTG CTCAT---CG 





            301                                                           360 
rabbitmRNA  CCGCTGCCGG GGCTGCAGCA GGGGACAAGT GTGGCCGGAA TGAGTTCCAA TGCCGGAACG 
 humanmRNA  CCGCGGCGGG GACTGCAGTG GGCGACAGAT GCGAAAGAAA CGAGTTCCAG TGCCAAGACG 
 mousemRNA  CTGCTGCCGG AGTTGCAGCA GAAGACTCAT GCAGCAGGAA CGAGTTCCAG TGTAGAGACG 
 ovinemRNA  CTGCGGGGGA GGCTGCAGTG GAAGACAACT GTGCGAGAAA TGAGTTTCAG TGCCGAGATG 
bovinemRNA  CTGTGGGGGA GGCTGCAGTG GAAGACAACT GTGGGAGAAA CGAGTTTCAG TGCCAAGATG 
 Consensus  CtGcgGcgGg ggcTGCAGtg GaaGACaa.T Gtgg.aGaAA cGAGTTcCAg TGccgagAcG 
 
            361                                                           420 
rabbitmRNA  GGAAGTGTAT CTCCTACAAG TGGGTGTGTG ACGGCAGCTC CGAGTGTCAG GACGGCTCGG 
 humanmRNA  GGAAATGCAT CTCCTACAAG TGGGTCTGCG ATGGCAGCGC TGAGTGCCAG GATGGCTCTG 
 mousemRNA  GAAAATGCAT CGCTAGCAAG TGGGTGTGCG ATGGCAGCCC CGAGTGCCCG GATGGCTCCG 
 ovinemRNA  GGAAATGCAT CTCCTATAAG TGGGTTTGTG ATGGGACCGC CGAGTGCCAA GACGGCTCTG 
bovinemRNA  GGAAATGCAT CTCCTATAAG TGGGTTTGTG ATGGGACCGC CGAGTGCCAA GACGGCTCTG 
 Consensus  GgAAaTGcAT CtCctacAAG TGGGT.TGtG AtGGcAgCgC cGAGTGcCag GAcGGCTCtG 
 
            421                                                           480 
rabbitmRNA  ACGAGTGGGA GCAGACCTGC ATGTCTCTCA CCTGCAAGTC CGATGACTTT AGCTGCGGCG 
 humanmRNA  ATGAGTCCCA GGAGACGTGC TTGTCTGTCA CCTGCAAATC CGGGGACTTC AGCTGTGGGG 
 mousemRNA  ATGAGTCCCC AGAGACATGC ATGTCTGTCA CCTGTCAGTC CAATCAATTC AGCTGTGGAG 
 ovinemRNA  ATGAATCCCA GGAGACGTGT AAGTCTGTCA CCTGCAAGAT GGGGGACTTC AGCTGTGGGG 
bovinemRNA  ATGAATCCCA GGAGACATGC AAGTCTGTCA CCTGCAAGAT GGGGGACTTC AGCTGTGGGG 
 Consensus  AtGAgTccca ggAGAC.TGc atGTCTgTCA CCTGcaAgtc cggggAcTTc AGCTGtGGgG 
 
            481                                                           540 
rabbitmRNA  GCCGCCTGAA CCGCTGCATC CCCGGGCACT GGAAATGCGA CGGCCAGCAG GACTGCGAGG 
 humanmRNA  GCCGTGTCAA CCGCTGCATT CCTCAGTTCT GGAGGTGCGA TGGCCAAGTG GACTGCGACA 
 mousemRNA  GCCGTGTCAG CCGATGCATT CCTGACTCCT GGAGATGTGA TGGACAGGTA GACTGTGAAA 
 ovinemRNA  GCCGTGTCAA CCGCTGCATT TCGGAGTCCT GGAGATGCGA TGGCCAGAAG GACTGCGAGA 
bovinemRNA  GCCGTGTCAA CCGCTGCATT TCGGGGTCCT GGAGATGCGA TGGCCAGGTG GACTGCGAGA 
 Consensus  GCCGtgTcAa CCGcTGCATt cC.gagtcCT GGAgaTGcGA tGGcCAggtg GACTGcGAga 
 
            541                                                           600 
rabbitmRNA  ACGGCTCCGA CGAGCTGGGC TGCGCGCCCA AGACGTGCTC CCAGGACGAG TTCCGCTGCG 
 humanmRNA  ACGGCTCAGA CGAGCAAGGC TGTCCCCCCA AGACGTGCTC CCAGGACGAG TTTCGCTGCC 
 mousemRNA  ATGACTCAGA CGAACAAGGC TGTCCCCCCA AGACGTGCTC CCAGGATGAC TTCCGATGCC 
 ovinemRNA  ATGGCTCGGA CGAGGAAGGC TGTCCCCCCA AGACGTGCTC CCAGGATGAG TTCCGTTGCA 
bovinemRNA  ATGGCTCGGA CGAAGAAGGC TGTTCCCCCA AGACGTGCTC CCAGGATGAG TTCCGCTGTA 
 Consensus  AtGgCTC.GA CGAgcaaGGC TGtcCcCCCA AGACGTGCTC CCAGGAtGAg TTcCGcTGc. 
 
            601                                                           660 
rabbitmRNA  CCGAGGGCGC GTGCATCTCC CGGCTGTTCG CCTGCGACGG GGAGCCGGAC TGCCCCGACG 
 humanmRNA  ACGATGGGAA GTGCATCTCT CGGCAGTTCG TCTGTGACTC AGACCGGGAC TGCTTGGACG 
 mousemRNA  AGGATGGCAA GTGCATCTCC CCGCAGTTTG TGTGTGATGG AGACCGAGAT TGCCTAGATG 
 ovinemRNA  ATGATGGCAA GTGCATTGCC CCGAAGTTCG TCTGTGACTT GGACCTGGAC TGCTTAGATG 
bovinemRNA  ATGACGGCAA GTGCATTGCC CCGAAGTTCG TCTGTGACTT GGACCTGGAC TGCTTAGATG 
 Consensus  a.GAtGGcaa GTGCATctCc CcGcaGTTcG tcTGtGAct. gGAcC.gGAc TGCttaGAtG 
 
 
            661                                                           720 
rabbitmRNA  GCTCGGACGA GGCCTCGTGC GCGCCGTCCA CCTGCGGCCC CGCCCACTTC CGGTGCAACA 
 humanmRNA  GCTCAGACGA GGCCTCCTGC CCGGTGCTCA CCTGTGGTCC CGCCAGCTTC CAGTGCAACA 
 mousemRNA  GCTCTGATGA GGCCCACTGC CAGGCCACCA CTTGTGGCCC CGCCCACTTC CGCTGCAACT 
 ovinemRNA  GCTCGGATGA GGCGTCCTGC CCCATGCCCA CCTGCAGCCC TGCCAACTTC CAATGCAACA 
bovinemRNA  GCTCGGATGA GGCGTCCTGC CCCATGCCCA CCTGCGGCCC TGCCAACTTC CAGTGCAACA 
 Consensus  GCTCgGAtGA GGCctccTGC ccg.tgccCA CcTGcgGcCC cGCCaaCTTC CagTGCAACa 
 
            721                                                           780 
rabbitmRNA  GCTCCTCCTG CGTCCCCGCG CTGTGGGCCT GCGACGGCGA GCCGGACTGC GACGATGGCT 
 humanmRNA  GCTCCACCTG CATCCCCCAG CTGTGGGCCT GCGACAACGA CCCCGACTGC GAAGATGGCT 
 mousemRNA  CATCCATATG CATCCCCAGT CTTTGGGCCT GCGACGGGGA TGTCGACTGT GTTGACGGCT 
 ovinemRNA  GCTCCATGTG CATCCCCCAG CTCTGGGCCT GCGACGGCGA CCCCGACTGC GACGATGGCT 
bovinemRNA  GCTCCATGTG CATCCCCCAG CTCTGGGCCT GCGATGGCGA CCCCGACTGT GACGATGGCT 






            781                                                           840 
rabbitmRNA  CCGACGAGTG GCCGGCGCGC TGCGGCGCCC GCCCCA---- --GCCCGCAG CCCGGCCGCG 
 humanmRNA  CGGATGAGTG GCCGCAGCGC TGTAGGGGTC TTTACGTG-- ----TTCCAA GGGGACAGTA 
 mousemRNA  CCGATGAGTG GCCACAGAAC TGCCAGGGCC GAGACACGGC ---CTCCAAA GGCGTTAGCA 
 ovinemRNA  CAGACGAGTG GCCAAAGCAC TGCGGGAGCC CCCACCCATC AGGCCCCCCG AAGGACGACA 
bovinemRNA  CAGATGAGTG GCCAAAGCAC TGCGGGACCC CCCACCCATC AGGCCCCCTG CAGGACAACA 
 Consensus  C.GAtGAGTG GCCa.aGcaC TGcgggggcC .ccaC.c..c ..gcccccag ..gGacagca 
 
            841                                                           900 
rabbitmRNA  GGCCCTGCTC CCGCCACGAG TTCCACTGTG GCAGCGGCGA GTGCGTGCAC GCGAGCTGGC 
 humanmRNA  GCCCCTGCTC GGCCTTCGAG TTCCACTGCC TAAGTGGCGA GTGCATCCAC TCCAGCTGGC 
 mousemRNA  GCCCCTGCTC CTCCCTGGAG TTCCACTGTG GTAGCAGTGA GTGTATCCAT CGCAGCTGGG 
 ovinemRNA  ACCCCTGCTC GGCCCTCGAG TTCCACTGCG GCAGTGGCGA GTGCATCCAC TCCAGCTGGC 
bovinemRNA  ACCCCTGCTC GGCCCTCGAG TTCCACTGCG GCAGTGGCGA GTGCATCCAC TCCAGCTGGC 
 Consensus  gcCCCTGCTC ggcCctcGAG TTCCACTGcg gcAGtgGcGA GTGcaTcCAc tccAGCTGGc 
 
            901                                                           960 
rabbitmRNA  GCTGCGACGG CGACGCCGAC TGCAGGGACG GCTCGGACGA GCGCGACTGC GCCGCGGCCA 
 humanmRNA  GCTGTGATGG TGGCCCCGAC TGCAAGGACA AATCTGACGA GGAAAACTGC GCTGTGGCCA 
 mousemRNA  TCTGTGACGG CGAGGCAGAC TGCAAGGACA AGTCAGATGA GGAGCACTGC GCGGTGGCCA 
 ovinemRNA  GTTGCGACAG TGACCCTGAC TGCAAGGACA AGTCTGACGA GGAGAACTGC GCTGTGGCCA 
bovinemRNA  ATTGCGACCA TGACCCTGAC TGCAAGGACA AGTCTGACGA GGAGAACTGC GCTGTGGCCA 
 Consensus  gcTGcGAcgg tGaccC.GAC TGCAaGGACa agTCtGAcGA GgagaACTGC GCtGtGGCCA 
 
            961                                                          1020 
rabbitmRNA  CGTGCCGCCC GGACGAGTTC CAGTGCTCGG ACGGGACGTG CATCCATGGC AGCCGGCAGT 
 humanmRNA  CCTGTCGCCC TGACGAATTC CAGTGCTCTG ATGGAAACTG CATCCATGGC AGCCGGCAGT 
 mousemRNA  CCTGCCGACC TGATGAATTC CAGTGTGCAG ATGGCTCCTG CATTCACGGT AGCCGCCAGT 
 ovinemRNA  CGTGCCGGCC TGATGAATTC CAGTGCTCTG ATGGGACCTG CATCCATGGC AGCCGGCAGT 
bovinemRNA  CGTGCCGGCC TGATGAATTC CAGTGCTCGG ATGGGACCTG CATCCATGGT AGCCGGCAGT 
 Consensus  CgTGcCG.CC tGAtGAaTTC CAGTGctC.G AtGGgaccTG CATcCAtGGc AGCCGgCAGT 
 
            1021                                                         1080 
rabbitmRNA  GTGACCAGCA GCAGGACTGC GGGGACATGA GCGACGAGGT GGGCTGCGTC AACGTGACAC 
 humanmRNA  GTGACCGGGA ATATGACTGC AAGGACATGA GCGATGAAGT TGGCTGCGTT AATGTGACAC 
 mousemRNA  GTGACCGTGA ACATGACTGC AAGGACATGA GCGACGAGCT CGGCTGCGTC AATGTGACAC 
 ovinemRNA  GCGACAGGGA GCCTGACTGT AAGGATCTGA GTGACGAGCT GGGCTGCGTC AACGTGACTC 
bovinemRNA  GCGACAGGGA GCCTGACTGT AAGGATCTGA GTGACGAGCT GGGCTGCGTC AACGTGACTC 
 Consensus  GtGACcgggA gcatGACTGc aaGGAcaTGA GcGAcGAgcT gGGCTGCGTc AAcGTGACaC 
 
            1081                                                         1140 
rabbitmRNA  TGTGCGAGGG GCCCGACAAG TTCAAGTGCC ACAGCGGGGA GTGCATCTCC CTGGACAAAG 
 humanmRNA  TCTGCGAGGG ACCCAACAAG TTCAAGTGTC ACAGCGGCGA ATGCATCACC CTGGACAAAG 
 mousemRNA  AGTGTGATGG CCCCAACAAG TTCAAGTGTC ACAGTGGGGA GTGCATCAGC TTGGACAAGG 
 ovinemRNA  TTTGCGAGGG GCCCAACAAG TTCAAGTGCC ACAGCGGCGA GTGCATCTCC CTGGACAAAG 
bovinemRNA  TTTGTGAGGG GCCCAACAAG TTCAAGTGCC AAAGCGGTGA GTGCATCTCC CTGGACAAAG 
 Consensus  t.TGcGAgGG gCCCaACAAG TTCAAGTGcC AcAGcGG.GA gTGCATCtcC cTGGACAAaG 
 
 
            1141                                                         1200 
rabbitmRNA  TGTGCAACTC CGCCAGGGAC TGCCAGGATT GGTCAGACGA GCCCATCAAA GAGTGCGCGA 
 humanmRNA  TCTGCAACAT GGCTAGAGAC TGCCGGGACT GGTCAGATGA ACCCATCAAA GAGTGCGGGA 
 mousemRNA  TGTGCGACTC CGCCCGCGAC TGCCAGGACT GGTCGGATGA GCCCATCAAG GAGTGCAAGA 
 ovinemRNA  TGTGCAACTC CATCAGGGAC TGCCGGGACT GGTCGGACGA GCCCCTCAAG GACTGCGGGA 
bovinemRNA  TGTGCAACTC CGTCAGGGAC TGCCGGGACT GGTCGGACGA GCCCCTCAAG GACTGTGGGA 





            1201                                                         1260 
rabbitmRNA  CCAATGAGTG CATGCGGGGC AACGGAGGCT GCTCCCACAC CTGCTTCGAC CTCAGAATCG 
 humanmRNA  CCAACGAATG CTTGGACAAC AACGGCGGCT GTTCCCACGT CTGCAATGAC CTTAAGATCG 
 mousemRNA  CCAACGAGTG TTTGGACAAC AATGGTGGCT GTTCCCACAT CTGCAAGGAC CTCAAGATTG 
 ovinemRNA  CCAATGAGTG TCTGGACAAC AAGAGCGGCT GCTCTCACAT CTGCAATGAC CTCAAGATCG 
bovinemRNA  CCAACGAGTG TCTGGACAAC AAGGGCGGCT GCTCTCACAT CTGCAATGAC CTCAAGATCG 




            1261                                                         1320 
rabbitmRNA  GCCACGAGTG TCATTGTCCC AAAGGCTACC GGCTGGTGGA CCAGCGACGC TGCGAAGATA 
 humanmRNA  GCTACGAGTG CCTGTGCCCC GACGGCTTCC AGCTGGTGGC CCAGCGAAGA TGCGAAGATA 
 mousemRNA  GCTCTGAGTG CCTGTGTCCC AGCGGCTTCC GGTTGGTGGA CCTCCACAGG TGTGAAGATA 
 ovinemRNA  GCTACGAGTG CCTGTGTCCT GAAGGCTTCC AGCTAGTGGA CAAGCACAGA TGCGAAGATA 
bovinemRNA  GCTACGAGTG CCTGTGTCCC GAAGGCTTCC AGCTAGTGGG CAAGCACAGA TGTGAAGATA 
 Consensus  GCtacGAGTG cCtgTGtCCc gaaGGCTtCC aGcTgGTGGa CcagCacaGa TGcGAAGATA 
 
            1321                                                         1380 
rabbitmRNA  TCAATGAGTG TGAGGACCCC GACATCTGCA GCCAGCTGTG TGTGAACCTG GCGGGCAGCT 
 humanmRNA  TCGATGAGTG TCAGGATCCC GACACCTGCA GCCAGCTCTG CGTGAACCTG GAGGGTGGCT 
 mousemRNA  TTGACGAGTG TCAGGAGCCA GACACCTGCA GCCAGCTCTG TGTGAACCTG GAAGGCAGCT 
 ovinemRNA  TCGATGAGTG TCAGAACCCT GACACCTGCA GCCAGCTCTG CGTGAACCTC GAGGGCAGCT 
bovinemRNA  TCGATGAGTG TCAGAACCCT GACACCTGCA GCCAGCTCTG CGTGAACCTC GAGGGCAGCT 
 Consensus  TcgAtGAGTG TcAGgAcCC. GACAcCTGCA GCCAGCTcTG cGTGAACCTg GagGGcaGCT 
 
            1381                                                         1440 
rabbitmRNA  ACAAGTGCGA GTGCCGGGCC GGCTTCCAGC TGGACCCCCA CAGCCAGGCC TGCAAGGCCG 
 humanmRNA  ACAAGTGCCA GTGTGAGGAA GGCTTCCAGC TGGACCCCCA CACGAAGGCC TGCAAGGCTG 
 mousemRNA  ACAAGTGTGA GTGCCAGGCC GGCTTCCACA TGGACCCACA CACCAGGGTC TGCAAGGCTG 
 ovinemRNA  ACAAATGCGA GTGCGAAGAG GGCTTCCGGC TGGAGCCCCT CACCAAGGCC TGCAAGGCCG 
bovinemRNA  ACAAATGCGA GTGTGAAGAG GGCTTCCGGC TGGAGCCCCT CACCAAGGCC TGCAAGGCCG 
 Consensus  ACAAgTGcgA GTGcgagGa. GGCTTCCagc TGGAcCCcCa CAccaaGGcC TGCAAGGCcG 
 
            1441                                                         1500 
rabbitmRNA  TGGACTCCAT CGCCTACCTC TTCTTCACCA ACCGGCACGA GGTGCGCAAG ATGACCCTGG 
 humanmRNA  TGGGCTCCAT CGCCTACCTC TTCTTCACCA ACCGGCACGA GGTCAGGAAG ATGACGCTGG 
 mousemRNA  TGGGCTCCAT AGGCTATCTG CTCTTCACCA ACCGCCACGA GGTCCGGAAG ATGACCCTGG 
 ovinemRNA  TGGGCACCAT CGCCTACCTC TTCTTCACCA ACCGCCATGA AGTGAGGAAG ATGACTCTGG 
bovinemRNA  TGGGCACCAT CGCCTACCTC TTCTTTACCA ACCGCCACGA AGTCAGGAAG ATGACTCTGG 
 Consensus  TGGgCtCCAT cGcCTAcCTc tTCTTcACCA ACCGcCAcGA gGTcaGgAAG ATGAC.CTGG 
 
            1501                                                         1560 
rabbitmRNA  ACCGTAGCGA GTACACAAGC CTCATCGCCA ACCTCAAGAA CGTGGTGGCC CTGGACGCGG 
 humanmRNA  ACCGGAGCGA GTACACCAGC CTCATCCCCA ACCTGAGGAA CGTGGTCGCT CTGGACACGG 
 mousemRNA  ACCGCAGCGA GTACACCAGT CTGCTCCCCA ACCTGAAGAA TGTGGTGGCT CTCGACACGG 
 ovinemRNA  ACCGAAGCGA GTATACCAGC CTCATCCCCA ACCTTAAGAA TGTGGTTGCC CTGGACACGG 
bovinemRNA  ACCGAAGCGA GTACACCAGC CTTATCCCCA ACCTTAAGAA CGTGGTCGCC CTGGACACGG 
 Consensus  ACCG.AGCGA GTAcACcAGc CTcaTCcCCA ACCT.AaGAA cGTGGT.GCc CTgGACaCGG 
 
            1561                                                         1620 
rabbitmRNA  AGGTGGCCAG CAACCGCATC TACTGGTCGG ACCTGTCCCA GCGCAAGATC TACAGCGCAC 
 humanmRNA  AGGTGGCCAG CAATAGAATC TACTGGTCTG ACCTGTCCCA GAGAATGATC TGCAGCACCC 
 mousemRNA  AGGTGACCAA CAATAGAATC TACTGGTCCG ACCTGTCCCA AAAAAAGATC TACAGCGCCC 
 ovinemRNA  AGGTGGCCAG TAACAGGATC TACTGGTCTG ACCTGTCCCA GAGGAAGATC TACAGTGCCC 
bovinemRNA  AGGTGGCCAG TAACAGGATC TACTGGTCTG ACCTGTCCCA GAGGAAGATC TACAGTGCCC 
 Consensus  AGGTGgCCAg cAAcaG.ATC TACTGGTCtG ACCTGTCCCA gag.AaGATC TaCAGcgCcC 
 
            1621                                                         1680 
rabbitmRNA  AGATCGACGG GGCGCACGGC TTCCCCGCCT ACGACACCGT CATCAGCAGC GACCTGCAGG 
 humanmRNA  AGCTTGACAG AGCCCACGGC GTCTCTTCCT ATGACACCGT CATCAGCAGA GACATCCAGG 
 mousemRNA  TGATGGACCA GGCCCCTAAC TTGTC---CT ACGACACCAT CATCAGTGAG GACCTGCATG 
 ovinemRNA  AGATCGATGA CGCCCCCGGC TTCTCCTCCT ACGACACCGT CATCGGTGAG AATCTCCAGG 
bovinemRNA  AGATCGACGG AGCCCCCGGC TTCTCCTCCT ACGACACCGT CATTGGCGAG GATCTCCAGG 
 Consensus  aGaTcGAcgg .GCcCccggC tTctCctcCT AcGACACCgT CATcaGcgag gAccTcCAgG 
 
            1681                                                         1740 
rabbitmRNA  CCCCCGATGG GCTGGCTGTG GACTGGATCC ACGGCCACAT CTACTGGACA GACTCCGTGC 
 humanmRNA  CCCCCGACGG GCTGGCTGTG GACTGGATCC ACAGCAACAT CTACTGGACC GACTCTGTCC 
 mousemRNA  CCCCTGACGG GCTGGCGGTA GACTGGATCC ACCGCAACAT CTACTGGACA GATTCAGTCC 
 ovinemRNA  CCCCCGACGG GCTGGCGGTG GACTGGATCC ACAGCAACAT CTACTGGACC GACTCCATCC 
bovinemRNA  CCCCCGATGG GCTGGCGGTG GATTGGATCC ACAGCAACAT CTACTGGACC GACTCCATCC 






            1741                                                         1800 
rabbitmRNA  TGGGCACCGT GTCCGTGGCC GACACCAGGG GGTTCAGGAG GAAGACACTG TTCCGGCAGG 
 humanmRNA  TGGGCACTGT CTCTGTTGCG GATACCAAGG GCGTGAAGAG GAAAACGTTA TTCAGGGAGA 
 mousemRNA  CAGGCAGCGT ATCTGTGGCT GACACCAAGG GCGTAAAGAG GAGGACACTG TTCCAAGAGG 
 ovinemRNA  TGGGCACCGT CTCCGTGGCT GACACCAAAG GGGTGAAGAG GAAGACACTG TTCCAGGAGG 
bovinemRNA  TGGGTACCGT CTCCGTGGCT GACACCAAAG GTGTGAAGAG GAAGACGCTC TTCCAGGAGG 
 Consensus  tgGGcAccGT cTCcGTgGCt GAcACCAagG G.gTgAaGAG GAagACacTg TTCcaggAGg 
 
            1801                                                         1860 
rabbitmRNA  AAGGCTCCAA GCCCAGGGCC ATCGTGGTGG ACCCCGCGCA CGGCTTCATG TACTGGACCG 
 humanmRNA  ACGGCTCCAA GCCAAGGGCC ATCGTGGTGG ATCCTGTTCA TGGCTTCATG TACTGGACTG 
 mousemRNA  CAGGGTCCAG ACCCAGAGCC ATCGTAGTGG ACCCTGTGCA TGGCTTCATG TACTGGACAG 
 ovinemRNA  AAGGCTCCAA GCCACGGGCC ATTGTGGTTG ATCCTGTCCA CGGCTTCATG TATTGGACTG 
bovinemRNA  AAGGCTCCAA ACCACGGGCC ATTGTGGTCG ATCCCGTCCA TGGCTTCATG TATTGGACTG 
 Consensus  aaGGcTCCAa gCCaaGgGCC ATcGTgGTgG AtCCtGt.CA tGGCTTCATG TAcTGGACtG 
 
            1861                                                         1920 
rabbitmRNA  ACTGGGGCGT CCCCGCCAAG ATCGAGAAAG GGGGCCTGAA CGGCGTGGAC GTCTACTCCC 
 humanmRNA  ACTGGGGAAC TCCCGCCAAG ATCAAGAAAG GGGGCCTGAA TGGTGTGGAC ATCTACTCGC 
 mousemRNA  ATTGGGGAAC ACCCGCCAAG ATCAAGAAAG GGGGTTTGAA TGGTGTGGAC ATCCACTCAC 
 ovinemRNA  ACTGGGGCAC CCCTGCCGAG ATCAAGAAGG GGGGCCTCAA CGGCGTGGAC GTTTACTCGC 
bovinemRNA  ACTGGGGCGC TCCTGCCGAG ATCAAGAAGG GGGGCCTCAA CGGCGTGGAC GTTTACTCGC 
 Consensus  AcTGGGGcac .CCcGCCaAG ATCaAGAAaG GGGGccTgAA cGGcGTGGAC gTctACTCgC 
 
            1921                                                         1980 
rabbitmRNA  TGGTGACCGA GGACATCCAG TGGCCCAATG GCATCACCCT GGATCTTTCC AGCGGCCGCC 
 humanmRNA  TGGTGACTGA AAACATTCAG TGGCCCAATG GCATCACCCT AGATCTCCTC AGTGGCCGCC 
 mousemRNA  TGGTGACCGA AAACATCCAG TGGCCAAATG GCATCACACT AGATCTTTCC AGTGGCCGTC 
 ovinemRNA  TGGTGACCGA GGACATCCAG TGGCCCAATG GCATCACTCT GGATCTTTCT GGAGGCCGCC 
bovinemRNA  TGGTGACCGA GGACATCCAG TGGCCCAACG GCATCACTCT AGATCTTTCT GGCGGCCGCC 
 Consensus  TGGTGACcGA ggACATcCAG TGGCCcAAtG GCATCAC.CT aGATCTttcc aG.GGCCGcC 
 
            1981                                                         2040 
rabbitmRNA  TCTACTGGGT GGACTCCAAG CTGCACTCCA TCTCCAGCAT CGACGTCAAC GGGGGCAACC 
 humanmRNA  TCTACTGGGT TGACTCCAAA CTTCACTCCA TCTCAAGCAT CGATGTCAAC GGGGGCAACC 
 mousemRNA  TCTATTGGGT TGATTCCAAA CTCCACTCTA TCTCCAGCAT CGATGTCAAT GGGGGCAATC 
 ovinemRNA  TCTACTGGGT CGACTCCAAA CTGCACTCCA TCTCCAGCAT CGATGTCAAC GGAGGGAACC 
bovinemRNA  TCTACTGGGT CGACTCCAAA CTGCACTCCA TCTCCAGCAT CGATGTCAAT GGGGGGAACC 
 Consensus  TCTAcTGGGT .GAcTCCAAa CTgCACTCcA TCTCcAGCAT CGAtGTCAAc GGgGGcAAcC 
 
            2041                                                         2100 
rabbitmRNA  GGAAGACGGT GCTGGAGGAC GAGCAGCGGC TGGCGCACCC CTTCTCTCTG GCCATCTTTG 
 humanmRNA  GGAAGACCAT CTTGGAGGAT GAAAAGAGGC TGGCCCACCC CTTCTCCTTG GCCGTCTTTG 
 mousemRNA  GGAAAACCAT TTTGGAGGAT GAGAACCGGC TGGCCCACCC CTTCTCCTTG GCCATCTATG 
 ovinemRNA  GGAAGACCGT GCTGGAGGAC AAGAAGAAGC TGGCACACCC CTTCTCCTTG GCCATCTTTG 
bovinemRNA  GGAAGACCGT GCTGGAGGAC AAGAAGAAGC TGGCGCACCC CTTCTCTTTG GCCATCTTTG 
 Consensus  GGAAgACcgT gcTGGAGGAc gAgaAgagGC TGGC.CACCC CTTCTCctTG GCCaTCTtTG 
 
            2101                                                         2160 
rabbitmRNA  AGGACAAAGT GTTCTGGACG GACGTCATCA ACGAAGCCAT CTTCAGTGCC AACCGCCTCA 
 humanmRNA  AGGACAAAGT ATTTTGGACA GATATCATCA ACGAAGCCAT TTTCAGTGCC AACCGCCTCA 
 mousemRNA  AGGACAAAGT GTATTGGACA GATGTCATAA ACGAAGCCAT TTTCAGTGCC AATCGACTCA 
 ovinemRNA  AGGATAAAGT ATTTTGGACG GATATTATCA ACGAAGCCAT TTTTAGTGCC AACCGCCTCA 
bovinemRNA  AGGATAAAGT ATTTTGGACG GATGTTATCA ACGAAGCCAT TTTTAGTGCC AACCGCCTCA 
 Consensus  AGGAcAAAGT aTttTGGACg GAtgTcATcA ACGAAGCCAT tTTcAGTGCC AAcCGcCTCA 
 
            2161                                                         2220 
rabbitmRNA  CCGGCTCCGA CGTCCACCTG GTGGCCGAGA ACCTGCTGTC CCCGGAGGAC ATCGTCCTGT 
 humanmRNA  CAGGTTCCGA TGTCAACTTG TTGGCTGAAA ACCTACTGTC CCCAGAGGAT ATGGTTCTCT 
 mousemRNA  CGGGTTCAGA TGTGAATTTG GTGGCTGAAA ACCTCTTGTC CCCGGAGGAC ATTGTCCTGT 
 ovinemRNA  CAGGCTCAGA CATCAGTCTG ATGGCAGAAA ACCTGTTATC GCCGGAGGAC ATTGTCCTTT 
bovinemRNA  CAGGTTCAGA CATCAGCCTG ATGGCAGAAA ACCTGTTATC GCCGGAGGAC ATTGTCCTTT 







            2221                                                         2280 
rabbitmRNA  TCCACAACCT CACGCAGCCC AGAGGGGTGA ACTGGTGCGA GAAGACGGCC CTCCCC---A 
 humanmRNA  TCCACAACCT CACCCAGCCA AGAGGAGTGA ACTGGTGTGA GAGGACCACC CTGAGC---A 
 mousemRNA  TCCACAAGGT CACACAGCCT AGAGGGGTGA ACTGGTGTGA GACAACAGCC CTCCTCCCCA 
 ovinemRNA  TCCACAACCT CACGCAGCCG AGAGGAGTGA ACTGGTGTGA GAGGACTTCC CTCCGC---A 
bovinemRNA  TCCACAACCT CACGCAGCCG AGAGGGGTGA ACTGGTGTGA GAGGACTGCC CTCCGC---A 
 Consensus  TCCACAAccT CACgCAGCC. AGAGGgGTGA ACTGGTGtGA GAggAC.gCC CTccgC...A 
 
            2281                                                         2340 
rabbitmRNA  ACGGCGGCTG CCAATACCTG TGCCTGCCGG CCCCACAGAT CAATAGCCAC TCGCCCAAGT 
 humanmRNA  ATGGCGGCTG CCAGTATCTG TGCCTCCCTG CCCCGCAGAT CAACCCCCAC TCGCCCAAGT 
 mousemRNA  ATGGTGGTTG CCAGTACCTG TGCCTGCCCG CCCCACAGAT CGGTCCCCAC TCGCCCAAAT 
 ovinemRNA  ATGGCGGCTG CCAGTACCTG TGTCTGCCGG CCCCACAGAT CAACCCCCGC TCACCCAAGT 
bovinemRNA  ATGGTGGCTG CCAGTACCTG TGTCTGCCGG CCCCACAGAT CAACCCCCGC TCACCCAAGT 
 Consensus  AtGGcGGcTG CCAgTAcCTG TGcCTgCCgG CCCCaCAGAT CaacccCCaC TCgCCCAAgT 
 
            2341                                                         2400 
rabbitmRNA  TCACCTGCGC CTGCCCCGAC GGCACGCTGC TGGCCGCGGA CATGCGGAGC TGCCGCACAG 
 humanmRNA  TTACCTGCGC CTGCCCGGAC GGCATGCTGC TGGCCAGGGA CATGAGGAGC TGCCTCACAG 
 mousemRNA  TCACCTGCGC CTGCCCTGAT GGCATGCTGC TGGCCAAGGA CATGCGGAGC TGCCTCACAG 
 ovinemRNA  TCACCTGTGC CTGCCCCGAT GGCATGCTGC TGGCCAAGGA CATGAGAAGC TGCCTCACAG 
bovinemRNA  TCACGTGTGC CTGCCCCGAC GGCATGCTGC TGGCCAAGGA CATGAGAAGC TGCCTCACAG 
 Consensus  TcACcTGcGC CTGCCCcGAc GGCAtGCTGC TGGCCaaGGA CATGaGgAGC TGCCtCACAG 
 
            2401                                                         2460 
rabbitmRNA  AGGCCGACGT GATCCTGAGC ACCCAGAGGG CGTCGACGGC CG-------- --CTCGGCCG 
 humanmRNA  AGGCTGAGGC TGCAGTGGCC ACCCAGGAGA CATCCACCGT CAGGCTAAAG GTCAGCTCCA 
 mousemRNA  AAGTCGACAC TGTACTGACC ACCCAGGGGA CATCCGCCGT CCGGCCTGTG GTCACCGCAT 
 ovinemRNA  AGTCTGAATC TGCAGTGACC ACTCGAGGAC CCTCCAC--- ---------G GTCAGCTCGA 
bovinemRNA  AGTCTGAATC TGCAGTGACC ACCCGAGGAC CCTCCAC--- ---------G GTCAGCTCGA 
 Consensus  AggctGA..c tgcagTGacC ACcCagggg. C.TCcaC.g. c........g gtCagctC.a 
 
            2461                                                         2520 
rabbitmRNA  CAGCTCACGG GCAGCC---- ---------- ---------C TGCCGGTACC ACACAGGAGC 
 humanmRNA  CAGCCGTAAG GACAC---AG CACACAACCA CCCGACCTGT TCCCGACACC TCCCGGCTGC 
 mousemRNA  CAGCTACCAG GCCACCGAAG CACAGTGAGG ATCTCTCAGC TCCCAGTACT CCTAGGCAGC 
 ovinemRNA  CAGCTGTGGG GCC------- ---------- ---------- ---------- -----GAAGC 
bovinemRNA  CAGCTGTGGG GCC------- ---------- ---------- ---------- -----GAAGC 
 Consensus  CAGCtgt.gG Gcc.c..... .......... .......... t.cc...ac. .c...G.aGC 
 
            2521                                                         2580 
rabbitmRNA  CCCTGACCGA GCCCACGCTC AGCACCTTGG AGACGGCGAC CACGTCCCAG CAAGCCCTGC 
 humanmRNA  CTGGGGCCAC CCCTGGGCTC ACCACGGTGG AGATAGTGAC AATGTCTCAC CAAGCTCTGG 
 mousemRNA  CTGTGGACAC CCCAGGGCTC AGCACAGTGG CGTCAGTGAC AGTGTCCCAC CAAGTCCAGG 
 ovinemRNA  GCACATCCAG CCCTGAGCTC ACCACAGCCG AGTCGGTGAC AATGTCCCAA CAAGCCCTGG 
bovinemRNA  GCACGGCCAG CCCTGAGCTC ACCACAGCCG AGTCGGTGAC AATGTCCCAA CAAGGCCAGG 
 Consensus  cc..ggcCa. cCCtg.GCTC AcCACagtgG aGtcgGtGAC aatGTCcCA. CAAGccCtGg 
 
            2581                                                         2640 
rabbitmRNA  ACAACGCCGA CGGCCGAGGC AGCGAGGGGA CGCCCAGGAG CGTGGGGGCC CTGTCCGTCG 
 humanmRNA  GCGACGTTGC TGGCAGAGGA AATGAGAAGA AGCCCAGTAG CGTGAGGGCT CTGTCCATTG 
 mousemRNA  GTGACATGGC TGGCAGAGGG AATGAGGAGC AGCCACATGG TATGAGGTTC CTGTCCATCT 
 ovinemRNA  GCGATGTTGC CGGCCGAGCG GACACGGAGA GGCCCGGGAG CGTGGGTGCC CTGTACATCG 
bovinemRNA  GTGACATTGC CAGCCAAGCG GACACGGAGA GGCCCGGGAG CGTGGGTGCC CTATACATCG 
 Consensus  gcgAcgttGc cgGCcgAGgg aacgaGgaGa .GCCc.ggaG cgTGgGggcc CTgTcCaTcg 
 
            2641                                                         2700 
rabbitmRNA  TCCTGCCCAT CGCGCTGCTG GGCCTGCTCT GCCTCGGCGC CCTGGTCCTG TGGAAGAACT 
 humanmRNA  TCCTCCCCAT CGTGCTCCTC GTCTTCCTTT GCCTGGGGGT CTTCCTTCTA TGGAAGAACT 
 mousemRNA  TCTTCCCTAT TGCACTGGTT GCCCTCCTTG TCCTTGGGGC CGTCCTGCTG TGGAGGAACT 
 ovinemRNA  TCCTCCCCAT TGCACTGCTC ATCCTCCTGG CCTTCGGGAC CTTCCTCGTC TGGAAGAACT 
bovinemRNA  TCCTCCCCAT CGCACTGCTC ATCCTCCTGG CCTTCGGAAC CTTCCTCCTC TGGAAGAACT 







            2701                                                         2760 
rabbitmRNA  GGCGGCTCCG CAGCGTCCAC AGCATCAACT TCGACAACCC GGTCTACCAG AAGACCACGG 
 humanmRNA  GGCGGCTTAA GAACATCAAC AGCATCAACT TTGACAACCC CGTCTATCAG AAGACCACAG 
 mousemRNA  GGCGGCTGAA GAACATCAAC AGCATAAACT TTGACAACCC AGTCTACCAG AAGACCACAG 
 ovinemRNA  GGCGGCTGAA GAGCATCAAC AGCATCAACT TCGACAACCC TGTGTACCAG AAAACCACGG 
bovinemRNA  GGCGGCTGAA GAGCATCAAC AGCATCAACT TCGACAACCC CGTGTACCAG AAGACCACGG 
 Consensus  GGCGGCTgaa gAgCaTCaAC AGCATcAACT TcGACAACCC .GTcTAcCAG AAgACCACgG 
 
            2761                                                         2820 
rabbitmRNA  AGGACGAGGT GCACATCTGC AGGAGCCAGG ACGGCTACAC CTACCCCTCG AGACAGATGG 
 humanmRNA  AGGATGAGGT CCACATTTGC CACAACCAGG ACGGCTACAG CTACCCCTCG AGACAGATGG 
 mousemRNA  AGGACGAGCT CCACATTTGC CGAAGCCAGG ATGGCTATAC CTACCCCTCA AGACAGATGG 
 ovinemRNA  AGGACGAGGT CCACATCTGC CGCAGCCAGG ACGGCTACAC CTACCCCTCG AGACAGATGG 
bovinemRNA  AGGATGAGGT CCACATCTGC CGCAGCCAGG ACGGCTACAC CTACCCCTCG AGACAGATGG 
 Consensus  AGGAcGAGgT cCACATcTGC cgcAgCCAGG AcGGCTAcAc CTACCCCTCg AGACAGATGG 
 
            2821                                                         2880 
rabbitmRNA  TCAGCCTGGA GGACGACGTG GCCTGAGCCG CCGCCTGGAT CTCGCCGCC- ---------- 
 humanmRNA  TCAGTCTGGA GGATGACGTG GCGTGAACAT CTGC------ ---------- ---------- 
 mousemRNA  TCAGCCTGGA GGACGATGTG GCATGAGCAG CCGGGAGAG- ------CCGT CTCTTTCCGG 
 ovinemRNA  TCAGCTTGGA GGATGACGCG GCATGAGCTG CTGCCTTGAG TCCTCTCCCT CCCTGGAACC 
bovinemRNA  TCAGCTTGGA GGATGACGTG GCGTGAGCTG CTGCCTTGAG TCCTCTCCCT CCCCCGAACC 
 Consensus  TCAGccTGGA GGAtGAcGtG GC.TGAgC.g CtGcct.ga. ..c.c.ccct c.c....... 
 
            2881                                                         2940 
rabbitmRNA  ---------- ---------- ---------- -------ACC CGCGGGCCTG AGCCGCCGCC 
 humanmRNA  ---------- ---------- ---------- ---CTGGAGT CCCGTCCCTG CCCAGA---- 
 mousemRNA  GATCCATTGC CAAGCTTAGG CAGAAAAGAC ACTCTCTCCA GACCTCCCCA TCCAGC---- 
 ovinemRNA  TGCCGCTGGT CACTCAAAGG CAGCAAAAAC ACTTTCTCCC CCGACCCTTG ACCTGCCCCC 
bovinemRNA  TGCTGCCAGT CACTCAAAGG CAGCAAGAAC ACTTTCTCCC CTGACCCTTG ACCTGCTCCC 
 Consensus  ........g. ca..c..agg cag.aa..ac act.tctccc c.c..cCctg acC.Gc..cc 
 
            2941                                                         3000 
rabbitmRNA  GCCGCCGCCT G--------- ---------- ---------- ---------- ---------- 
 humanmRNA  -ACCCTTCCT GAGACCTCGC CGGCCT-TGT TTTATTCAAA GACAGAGAAG ACCAAAGCAT 
 mousemRNA  -ACTGGTCCT GCCACCTCCC TGGGCTCTGT GTTGCTCAAA GCAAGATAAG AGCAAAGCTG 
 ovinemRNA  AACCCTTCCT GAGACCTCCG CGCCAAAAGC ACTGTTGGGG ACTGCAGCC- ------TGTC 
bovinemRNA  AACCCTTCCT GAGACTTCCG CGCCAAAAGC GCTGTTGGGG ACTGCCGCCC AGGCACTGTC 
 Consensus  .aCccttCCT Gagacctcc. cg.c....g. ..tgtt.... .c...ag... a...a...t. 
 
            3001                                                         3060 
rabbitmRNA  ---------- ---------- ---------- -CCCGGGCCG TGTTTTATAT ATTTATTCGC 
 humanmRNA  TGCCTG---- ---------- ---------- -CCAGAGCTT TGTTTTATAT ATTTATTCAT 
 mousemRNA  GGCTGGGGGC CAAGCTCAGC TGCCTGTCTG CCCCAGGTTC TGTTTTATAT ATTTATTGTC 
 ovinemRNA  TGCCTGTCTG ---------- ---------- -CCAGAGCTT TGTTTTATAT ATTTATTTTT 
bovinemRNA  TGCCGGTCTG ---------- ---------- -CCAGAGCTT TGTTTTATAT ATTTATTTTT 
 Consensus  tgcc.g.... .......... .......... .CCagaGctt TGTTTTATAT ATTTATT.tt 
 
            3061                                                         3120 
rabbitmRNA  CCGGGATGGG GC-------- ---------- ---------- ---------- ---------- 
 humanmRNA  CTGGGAGGCA GAACAGGCTT CGGACAGTGC CCATGCAATG GCTTGGGTTG GGATTTTGGT 
 mousemRNA  TGGGGA--CA GAAAAGGCTA CTGGCTGTGC TTGAAATTCG AATTCTGCCT GGGAATTTTT 
 ovinemRNA  CTGGGAGGCA GAACAGGCAT CAGACGGCAC CCACGGGCAG CAGTTGGGTT GCTTTTTTTT 
bovinemRNA  CTGGGAGGCA GAACAGGCTT CAGACGGTGC CCACGGGCGG CAGTTGCGTT GCTTTTTTTT 
 Consensus  ctGGGAggca Gaacaggctt c.gac.gtgc cca.g....g .a.t.gg.tt g..ttttttt 
 
            3121                                                         3180 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  TTC--TTCCT TTCCTCGTGA AGGATAAGAG AAACAGGCCC GGGGGGACCA GGATGACACC 
 mousemRNA  TTT--TTTCT CCCATCTTCA TTTCCTTGGA AGCCAAATAG G--------- ---------- 
 ovinemRNA  CTTCCTTTCT TTACATGTGA AGGAGAAAGG CAGAACAGCT GGGGAATCTG ---------- 
bovinemRNA  CTTCCTTTCT TCACACGTGA AGGAGAAAGG CAGAACAGCT GGGGAATCTG ---------- 







            3181                                                         3240 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  TCCATTTCTC TCCAGGAAGT TTTGAGTTTC TCTCCACCGT GACACAATCC TCAAACATGG 
 mousemRNA  -------CTG TCCCAGAAGC TTCTGAATTC TACTCTTTTC AACACTAAC- ---------- 
 ovinemRNA  -----TCTTC TCCGGGAATC TCTGAGCTGC TCTCCTTCTA GACACACTCC TTCCT----- 
bovinemRNA  -----TCCTC TCCGGGAATC TCTGAGCTGC TCTCCTTCTA GACACACTCC TCCCT----- 
 Consensus  .....t.ctc tcc.ggaa.c t.tgag.t.c tctccttct. gacaca.tcc t......... 
 
            3241                                                         3300 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ----CGGCTG 
 humanmRNA  AAGATGAAAG GGGAGGGGAT GTCAGGCCCA GAGAAGCAAG TGGCTTTCAA CACACAACAG 
 mousemRNA  ACGGAGGAGG AAGAGACCCA CCCAGGCAGA GAGAAGCCTG CTGG-----A CATGAGACAG 
 ovinemRNA  --GGAGGGAA TGGCAGACAG ACACGGAGCC GGAAAGCTAG TGGCTTTGAA CGCACGAAAG 
bovinemRNA  --GGAGGGAA TGACGGAGGG ACGTGGAGCC GGAAAGCTAG TGGCTTTGAA TGCACGAGAG 
 Consensus  ..ggagg.a. .gg.gg.... .c..gg..c. g..aagc.ag tggcttt.aa c.cacgacaG 
 
            3301                                                         3360 
rabbitmRNA  CTCTCTGGAC AGAGGGGGGC CCGGGCCTCC ---------- ----CTGCAC TGCGCCCGCG 
 humanmRNA  CAGATGGCAC CAACGGGACC CCCTGGCCCT GCCTCATCCA CCAATCTCTA AGCCAAACCC 
 mousemRNA  CAGGTACTAC TGACCGGGTC CTGGGTACC- ---------- ---------A TAGCCAGTCC 
 ovinemRNA  CAGGTGCTAC CCACAGGGTC CCAGGTGGCT GCTGTTGCCA CCTACCCTCT AGCCCAGGCC 
bovinemRNA  CAGGTGCTAC CCACAGGGTC CCAGGTGGCT GCTGTTGCCA CCCACCCTCT AGCCCAGGCC 
 Consensus  CaggtgctAC c.Ac.GGgtC Cc.gGt..Ct gc.....cca cc.acc.... agcccaggCc 
 
            3361                                                         3420 
rabbitmRNA  CTCATCTCAG GAGCTC-CGT GTTTACCT-- ---------- ---------- ---------- 
 humanmRNA  CTAAACTCAG GAGTCAACGT GTTTACCTCT TCTATGCAAG CCTTGCTAGA CAGCCAGGTT 
 mousemRNA  CTAACCTCAG GACTTCCTGC ATTGACCTT- ---------- ---------- ---------- 
 ovinemRNA  CCACACTCAG GACTGAACGT GTTTACTTCT GCCAGGCAAG CCTGC----- --GGGATGGC 
bovinemRNA  CCACACTCAG GACTGAACGT GTTTACTTCT GCCAGGCAAG CCTGC----- --GGGATGGC 
 Consensus  CtaaaCTCAG GAct.aacGt gTTtACcTct .c.a.gcaag cct....... ..g..a.g.. 
 
            3421                                                         3480 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  AGCCTTTGCC CTGTCACCCC CGAATCATGA CCCACCCAGT GTCTTTCGAG GTGGGTTTGT 
 mousemRNA  ---------- ---------- ---------- -CATCCCAGA GCCTTCCTGC CTGACTCTGC 
 ovinemRNA  CAGAATTGGT CTGCCACCCC CTGGTCAGGA TCAAACTAGG GTTTTCCAAG CAGGGTTTGT 
bovinemRNA  CAGAGTTGGT CTGCCACCCC CTGGTCAGGA TCAAACTAGG GTTTTCCAAG CTGGGTTTGT 
 Consensus  .....ttg.. ctg.cacccc c...tca.ga .caa.c.ag. gt.ttcc.ag ctgggtttgt 
 
            3481                                                         3540 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  ACCTTCCTT- --AAGCCAGG AAAGGGATTC ATGGCGT-CG GAAATGATCT GGCTGAATCC 
 mousemRNA  CGCCCCCATC AGAAGCCAGG AAAGTGACTC GTGACATTCG GTACTGATCT TGCTGGATCT 
 ovinemRNA  CCTCCACTT- --AAGCCAGG AGGGGACCCT GGGTCCAACC TTCCAGGAGT GGCACCCGCT 
bovinemRNA  CCTCCACTT- --AAGCCAGG AGGGGACCCT GGGTCCAACC TTCCAGGAGT GGCGCCCGCT 
 Consensus  cc.cc.ctt. ..aagccagg a..gg..c.. g.g.c...c. .t.c.g...t ggc.....ct 
 
            3541                                                         3600 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  GTGGTGGCAC CGAGACCAAA CTCATTCACC AAATGATGCC ACTTCCCAGA ---------- 
 mousemRNA  TGAGGCCGGC AGCTGCCAGT GATGGATACC CGCTCATGCC TTTGCCAAAA CGTCACCCGT 
 ovinemRNA  GAA------- -----CCCTA TTCATTCACC AAAACCCAGA TCATCCCCAG AGAAA----- 
bovinemRNA  GAA------- -----CCCTA TTCATTCACC AAAACCCCGA TCATCCCCAA AGAAA----- 
 Consensus  g.a....... .....cc..a .tcattcacc aaa.c..... tc.tccc.aa .g..a..... 
 
            3601                                                         3660 
rabbitmRNA  ---------- ---------- --CGCCGGTT GCCCTTAACT G---TCCGAG AAGTGCCTGC 
 humanmRNA  --------GG CAGAGCCTGA GTCACTGGTC ACCCTTAAT- ---ATTTATT AAGTGCCTGA 
 mousemRNA  TCCTGGAGGG ACAAGCCCAA GTCGCCATTC TCCCTTAAT- ---ATTTATC AAGTGCCTGA 
 ovinemRNA  ---------- ACAAATTCGA GCCACCAGTC GCCCTTAACG TACATGTATT AAGTGCCTGA 
bovinemRNA  ---------- ACAAATGCGA GCCACCAGTC GCCCTTAACG TTCATGTATT AAGTGCCTGA 







            3661                                                         3720 
rabbitmRNA  GCCCGCCCAC GCCA------ ---------- ---------- ---------- ---------- 
 humanmRNA  GACACCCGGT TACCTTGGCC GTGAGGACAC GTGGCCTGCA CC-------- ---------- 
 mousemRNA  GACAACTGGT TGCCTTGCTC ---AGGAGTC CTGGCCTGCT CA-------G TGTCCTGCTG 
 ovinemRNA  GACCCCC--T TACTTTGTGC GTGAAGATGA GCAGTTCCCA CCTCTAACT- -ATCCGTCTG 
bovinemRNA  GACCCCC--T TACTTTGTGC GTGAAGATGA GCAGCTCCCA CCTCTAACTG TATCCTTCTG 
 Consensus  GaCccCc..t taC.ttg..c gtga.ga... g..gc...ca cc........ ..tcc..ctg 
 
            3721                                                         3780 
rabbitmRNA  ---------- GGTCCCTGGT CCCCGGCAGC GTG------- ---------- ---------- 
 humanmRNA  --CAGGTGTG GCTGTCAGGA CACCAGCCTG GTGCCCATCC TCCCGACCCC TACCCACTTC 
 mousemRNA  CTCAGGGGTG GCCGGCAGGA CCCCTGTCCT GTGCCCAGCC CCCGAGTCTC CGAGTGAGGC 
 ovinemRNA  TCTGGGAGTG GGTATCTGGA CCCCATCCCT G--------- ---------- ---------- 
bovinemRNA  TCCGGGAGTG GGTGTCTGGA CCCCAGCCCC G--------- ---------- ---------- 
 Consensus  ..c.gg.gtg GgtgtCtGGa CcCCagccc. Gtg....... .......... .......... 
 
            3781                                                         3840 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  CATTCCCGTG GTCTCCTTGC ACTTTCTCAG TTCAGAGTTG TACACT---- --GTGTACAT 
 mousemRNA  --TTGCACTT CTCTCTGCGC ACTTTTCCCG TTCTGTGCTG GGCACCCACG TGGTCCACAT 
 ovinemRNA  ---------- --CCCCTTGC ACTTTTTCAG TTCAGGGTCG TACACT---- --GTGTAAAG 
bovinemRNA  ---------- --CCCCTTGC ACGTTTCCAG TTCAGGGTCG AACACT---- --GCGTAAAG 
 Consensus  .......... ..c.ccttgc actttt.cag ttcag.gt.g .acact.... ..gtgta.a. 
 
            3841                                                         3900 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  TTGGCAT--- ---------- ---------- ---------- ---------- ---------- 
 mousemRNA  TTGTACTCCT AGGTTGCACT GACCCTGGTG CATTGGATGG GACCTCAGGC CGGAAGTGGC 
 ovinemRNA  TCGACATTCT A--------- ---------- ---------- ---------- ---------- 
bovinemRNA  TCGACATTCT A--------- ---------- ---------- ---------- ---------- 
 Consensus  t.g.cat.ct a......... .......... .......... .......... .......... 
 
            3901                                                         3960 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 mousemRNA  CCCGAATCAT TGACCACAGA AGATAATTGC CAGGCTCCAA GCATCCATTG CCTTCTTCAG 
 ovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
bovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 Consensus  .......... .......... .......... .......... .......... .......... 
 
            3961                                                         4020 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  ---------- ---------- ---------- --TTGTGTTA TTATTTTGCA CTGTTTTCTG 
 mousemRNA  TACTGGGGGG AACTCAGGGC CTCTGTCTGG TGTTTAGTTA GTCTGTTTGT TTGTTTGTTT 
 ovinemRNA  ---------- ---------- ---------- -------TTA TTATTTTGCA CTACTTTCCG 
bovinemRNA  ---------- ---------- ---------- -------TTA TTATTTTGCA CTACTTTCCG 
 Consensus  .......... .......... .......... .......tta ttattttgca ct..tttc.g 
 
            4021                                                         4080 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  TCGTGTGTGT TGGGATGG-- ---------- ---------- ------GATC CCAGGCCAGG 
 mousemRNA  GTTTGTTTGT TTGGTGGTTT CTGGCTCTGC ACAGCAGAGT TGTTTAGCTC CTCTGGTAAC 
 ovinemRNA  TTCTGGTTCC CTTCTGGCTG CA-------- --AAGAGTCT GGGTTGATGA TTGGTACCAA 
bovinemRNA  TTCTGGTTCC CTTCTGGCTG CA-------- --AAGAGTCT GGATTGATGA CTGGTACCGA 
 Consensus  tt.tg.tt.. .t..tgg.t. c......... ..a..ag..t .g.tt..... ct.g..c... 
 
            4081                                                         4140 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  GAAAGCCCGT GTCAATGAA- ---------- --TGCCGGGG ACAGAGAGGG GCAGG----- 
 mousemRNA  GTCATCCTCT CTCACAGAGA CATCCAGCCT GCTGAAGGGG AGAGATGGGG CGAGGGGAGG 
 ovinemRNA  CCTGGCCC-- ---------- ------CTCT CCCAGCATGT AGGGAGATGT GTGTGCGGTG 
bovinemRNA  CCCGGCCCTT CTCCCAGACC CGGCCTCTCT CCCAGCACGT AGGGAGACCT GTGCGCGGTG 







            4141                                                         4200 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  ---------- ---------- -------TTG ACCGGGACTT CAAAGCCGTG ATCGTGAATA 
 mousemRNA  GATACACGCA TGGTTTCTCA GGTGTGGTGG CACTTGGCTT TAATCCTATG CTCAAGAGGA 
 ovinemRNA  GC-------- ---------- -------TTG ATCATGACTT CAAAGCCAAG ATTACGACTA 
bovinemRNA  GC-------- ---------- -------TTC ATCATGACTT CAAAGCCAAA ATTACGACTA 
 Consensus  g......... .......... .......ttg a.c.tgactt caaagcca.g at.a.ga.ta 
 
            4201                                                         4260 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  TCGAG----- ---------- ---------- ---------- ---------- ---------- 
 mousemRNA  AGAGGTGGGC ACATGTCTGA GGTCCAAGCC TACATAGTGA GACCTTATAT ATCTAAAAAC 
 ovinemRNA  GATGATCTG- ---------- ---------- ---------- ---------- ---------- 
bovinemRNA  GACGATCTG- ---------- ---------- ---------- ---------- ---------- 
 Consensus  ...g.t..g. .......... .......... .......... .......... .......... 
 
            4261                                                         4320 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 mousemRNA  CAAAAGAAAT CCCAGACTAT TTGGTGGGAC TTGGAAGAAT ACTTAGAAAT TGCCACAGAT 
 ovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
bovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 Consensus  .......... .......... .......... .......... .......... .......... 
 
            4321                                                         4380 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 mousemRNA  TTGTCACATG GGTAACCTAA GAAGACAGTG GTGGCCTTAC TTGGATTCCT GGGTAGATCC 
 ovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
bovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 Consensus  .......... .......... .......... .......... .......... .......... 
 
            4381                                                         4440 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 mousemRNA  ACCTGTCCAC TACTCAAGAC ACAAGGGCAC ACTGCCCAGC CCACTGGGAC ACTTGTAAAG 
 ovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
bovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 Consensus  .......... .......... .......... .......... .......... .......... 
 
            4441                                                         4500 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  ---------- ---------- --AACTGCCA TTGTCGTCTT TATGTCCGCC CA-------- 
 mousemRNA  AGCTCTGTAA TGTGCCGATG GCACCTGGCT CGGTTTTCAT TCTGTATATT CAAGGATATC 
 ovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
bovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 Consensus  .......... .......... .......... .......... .......... .......... 
 
            4501                                                         4560 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  ---------- ---------- ---------- -----CCTAG TGCTTCCACT TCTATGCAAA 
 mousemRNA  ACACATATGT ATTAAATCTA TTTATTTTTG CAAACCCTGA TTGCTGCACC TCTCTGCAAT 
 ovinemRNA  ---------- ---------- ---------- -----CCTAC TGTTTCCACT TCTAGGCAGA 
bovinemRNA  ---------- ---------- ---------- -----CCTAC TGTTTCCACT TCTAGGCAGA 
 Consensus  .......... .......... .......... .....ccta. tg.ttccact tcta.gca.a 
 
            4561                                                         4620 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  TGCCTCC--- ---------- ---------- ---------- ---------- ---------- 
 mousemRNA  TTCTCCAGGT TAGGCTGGGG TGATACTCTG GGATGCTCTG TATACAAAGA TGATTTGAAT 
 ovinemRNA  GGCCACTG-- ---------- ---------- ---------- ---------- ---------- 
bovinemRNA  GGCCACTG-- ---------- ---------- ---------- ---------- ---------- 







            4621                                                         4680 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 mousemRNA  GGGCTGATCT CAGGCCTGTC CTGTGCGTTG CTTTGAGTGG GTGGGAACTG CTTTGAAACC 
 ovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
bovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 Consensus  .......... .......... .......... .......... .......... .......... 
 
            4681                                                         4740 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 mousemRNA  CTTGTTCAGA TGTTTTTATA GGCTGAAAAT ATCATACTGT GATGGATTAA ATTCTTTTTT 
 ovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
bovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 Consensus  .......... .......... .......... .......... .......... .......... 
 
            4741                                                         4800 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  ---------- -------AAG CCATTCACTT CCCCAATCTT G--------- ---------- 
 mousemRNA  GGAAAAAAAA AAAAAAAAAA GCAGACTCCT CCCCCGCCTG GAAACCTCGC CCCTAGTACT 
 ovinemRNA  ---------- --------AG CCATTCATAT CCCC------ ---------- ---------- 
bovinemRNA  ---------- --------AG CCATTCATAT CCCC------ ---------- ---------- 
 Consensus  .......... ........ag ccattca..t cccc...... .......... .......... 
 
            4801                                                         4860 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 mousemRNA  GGGAATGACT CTGGGCGTGC GGCGTAGTTT GCAGCCGGGA CACCGTGAGG CTTGCGAGCC 
 ovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
bovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 Consensus  .......... .......... .......... .......... .......... .......... 
 
            4861                                                         4920 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 mousemRNA  CAGATTCGCA GCCGAGACAC CGTGGGGCCC GCGATCCAGT GTTTGCAGCG GGAACATTTC 
 ovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
bovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 Consensus  .......... .......... .......... .......... .......... .......... 
 
            4921                                                         4980 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  ----TCGTTG ATGGGTATGT GTTTAAAACA TGCACGGTGA GGCCGGGCGC AGTGGCTCAC 
 mousemRNA  GGGGTCTGTG ATCCGAGTGA GGACGCAACG CAGAAGCTAA GGATGAGCAC CGCGGATCTG 
 ovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
bovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 Consensus  .......... .......... .......... .......... .......... .......... 
 
            4981                                                         5040 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  GCCTGT---- ---------- ---------- ---------- ---------- ---------- 
 mousemRNA  ATGCGTCGCT GGGTCATCGC CCTGCTCCTG GCTGCTGCCG GAGTTGCAGC AGAAGACTCA 
 ovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
bovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 Consensus  .......... .......... .......... .......... .......... .......... 
 
            5041                                                         5100 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 mousemRNA  TGCAGCAGGA ACGAGTTCCA GTGTAGAGAC GGAAAATGCA TCGCTAGCAA GTGGGTGTGC 
 ovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
bovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 







            5101                                                         5160 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 mousemRNA  GATGGCAGCC CCGAGTGCCC GGATGGCTCC GATGAGTCCC CAGAGACATG CATGTCTGTC 
 ovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
bovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 Consensus  .......... .......... .......... .......... .......... .......... 
 
            5161                                                         5220 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  ---------- --AATCCCAG CACTTTGGGA GGCCGAGGCG GGTGGATCAT ---------- 
 mousemRNA  ACCTGTCAGT CCAATCAATT CAGCTGTGGA GGCCGTGTCA GCCGATGCAT TCCTGACTCC 
 ovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
bovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 Consensus  .......... .......... .......... .......... .......... .......... 
 
            5221                                                         5280 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 mousemRNA  TGGAGATGTG ATGGACAGGT AGACTGTGAA AATGACTCAG ACGAACAAGG CTGTCCCCCC 
 ovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
bovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 Consensus  .......... .......... .......... .......... .......... .......... 
 
            5281                                                         5340 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  ---------- ---------- -----GAGGT CAGGAGATCG AGACCATC-- ---------- 
 mousemRNA  AAGACGTGCT CCCAGGATGA CTTCCGATGC CAGGATGGCA AGTGCATCTC CCCGCAGTTT 
 ovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
bovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 Consensus  .......... .......... .......... .......... .......... .......... 
 
            5341                                                         5400 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  ---------- ---------- ---------- ---------- ---------- -CTGGCTAAC 
 mousemRNA  GTGTGTGATG GAGACCGAGA TTGCCTAGAT GGCTCTGATG AGGCCCACTG CCAGGCCACC 
 ovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
bovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 Consensus  .......... .......... .......... .......... .......... .......... 
 
            5401                                                         5460 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  ACGTGAAACC CCGTC----- ---------- ---------- ---------- ---------- 
 mousemRNA  ACTTGTGGCC CCGCCCACTT CCGCTGCAAC TCATCCATAT GCATCCCCAG TCTTTGGGCC 
 ovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
bovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 Consensus  .......... .......... .......... .......... .......... .......... 
 
            5461                                                         5520 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 mousemRNA  TGCGACGGGG ATGTCGACTG TGTTGACGGC TCCGATGAGT GGCCACAGAA CTGCCAGGGC 
 ovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
bovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 Consensus  .......... .......... .......... .......... .......... .......... 
 
            5521                                                         5580 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 mousemRNA  CGAGACACGG CCTCCAAAGG CGTTAGCAGC CCCTGCTCCT CCCTGGAGTT CCACTGTGGT 
 ovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
bovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 







            5581                                                         5640 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  ---------- ---------- ---------- ---------- --------TC TACTAAAAAT 
 mousemRNA  AGCAGTGAGT GTATCCATCG CAGCTGGGTC TGTGACGGCG AGGCAGACTG CAAGGACAAG 
 ovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
bovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 Consensus  .......... .......... .......... .......... .......... .......... 
 
            5641                                                         5700 
rabbitmRNA  ---------- ---------- ---GGGCGGG GGCTGGGCGG AGCGCGGCCC GGGCGTGCAT 
 humanmRNA  ACAAAAAATT AGCCGGGCGT GGTGGCGGGC ACCTGTAGTC CCAGCTACTC GGGAGGCTGA 
 mousemRNA  TCAGATGAGG AGCACTGCGC GGTGGCCACC TGCCGACCTG ATGAATTCCA GTGTGCAGAT 
 ovinemRNA  ------GACA AGCCCGTCAT GGTTGGCTGG TGTCCATCTG AAACACGCAT GGCCGGTCTA 
bovinemRNA  ------GACA AGCCCATCAT GGTTGGCTGG TGTCCATCTG AAACATGCAT GGCAGGTCTG 
 Consensus  ......ga.. agccc..c.t ggtgGgc.gg tgccga.ctg a.a.atgC.. Ggg.Gg.c.. 
 
            5701                                                         5760 
rabbitmRNA  GGCGTT---- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  GGCAGGAGAA TGGTGTGAAC CCGGGAAGCG GAGCTTGCAG ---------- ---------- 
 mousemRNA  GGCTCCTGCA TTCACGGTAG CCGCCAGTGT GACCGTGAAC ATGACTGCAA GGACATGAGC 
 ovinemRNA  CCCTGTAAGA T--------- ---------- ---------- ---------- ---------- 
bovinemRNA  CCCTGTAAGA T--------- ---------- ---------- ---------- ---------- 
 Consensus  ggCtgta..a t......... .......... .......... .......... .......... 
 
            5761                                                         5820 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 mousemRNA  GACGAGCTCG GCTGCGTCAA TGTGACACAG TGTGATGGCC CCAACAAGTT CAAGTGTCAC 
 ovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
bovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 Consensus  .......... .......... .......... .......... .......... .......... 
 
            5821                                                         5880 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  ---------- ---------T GAGCCGAGAT TGCGCCACTG CAGTCCGCAG TCTGGCCTGG 
 mousemRNA  AGTGGGGAGT GCATCAGCTT GGACAAGGTG TGCGACTCCG CCCGCGACTG CCAGGACTGG 
 ovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
bovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 Consensus  .......... .......... .......... .......... .......... .......... 
 
            5881                                                         5940 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  GCGACAGAGC GAGACTCCGT CTCAAAAAAA AAAAACAA-- ---AAAAAAA CCATGCATGG 
 mousemRNA  TCGGATGAGC CCATCAAGGA GTGCAAGACC AACGAGTGTT TGGACAACAA TGGTGGCTGT 
 ovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
bovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 Consensus  .......... .......... .......... .......... .......... .......... 
 
            5941                                                         6000 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  TGCATCAGCA GCCCATGGC- ---------- ---------- ---------- ---------- 
 mousemRNA  TCCCACATCT GCAAGGACCT CAAGATTGGC TCTGAGTGCC TGTGTCCCAG CGGCTTCCGG 
 ovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
bovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 Consensus  .......... .......... .......... .......... .......... .......... 
 
            6001                                                         6060 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 mousemRNA  TTGGTGGACC TCCACAGGTG TGAAGATATT GACGAGTGTC AGGAGCCAGA CACCTGCAGC 
 ovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
bovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 







            6061                                                         6120 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 mousemRNA  CAGCTCTGTG TGAACCTGGA AGGCAGCTAC AAGTGTGAGT GCCAGGCCGG CTTCCACATG 
 ovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
bovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 Consensus  .......... .......... .......... .......... .......... .......... 
 
            6121                                                         6180 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  ----CTCTGG CCAGGCATGG CGAGGCTGAG GTGGGAGGAT GGTTT----- ---------- 
 mousemRNA  GACCCACACA CCAGGGTCTG CAAGGCTGTG GGCTCCATAG GCTATCTGCT CTTCACCAAC 
 ovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
bovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 Consensus  .......... .......... .......... .......... .......... .......... 
 
            6181                                                         6240 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  ------GAGC TCAGGCATTT GAGGCTGTCG TGAGCTATGA TTATGCCACT GCTTTCCAGC 
 mousemRNA  CGCCACGAGG TCCGGAAGAT GACCCTGGAC CGCAGCGAGT ACACCAGTCT GCTCCCCAAC 
 ovinemRNA  ------GTGC TCTGGGCGCA GGAATTTCAT GGGATTCATT AAACAAGAAT GCTTTC---- 
bovinemRNA  ------GTGC TCTGGGCTCG GGAATTTCAT GGGATTCATT AAACAAGAAT GCTTTC---- 
 Consensus  ......g.gc tc.gg..... g....t..a. .g.a.t.a.t a.ac.aga.t gctttc.... 
 
            6241                                                         6300 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  CTGGGCAACA TAGTAAGACC CCA------- ---------- ---------- ---------- 
 mousemRNA  CTGAAGAATG TGGTGGCTCT CGACACGGAG GTGACCAACA ATAGAATCTA CTGGTCCGAC 
 ovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
bovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 Consensus  .......... .......... .......... .......... .......... .......... 
 
            6301                                                         6360 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  -TCTCTTAAA AAATGAATT- ---------- ---------- ---------- ---------- 
 mousemRNA  CTGTCCCAAA AAAAGATCTA CAGCGCCCTG ATGGACCAGG CCCCTAACTT GTCCTACGAC 
 ovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
bovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 Consensus  .......... .......... .......... .......... .......... .......... 
 
            6361                                                         6420 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 mousemRNA  ACCATCATCA GTGAGGACCT GCATGCCCCT GACGGGCTGG CGGTAGACTG GATCCACCGC 
 ovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
bovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 Consensus  .......... .......... .......... .......... .......... .......... 
 
            6421                                                         6480 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  ---------T GGCCAGACAC AGGTGCCTCA CGCCTGTAAT CCCAGCACTT TGGGAGGCTG 
 mousemRNA  AACATCTACT GGACAGATTC AGTCCCAGGC AGCGTATCTG TGGCTGACAC CAAGGGCGTA 
 ovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
bovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 Consensus  .......... .......... .......... .......... .......... .......... 
 
            6481                                                         6540 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  AGCTGGATCA CTTGAGTTCA GGAGTTGGAG ACCAGGCCT- ---------- ---------- 
 mousemRNA  AAGAGGAGGA CACTGTTCCA AGAGGCAGGG TCCAGACCCA GAGCCATCGT AGTGGACCCT 
 ovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
bovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 







            6541                                                         6600 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  ---------- ---------- ---------- ---------- ----GAGCAA CAAAGCGAGA 
 mousemRNA  GTGCATGGCT TCATGTACTG GACAGATTGG GGAACACCCG CCAAGATCAA GAAAGGGGGT 
 ovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
bovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 Consensus  .......... .......... .......... .......... .......... .......... 
 
            6601                                                         6660 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  TCCCATCTCT ACAAAAACCA AAAAGTTA-- ---------- ---------- ---------- 
 mousemRNA  TTGAATGGTG TGGACATCCA CTCACTGGTG ACCGAAAACA TCCAGTGGCC AAATGGCATC 
 ovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
bovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 Consensus  .......... .......... .......... .......... .......... .......... 
 
            6661                                                         6720 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 mousemRNA  ACACTAGATC TTTCCAGTGG CCGTCTCTAT TGGGTTGATT CCAAACTCCA CTCTATCTCC 
 ovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
bovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 Consensus  .......... .......... .......... .......... .......... .......... 
 
            6721                                                         6780 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  ---------- ---------- -------AAA ATCAGCTGGG TACGGTGGCA CGTGCCTGTG 
 mousemRNA  AGCATCGATG TCAATGGGGG CAATCGGAAA ACCATTTTGG AGGATGAGAA CCGGCTGGCC 
 ovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
bovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 Consensus  .......... .......... .......... .......... .......... .......... 
 
            6781                                                         6840 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  ATCCCA---- ---------- ---------- ---------- ---------- ---------- 
 mousemRNA  CACCCCTTCT CCTTGGCCAT CTATGAGGAC AAAGTGTATT GGACAGATGT CATAAACGAA 
 ovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
bovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 Consensus  .......... .......... .......... .......... .......... .......... 
 
            6841                                                         6900 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  ---------- ---------- ---------- ------GCTA CTTGGGAGGC TGAGGCAGGA 
 mousemRNA  GCCATTTTCA GTGCCAATCG ACTCACGGGT TCAGATGTGA ATTTGGTGGC TGAAAACCTC 
 ovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
bovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 Consensus  .......... .......... .......... .......... .......... .......... 
 
            6901                                                         6960 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  GGATCGCCTG AGCCCAG--- ---------- ---------- ------GAGG TGGAGGTTGC 
 mousemRNA  TTGTCCCCGG AGGACATTGT CCTGTTCCAC AAGGTCACAC AGCCTAGAGG GGTGAACTGG 
 ovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
bovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 Consensus  .......... .......... .......... .......... .......... .......... 
 
            6961                                                         7020 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  AGTGAGCCAT GATCGAGCCA CTGCACT--- ---------- -------CCA GCCTGGGCAA 
 mousemRNA  TGTGAGACAA CAGCCCTCCT CCCCAATGGT GGTTGCCAGT ACCTGTGCCT GCCCGCCCCA 
 ovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
bovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 







            7021                                                         7080 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  CAGATGAAGA CCCTATTTCA GAAATACAAC T--------- ---------- ---------- 
 mousemRNA  CAGATCGGTC CCCACTCGCC CAAATTCACC TGCGCCTGCC CTGATGGCAT GCTGCTGGCC 
 ovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
bovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 Consensus  .......... .......... .......... .......... .......... .......... 
 
            7081                                                         7140 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  ---------- ---------- ------ATAA AAAAATAAAT AAATCCTCCA GTCTGGATCG 
 mousemRNA  AAGGACATGC GGAGCTGCCT CACAGAAGTC GACACTGTAC TGACCACCCA GGGGACATCC 
 ovinemRNA  ---------- ---------- ---------- -----TGAAA TTGCCACACA TATCATAT-- 
bovinemRNA  ---------- ---------- ---------- -----TGAAA TTACCACACA TATCATAT-- 
 Consensus  .......... .......... .......... .....tgaa. t.accac.ca ....a.at.. 
 
            7141                                                         7200 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  TTTGACGGGA CTTCAG---- ---------- ---------- ---------- ---------- 
 mousemRNA  GCCGTCCGGC CTGTGGTCAC CGCATCAGCT ACCAGGCCAC CGAAGCACAG TGAGGATCTC 
 ovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
bovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 Consensus  .......... .......... .......... .......... .......... .......... 
 
            7201                                                         7260 
rabbitmRNA  ---------- ---------- --------TT AGCTTTGCAC CTCGCAAGCC GCGCGAGTCT 
 humanmRNA  ---------- GTTCTTTCTG AAATCGCCGT GTTACTGTTG CACTGATGTC CGGAGAGACA 
 mousemRNA  TCAGCTCCCA GTACTCCTAG GCAGCCTGTG GACACCCCAG GGCTCAGCAC AGTGGCGTCA 
 ovinemRNA  ---------- ---------- --------TT ATGACCACTG GGGGGGTGGG GGTCGGGTGG 
bovinemRNA  ---------- ---------- --------TT ATGACCACTG GGGGG-TGGG GGTTGGATGG 
 Consensus  .......... .......... ........tt at.acc.ctg ggcggatg.c ggt.G.gtc. 
 
            7261                                                         7320 
rabbitmRNA  GTGACGACAT ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  GTGACAGCCT CCGTCAGACT CCCGCGTGAA ---GATGTCA CAAGGGATTG GCAATTGTCC 
 mousemRNA  GTGACAGTGT CCCACCAAGT CCAGGGTGAC ATGGCTGGCA GAGGGAATGA GGAGCAGCCA 
 ovinemRNA  GGGGCAGCCT CCCATGGAAA C--------- ------ATCT GAGTTGATTG GCTACCGTAC 
bovinemRNA  GGAGCAGCCT CCCATGGAAA C--------- ------GTCT GAGTGGGTTG ACTACTGTAC 
 Consensus  GtgaCagccT ccca..ga.. c......... ......gtc. gag.ggattg gc.ac.gt.c 
 
 
            7321                                                         7380 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  CCAGG----- ---------- ---------- ---------- ---------- ---------- 
 mousemRNA  CATGGTATGA GGTTCCTGTC CATCTTCTTC CCTATTGCAC TGGTTGCCCT CCTTGTCCTT 
 ovinemRNA  AGCC------ ---------- ---------- ---------- ---------- ---------- 
bovinemRNA  AACC------ ---------- ---------- ---------- ---------- ---------- 
 Consensus  .......... .......... .......... .......... .......... .......... 
 
            7381                                                         7440 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 mousemRNA  GGGGCCGTCC TGCTGTGGAG GAACTGGCGG CTGAAGAACA TCAACAGCAT AAACTTTGAC 
 ovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
bovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 Consensus  .......... .......... .......... .......... .......... .......... 
 
            7441                                                         7500 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 mousemRNA  AACCCAGTCT ACCAGAAGAC CACAGAGGAC GAGCTCCACA TTTGCCGAAG CCAGGATGGC 
 ovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
bovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 






            7501                                                         7560 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 mousemRNA  TATACCTACC CCTCAAGACA GATGGTCAGC CTGGAGGACG ATGTGGCATG AGCAGCCGGG 
 ovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
bovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 Consensus  .......... .......... .......... .......... .......... .......... 
 
            7561                                                         7620 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  ---------- ---------- ---------- ---------- GACAAAACAC TGTGTCCCCC 
 mousemRNA  AGAGCCGTCT CTTTCCGGGA TCCATTGCCA AGCTTAGGCA GAAAAGACAC TCTCTCCAGA 
 ovinemRNA  ---------- ---------- ---------- ---------- -ACAGAACAC GG-CACGGC- 
bovinemRNA  ---------- ---------- ---------- ---------- -ACAGAACAC GGGCACCCC- 
 Consensus  .......... .......... .......... .......... .aca.aacac .g.c.cc.c. 
 
            7621                                                         7680 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  CC-------- ---------- ---------- ---------- ---------- ---------- 
 mousemRNA  CCTCCCCATC CAGCACTGGT CCTGCCACCT CCCTGGGCTC TGTGTTGCTC AAAGCAAGAT 
 ovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
bovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 Consensus  .......... .......... .......... .......... .......... .......... 
 
            7681                                                         7740 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 mousemRNA  AAGAGCAAAG CTGGGCTGGG GGCCAAGCTC AGCTGCCTGT CTGCCCCAGG TTCTGTTTTA 
 ovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
bovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 Consensus  .......... .......... .......... .......... .......... .......... 
 
            7741                                                         7800 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 mousemRNA  TATATTTATT GTCTGGGGAC AGAAAAGGCT ACTGGCTGTG CTTGAAATTC GAATTCTGCC 
 ovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
bovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 Consensus  .......... .......... .......... .......... .......... .......... 
 
            7801                                                         7860 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 mousemRNA  TGGGAATTTT TTTTTTTCTC CCATCTTCAT TTCCTTGGAA GCCAAATAGG CTGTCCCAGA 
 ovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
bovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 Consensus  .......... .......... .......... .......... .......... .......... 
 
 
            7861                                                         7920 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 mousemRNA  AGCTTCTGAA TTCTACTCTT TTCAACACTA ACACGGAGGA GGAAGAGACC CACCCAGGCA 
 ovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
bovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 Consensus  .......... .......... .......... .......... .......... .......... 
 
            7921                                                         7980 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 mousemRNA  GAGAGAAGCC TGCTGGACAT GAGACAGCAG GTACTACTGA CCGGGTCCTG GGTACCATAG 
 ovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
bovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 






            7981                                                         8040 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 mousemRNA  CCAGTCCCTA ACCTCAGGAC TTCCTGCATT GACCTTCATC CCAGAGCCTT CCTGCCTGAC 
 ovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
bovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 Consensus  .......... .......... .......... .......... .......... .......... 
 
            8041                                                         8100 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  ---------- ---------- --AGTGCAGG GAACCGTGAT AAGCCTTTCT GGTTTCGGAG 
 mousemRNA  TCTGCCGCCC CCATCAGAAG CCAGGAAAGT GACTCGTGAC ATTCGGTACT GATCTTGCTG 
 ovinemRNA  ---------- ---------- ----TGCCGG AGACTGTGAA CACCTTTTCT CTTTCTGAAG 
bovinemRNA  ---------- ---------- ----TGCCGG AGACTGTGAA CACCTTTTCT CTTTCTGAAG 
 Consensus  .......... .......... ....tgc.gg ..ac.gtga. .a.c.tttct ..tt.tg.ag 
 
            8101                                                         8160 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  CACGTAAATG CGTCCCTG-- --------TA CAGATAGTGG GGA------- ---------- 
 mousemRNA  GATCTTGAGG CCGGCAGC-- --------TG CCAGTGATGG ATACCCGCTC ATGCCTTTGC 
 ovinemRNA  CATGTAAATA ACACCCCCAC CACCGCCATG CAGACAGGGG GGA------- ---------- 
bovinemRNA  CATGTAAATA ACACCCCCAC CACCGCCGTG CAGACAGTGG GGA------- ---------- 
 Consensus  catgtaaat. .c.ccc.c.. ........tg caga.agtgg gga....... .......... 
 
            8161                                                         8220 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 mousemRNA  CAAAACGTCA CCCGTTCCTG GAGGGACAAG CCCAAGTCGC CATTCTCCCT TAATATTTAT 
 ovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
bovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 Consensus  .......... .......... .......... .......... .......... .......... 
 
            8221                                                         8280 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 mousemRNA  CAAGTGCCTG AGACAACTGG TTGCCTTGCT CAGGAGTCCT GGCCTGCTCA GTGTCCTGCT 
 ovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
bovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 Consensus  .......... .......... .......... .......... .......... .......... 
 
 
            8281                                                         8340 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 mousemRNA  GCTCAGGGGT GGCCGGCAGG ACCCCTGTCC TGTGCCCAGC CCCCGAGTCT CCGAGTGAGG 
 ovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
bovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 Consensus  .......... .......... .......... .......... .......... .......... 
 
            8341                                                         8400 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 mousemRNA  CTTGCACTTC TCTCTGCGCA CTTTTCCCGT TCTGTGCTGG GCACCCACGT GGTCCACATT 
 ovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
bovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 Consensus  .......... .......... .......... .......... .......... .......... 
 
            8401                                                         8460 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 mousemRNA  TGTACTCCTA GGTTGCACTG ACCCTGGTGC ATTGGATGGG ACCTCAGGCC GGAAGTGGCC 
 ovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
bovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 






            8461                                                         8520 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 mousemRNA  CCGAATCATT GACCACAGAA GATAATTGCC AGGCTCCAAG CATCCATTGC CTTCTTCAGT 
 ovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
bovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 Consensus  .......... .......... .......... .......... .......... .......... 
 
            8521                                                         8580 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- --------TT 
 humanmRNA  ---------- ---------- ---------- ---------- -----TTTTT TGTTATGTTT 
 mousemRNA  ACTGGGGGGA ACTCAGGGCC TCTGTCTGGT GTTTAGTTAG TCTGTTTGTT TGTTTGTTTG 
 ovinemRNA  ---------- ---------- ---------- ---------- -----TTTTT TGTTATGTTT 
bovinemRNA  ---------- ---------- ---------- ---------- -----CTTTT TGTTATGTTT 
 Consensus  .......... .......... .......... .......... .....ttttt tgttatgtTt 
 
            8581                                                         8640 
rabbitmRNA  GCACTTTGTG CGTTTCTGG- ---------- ---------- ---------- ---------- 
 humanmRNA  GCACTTTGTA TATTGGTTG- ---------- ---------- ---------- ---------- 
 mousemRNA  TTTGTTTGTT TGGTGGTTTC TGGCTCTGCA CAGCAGAGTT GTTTAGCTCC TCTGGTAACG 
 ovinemRNA  GCACTTTGTA TATTTGTTG- ---------- ---------- ---------- ---------- 
bovinemRNA  GCACTTTGTA TATTTGTTG- ---------- ---------- ---------- ---------- 
 Consensus  gcacTTTGTa tatTtgTtg. .......... .......... .......... .......... 
 
            8641                                                         8700 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 mousemRNA  TCATCCTCTC TCACAGAGAC ATCCAGCCTG CTGAAGGGGA GAGATGGGGC GAGGGGAGGG 
 ovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
bovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 Consensus  .......... .......... .......... .......... .......... .......... 
 
            8701                                                         8760 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 mousemRNA  ATACACGCAT GGTTTCTCAG GTGTGGTGGC ACTTGGCTTT AATCCTATGC TCAAGAGGAA 
 ovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
bovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 Consensus  .......... .......... .......... .......... .......... .......... 
 
            8761                                                         8820 
rabbitmRNA  ---------- ---------- ---------- AGACGCTGAG CACATGTATA GAAAT----- 
 humanmRNA  ---------- ---------- ---------- AAACTGTTAT CACTTATATA TATATATATA 
 mousemRNA  GAGGTGGGCA CATGTCTGAG GTCCAAGCCT ACATAGTGAG ACCTTATATA TCTAAAAACC 
 ovinemRNA  ---------- ---------- ---------- AAACATTTCT CACTTACGTG TATATATAT- 
bovinemRNA  ---------- ---------- ---------- AAACATTTCT CACTTATGTG TATATATAT- 
 Consensus  .......... .......... .......... AaAca.Ttat caCtTataTa tatAtatat. 
 
 
            8821                                                         8880 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 mousemRNA  AAAAGAAATC CCAGACTATT TGGTGGGACT TGGAAGAATA CTTAGAAATT GCCACAGATT 
 ovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
bovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 Consensus  .......... .......... .......... .......... .......... .......... 
 
            8881                                                         8940 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 mousemRNA  TGTCACATGG GTAACCTAAG AAGACAGTGG TGGCCTTACT TGGATTCCTG GGTAGATCCA 
 ovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
bovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 






            8941                                                         9000 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 mousemRNA  CCTGTCCACT ACTCAAGACA CAAGGGCACA CTGCCCAGCC CACTGGGACA CTTGTAAAGA 
 ovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
bovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 Consensus  .......... .......... .......... .......... .......... .......... 
 
            9001                                                         9060 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  ---------- ---------- ---------- ---------- ---------- --------CA 
 mousemRNA  GCTCTGTAAT GTGCCGATGG CACCTGGCTC GGTTTTCATT CTGTATATTC AAGGATATCA 
 ovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
bovinemRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 Consensus  .......... .......... .......... .......... .......... .......... 
 
            9061                                                         9120 
rabbitmRNA  ---------- -------TAT TTATTTTTGC TAACGCTGGC TGCTGTGTG- ---------- 
 humanmRNA  CACATATATA TAAAATCTAT TTATTTTTGC AAACCCTGGT TGCTGTATTT GTTCAGTGAC 
 mousemRNA  CACATATGTA TTAAATCTAT TTATTTTTGC AAACCCTGAT TGCTGCACCT CTCTGCAATT 
 ovinemRNA  ---ATAAAAG AAAGATCTAT TTATTTTTGC AAATCCTGGT TGCTGCAA-- ---------- 
bovinemRNA  ---A--AAAG AAAGATCTAT TTATTTTTGC AAATCCTGGT TGCTGCAA-- ---------- 
 Consensus  ...ata.a.. .aa.atcTAT TTATTTTTGC aAAccCTGgt TGCTGca... .......... 
 
            9121                                                         9180 
rabbitmRNA  ---------- ---------- ---------- ---------- ---------- ---------- 
 humanmRNA  TATTCTCGGG GCCCTGTGTA GGGGGTTATT GCCTCTGAAA TGCCTCTTCT TTATGTACAA 
 mousemRNA  TCTCCAGGTT AGGCTG---- --GGGTGATA CTCTGGGA-- ------TGCT CTGTATACAA 
 ovinemRNA  ---------- ---------- ---------- -------AGA TGCCTCGTCT TTCTGTACAA 
bovinemRNA  ---------- ---------- ---------- -------AGA TGCCTCGTCT TTCTGTACAA 
 Consensus  .......... .......... .......... .......a.a tgcctc.tct tt.tgtacaa 
 
 
            9181                                                         9240 
rabbitmRNA  ---------- ---------- ---------- ---------- ------CAGC GGCGCGGGGC 
 humanmRNA  AGATTATTTG CACGAACTGG ACTGTGTGCA ACGCTTTTTG GGAGAATGAT GTCCCCGTTG 
 mousemRNA  AGATGATTTG AATGGGCTGA TCTCAGGCC- ---------- ---------T GTCCTGTGCG 
 ovinemRNA  AGCTTAGTTG AGCGTGCCGT GCACAGCCCT C----TTCAA GAGAATCAGG TTCTATGTTG 
bovinemRNA  AGCTTATTTG AGCGTGCCGT GCACAGCCCT C----TTCAA GAGAATCAGG TTCTGTGTTG 
 Consensus  ag.ttatttg a.cg.gc.g. .c.cag.cc. .....tt... g...a.cag. gtC...gttg 
 
 
            9241                                                         9300 
rabbitmRNA  CGCCCGTGGG GGGGTGGGGG AGGGCTCCGT GCCGCCTTTG AACCACTGTA TAGAGAGTTT 
 humanmRNA  TATGTATGAG TGGCTTCTGG GAGATGGGTG TCACTTTTTA AACCACTGTA TAGAAGGTTT 
 mousemRNA  TTGCTTTGAG TGGGT----- ------GGGA ACTGCTTTGA AACCCTTGTT CAGATGTTTT 
 ovinemRNA  TATATATGAG TTGCTTTTTG AGGATGGGTG TCGCTTTTTA AACCACTGTA TAGAATGTTT 
bovinemRNA  TATATATGGG TTGCTTTTTG AGGATGGGTG TCGCTTTTTA AACCACTGTA TAGAATGTTT 
 Consensus  tat.taTGaG tgGcTt.t.g aggatgggtg tC.cttTTta AACCacTGTa tAGAa.gTTT 
 
 
            9301                                                         9360 
rabbitmRNA  TTATAGCCTG AAGGGG-TCC CTGTGGTTGA TTAAACTTCT TTAACGAGT             
 humanmRNA  TTGTAGCCTG AA-TGTCTTA CTGTGATCAA TTAAATTTCT TAAATGAACC AATTTGTCTA 
 mousemRNA  TATAGGCTGA AAATATCATA CTGTGATGGA TTAAATTCTT TTTTGGAAAA AAA------A 
 ovinemRNA  TTATAGCCTG AA-TGCCTTA CTGTGATCAA TTATATTTCT TAAATAAAGT ATTTGACT-- 
bovinemRNA  TTATAGCCTG AA-TGCCTTA CTGTGATCGA TTACATTTCT TAAATAAAGT ATTTGACT-- 
 Consensus  TtataGCctg AA.tg.ctta CTGTGaTcgA TTAaAtTtcT TaaatgAa.. a.tt...... 
 
 
            9361  9370 
rabbitmRNA             
 humanmRNA  AAAAAAAAAA 
 mousemRNA  AAAAAAAAAA 
 ovinemRNA  -AAACCGGAA 
bovinemRNA  -AAATCGGAA 
 Consensus  .aaa....aa 
164 
 





































Appendix F: Budget  
 
Order Date Catalog # Name Unit 
Size 
Price  Quantity Total Price 
(excluding 
S+H) 
Supplier  Shipping 
Price 
4/3/11 M0530S Phusion® High-
Fidelity DNA 
Polymerase 
100 units $103.00  2 $206.00  New England 
BioLabs Inc.  
4/3/11 R0552S    AgeI 300 units $65.00  1 $65.00  New England 
BioLabs Inc.  
$19.00  
6/9/11 552846 Bright Linearized 
Baculovirus DNA 
2.5 µg $343.00  1 $343.00  BD Biosciences $30.00  
6/9/11 PAB8804 LDL-R Antibody  100 µg $313.20  1 $313.20  Acris Antibodies 
Inc. 
$32.00  
10/25/11 Strain code: 
052 
Female New Zealand 
White (NZW) Rabbit 






5326 Rabbit Feed – Rabbit 
Diet HF  







N/A Bedding – Paper Chip 
SSP brand 
N/A $13.15  28 $368.20  Quality Lab $25.00  
11/4/12 E2HL-100 EnzyChrom™ AF 
HDL and LDL/VLDL 
Assay Kit 
N/A $359.00  1 $359.00  BioAssay Systems $34.00  
11/4/12 3460-08 MaxDiscovery™ 
Alanine Transaminase 
(ALT) Color Endpoint 
Assay Kit 
N/A $268.00  2 $536.00  Bio Scientific $25.00  
11/4/12 Z5030033 Alkaline Phosphatase 
Assay Kit 
N/A $395.00  1 $395.00  BioChain $37.00  
11/4/12 G5635-1KU β-Galactosidase 
from Escherichia coli 
N/A $64.90  1 $64.90  Sigma-Aldrich $8.00  
2/1/11 19-098-930 Fisherbrand* 
Polylatex Shoe Cover 
Size XL 
N/A $51.39  2 $102.78  Fisher Scientific  $5.00  
6/21/11 12658‐027 Sf‐900™ III SFM 
(1X), liquid 







Light-Duty Lab Coat 
50 units $117.66  1 $117.66  Fisher Scientific  $11.00  




List of Abbreviations  
 
AAV6: Adeno-Associated Virus Serotype 6 
 
AAV8: Adeno-Associated Virus Serotype 8 
 
CAP: Capsid protein 
 
CMV Promoter: Cytomegalovirus promoter  
 
cDNA: Complementary DNA 
 
FH: Familial hypercholesterolemia  
 
HCR-ApoE-hAAT promoter: Hepatic control region Apolipoprotein 
enhancer/alpha1-antitrypsin promoter  
 
HDL: High-density lipoprotein 
 
IACUC: Institutional Animal Care and Use Committee 
 
ITR: Inverted terminal repeat 
 
LDL-R: Low density lipoprotein receptor 
 
ORF: Open reading frame  
 
PBS: Phosphate buffered saline 
 
PCR: Polymerase chain reaction 
 
PEG: Polyethylene glycol 
rAAV: Recombinant adeno-associated viral vector 
 
qPCR: Quantitative-polymerase chain reaction 
 
q-RT-PCR: Quantitative-real time-polymerase chain reaction 
 
REP: Replication protein 
 
RLM-RACE: RNA ligase mediated rapid amplification of cDNA ends  
 




SDS-PAGE: Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
 
UTR: Untranslated region  
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